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PREFACE.
The work presented in this thesis was carried out in the laboratory 
of Professor A.3. Douglas, in the University Department of Medicine,
Glasgow Royal Infirmary. While performing this work I held the post of 
biochemist. I was directed in the experimental work for this thesis bjr 
Professor B.M. McGirr, Professor U.S. Douglas and Dr G.P. Hchicol. Specific 
mention must be made of some portions of The work which I did not personally 
perform. Mrs S. Beaton and Miss H. Moss carried out the ultracentrifugation 
runs on the Spinco, Model 3, Ultracentrifuge (chapter 9) and Dr a.H.C.
Uttley examined one of the fibrinogen degradation products in the Chandler 
tube (chapter 10). Some of the work described in this thesis has been 
published, as described below, and some further portions are being prepared 
for publication
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CHAPTER 1 
INTRODUCTION
Interest in platelets has been stimulated in the last two decades 
with the increased recognition of the importance of their physiological 
and pathological role. It is now well established that normal haemostasis, 
after'vascular injury, is mainly achieved by the formation of a ‘haemostatic 
plug*, consisting of densely packed platelets, which seals the injured 
vessel, thus preventing excessive loss of blood. It has also been 
established that the formation of thrombi, leading to the occlusion of blood 
vessels, is, in large part due to the formation of platelet masses which slow 
the blood flow until fibrin formation occurs in the stagnant portion of the 
occluded vessel.
For twenty years anticoagulant drugs have been widely used in the treatment 
of thrombo-embolic disease; these drugs are administered with the intention 
of limiting fibrin deposition. These conventional anticoagulant drugs 
have been shown to interfere with platelet aggregation in vitro (Cunningham, 
McNicol and Douglas, 1965). More recently activators of the fibrinolytic 
enzyme system have become available for use in human therapeutics for the 
purpose of dissolving intravascular fibrin; the use of these agents is 
referred to as thrombolytic therapy. The present study was undertaken to 
investigate the relationships between the fibrinolytic enzyme system and 
certain aspects of platelet aggregation.
A number of standard in vitro techniques are available which enable 
quantitative assessment of the ability of platelets to clump. Three
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such techniques have been modified, to determine the effect of fibrinolytic 
agents on platelet function. The first method, using recalcified plasma, 
measures platelet aggregation, which precedes fibrin formation, in an 
artificial circulation (Chapter 4 ). Within the last ten years one chemical 
agent, adenosine-di-phosphate (ADP), has been identified which is currently 
thought to play a fundamental role in initiating platelet aggregation both 
in vivo and in vitro. Advantage has been taken of the fact that, with ADP, 
platelet aggregation may be induced in platelet rich plasma without subsequent 
fibrin formation and consequently without interference by coagulation reactions 
leading to clot formation (Chapter 5)» The third method used in the present 
study enables platelet function to be assessed in the presence of red cells 
by measuring the ability of platelets to adhere to glass and to each other 
on passage of blood through a column of glass beads (Chapter 6).
There is still some doubt as to the specific aspect of platelet function 
which is measured by any given in vitro technique. Accordingly, an attempt 
was made to correlate the results obtained from the use of the three different 
techniques of measuring platelet aggregation (Chapter 7)«
From the investigations of the effects of fibrinolytic agents on platelet 
function it was found that in vitro the enzymes could accelerate platelet 
aggregation (Chapters 4, 5 and 6) : the effects of the products of proteolysis 
of fibrinogen were investigated as the possible agents by which this effect
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might be mediated. Fibrinogen proteolysis products were fractionated by 
column chromatography (Chapter 8), their physical and chemical characteristics 
were determined (Chapter 9) and their effect on platelet aggregation 
investigated (Chapter 10).
This thesis is presented in two volumes. The first contains the text 
and references and the second figures and tables. The text begins with an 
historical introduction followed by an account of some current concepts of the 
components and function of the platelet and an outline of possible mechanisms 
of platelet aggregation. An outline is also presented of some of the in vitro 
tests available to study platelet aggregation. There follows a description 
of the methods used in the work for this thesis and thereafter the 
presentation and discussion of the investigative work mentioned above. The 
figures are numbered in order of their introduction in the text and the 
tables are set out in two appendices. The first appendix contains independent 
tables in order as they are referred to in the text and the second appendix 
contains the tables from which the figures were drawn as indicated in the 
text and in the figure legends.
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CHAPTER 2 
PLATELETS AMD HAEMOSTASIS 
HISTORICAL INTRODUCTION 
It was not until the middle of the nineteenth century that microscopists 
recognised corpuscles in blood which we know today as platelets. The first 
description of a platelet was reported by Bonne in 1842 and was confirmed by 
Zimmerman in 1845 who also remarked on the tendency of the cells to clump 
together. Buring the course of the next fifty years a number of workers ob­
served platelets in blood and gradually came to recognise their functional 
significance in haemostasis and thrombus formation. In 1865 Schultze 
reported that platelets exhibited a tendency to clump and to form granular 
masses. This observation was confirmed by Riess (1372) and extended by 
Osier (1874), who stated that the 'granular masses' of Schultze resulted from 
the agglutination of small bodies which occurred as single units in the 
circulation. The clumping phenomenon of platelets in vitro was also remarked 
upon by Vulpian (1873), who noted the presence in blood of colourless corpuscles 
which had the properties of sticking to and accumulating in clumps on a cover 
glass, and by Ranvier (1873)> who observed microscopic changes in platelets 
and the formation of fibrin in a drop of shed blood. In 1882, Bizzozero, 
extending the work of Hayem (1877; 1878) recognised the platelet as a distinct 
element in blood within the vessels and indicated the part it plays in
thrombosis since he was able to show that white thrombi, which had previously 
been thought to consist solely of leukocytes (Zahn, 1875), consisted almost 
exclusively of platelets. The observations of Bizzozero were confirmed and 
extended by a number of authors, Howell (1884-), Eberth and Schimmelbusch (1885) 
and Laker (1889). Eberth and S chimmelbuach (1885) made the important 
discovery that blood corpuscles run in the centre of the blood stream and that 
slowing or stasis of the circulation is followed by migration of leukocytes 
and platelets to the periphery of the stream. They also recognised that 
platelet changes occur during blood coagulation but, unlike Bizzozero (1882) 
who believed that platelet changes preceded blood coagulation, they believed the 
two processes were concurrent. Thus by the 1880*s the function of the platelet 
and its importance in thrombus formation was well recognised. It was at this 
time that the importance of the role of platelet thrombi in the arrest of 
bleeding was proposed by Hayem (1882) and by Lubnitzky (1885)0 But it was 
not until 1912, however, that this role of the platelet in spontaneous 
haemostasis was convincingly demonstrated by Duke.
While these early workers recognised the functions of platelets in 
haemostasis and thrombus formation there was some confusion concerning the 
origin of these cells in blood. In 1865» Schultze had reported that platelets 
were formed from leukoctyes and this view was supported by Riess (1872). |
Hayem (1878), however, believed that the platelets were precursors of
erythrocytes and it was not until the beginning of the twentieth century 
that Wright (1910) found the true origin of platelets from the megakaryocytes.
Thus, by the beginning of the nineteenth century, much of our present 
knowledge of the platelet and its haemostatic function had been documented. 
There was scant information concerning the platelet until the early 1940's 
when the advent of refined microscopic techniques stimulated a renewal of 
interest in the platelet. Since then, the platelet has been investigated 
at many biochemical levels and its structure, biochemical composition and 
function have been extensively documented.
The Platelet
Electronmicroscopy has enabled the ultrastructure of the platelet to be 
precisely defined and it has been shorn to consist of osmophilic o C  granules, 
vacuoles and a few mitochondria randomly distributed within the platelet 
hyaloplasm which is enclosed within a unit cell membrane (Castaldi et al., 
1962; Firkin et al., 1965; Movat et al., 1965; White et al., 1965)*
Closely associated with the surface of the platelet, in what has been referred 
to as the 'plasmatic atmosphere1 of the platelet (Roskam, 1923) are many if 
not all the coagulation factors (Adelson et al., 1961; Iatridis and Ferguson, 
1965). In addition to its ability to contribute to coagulation by the 
presence of a microcosm of coagulation factors associated with the platelet 
surface, the platelet can contribute coagulation factors which are normally 
contained within the cellular membrane. These factors include a
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phospholipid which contributes to the interaction of plasma coagulation 
proteins in the formation of the intrinsic prothrombin activator (Ferguson,
1960; Horowitz and Marcus,- 1964; Macfarlane, 1964; Marcus and Spaet, 1958; 
Marcus and Zucker, 1965a; Seegers, 1961) and a protein or high molecular 
weight polypeptide which has the ability to directly neutralize heparin 
(Deutsch and Kain, 1961; Godal, 1962; Marcus and Zucker, 1965b). Disrupted 
platelets can also exhibit antifibrinolvtic activity (Alkjaersig, 1961;
Johnson and Schneider, 1953)* Another intracellular protein of the platelet 
which has been identified is one which can be clotted by thrombin and which 
exhibits a similar immunological pattern to that of fibrinogen (Castaldi and 
Caen, 1965; Gokcen and Tunis, 1963; Grette, 1962; Seligmann et al., 1957; 
Sokal, 1962; Ware et al., 1948). One of the striking features of platelet 
biochemistry is the very high energy store, in the form of adenosine-tri­
phosphate (ATP) which this cell possesses (Bora 1956a and 1958: Fantl and Ward,
1956). The capacity to act as a store of certain biologically active 
compounds appears to be one of the functions of the platelet since it has been 
shown that normally all the serotonin of the blood is contained within the 
platelet (Zucker, 1962). These platelet components all contribute, in their 
various ways, to the role of the platelet in haemostasis.
The functions of the platelet 
In the last two decades, interest in the function of the platelet in 
haemostasis has been renewed. Progress has been made along two complementary
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lines of investigation; j^ i vivo techniques have been developed by,
among others, Hughues (1962), Roskam (1961) and Zucker (1947), which j
\
have confirmed and extended the observations of the nineteenth century 
workers, and several useful in vitro techniques have been devised (Born,
1962a; Hellem, 1960; Salzman, 1963; Wright, 1941)» Indeed, it has been 
from the application of these two modes of investigation that some 
understanding of how platelets clump and the mechanisms which enable them 
to exhibit this phenomenon has been obtained.
In figure 1 is shown an outline of the functions currently ascribed to 
platelets in haemostasis.
Platelets in thrombus formation. Outlined in figure 2 is a diagrammatic 
representation of the currently accepted reaction sequence of thrombus 
formation (Glynn et al., 1966; Hellem and Owren, 1964; Ettscher, 1967;
Mustard et al., 1964a; Owren, 1966; Poole and French, 1961; Roskam,
1961; Spaet, 1964). The platelet is the first and most important formed 
element demonstrable at a break in the vascular lining^ (French and 
Poole, 1963; Jorgensen and Borchgrevink, 1963; Kjaerheim and Hovig;
1962; Roskam, 1961; Zucker, 1947)* The adhesion of platelets to 
subendothelial tissue appears initially to be independent of blood 
coagulation (Jorgensen and Borchgrevink, 1964; Mustard et al,, 1964a) and 
is thought to be initiated by adenosine-di-phosphate (ADP) release since 
ADP may be liberated from damaged tissue (Born et al., 1964; Honour and 
Mitchell, 1963) and it has been shown to emerge from erythrocytes under certain
conditions (Gaarder et al., 1961; Hellem 1960; Ilaser-Glansmarm and Huscher, 
1962). 3 ince Hovig and Holmsen (1963) have shown that ADP is released from
platelets when they come into contact with collagen and that the ATP content 
of platelets diminishes during clotting (Born 1956b and 1958) or when they begin 
to lose their morphological integrity (Zucker and Borrelli, 1961) it is thought 
that a platelet plug develops round the platelets already adhering to the site 
of lesion, under the stimulus of ADP in the surrounding medium (Hellem and 
Owren, 1964; Mustard et al., 1964; Spaet, 1964)# The platelets in the plug 
gradually lose their morphological integrity (Castaldi et al., 1962; Rosenthal 
and Vvas, 1961; Sharp, 1961) and ADP, serotonin and possibly phospholipid are 
released from the cells (G-rette, 1962; Hardisty and Hutton, 1966; Mustard et al. 
1964a; Spaet and Cintron, 1965). These platelet alterations are rapidly 
followed by fibrin formation round the platelet plug (Jorgensen and Borchgrevink, 
1963; Kjaerheim and Hovig, 1962; Sharp, 1961) and a thrombus is thus formed. 
Platelet aggregation produced by ADP is reversible (Born, 1962b and 1965;
Born and Cross, 1963h; Mitchell and Sharp, 1964) and consequently the initial 
stage of thrombus formation is thought to be reversible and it is not until 
platelets begin to lose their morphological integrity and the plug becomes 
impermeable to blood flow that the process becomes irreversible (Hellem and 
Owren, 1964),
Platelets in coagulation. The main function of platelets in coagulation, apart 
from supplying a microcosm of coagulation factors in their ’plasmatic 
atmosphere1, is the release of a phospholipid, platelet factor 3> which acts
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as a cofactor in the formation of blood thromboplastin (ilacfarlane, 1964; 
Seegers et al., 1962). Unlike the role of the platelet in thrombus formation, 
the platelet contribution to coagulation is made at a relatively late stage in 
the reaction sequence and platelet clumping is not an essential step in the 
reaction sequence since traces of thrombin are sufficient to release the 
phospholipid to the coagulation system (Kacfarlane, 1966; Marcus and 
Zucker, 1965a).
Platelets and vasoconstriction. The blood serotonin, which is transported 
in the platelets, may be released from these cells by the action of thrombin 
(Grette, 1962) or by contact with connective tissue particles (Spaet and 
Zucker, 1964), This process may facilitate haemostasis by stimulating 
contraction of the vessel wall.
Platelets and clot retraction. The way in which platelets organise a fibrin 
clot has been studied extensively (liarcus and Zucker, 1965c) and lias been 
demonstrated to be dependent on the presence of a contracile protein, 
thrombosthenin, within the platelet (Bettex-Galland and Buscher, 1961;
Grette 1962). Thus platelets are able to contribute to the maintenance of 
vascular patency.
Capillary integrity. Platelets have been demonstrated to play an 
essential role in the maintenance of vascular integrity but their precise 
function in this process has not been firmly established (Marcus and 
Zucker 1965d).
Although the role of the platelet in haemostasis is now well 
established and some insight into the manner in which platelets become
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organized within a thrombus has been achieved, the precise mechanism 
involved in the clumping of platelets has not as yet been fully elucidated.
Mflnhart-Lqm of platelet aggregation 
In 1962 it was proposed that the adenosine nucleotide, ADP, might be 
the compound responsible for the formation of haemostatic plugs (Born, 
1962b). This possibility was suggested by the discovery of a factor, 
present in erythrocytes, which could increase platelet adhesiveness 
(Hellem, 1960), by the subsequent identification of this factor as ADP 
(Gaarder et al., 1961) and by the demonstration that the ATP content of 
platelets was diminished during clotting (Born, 1956b) and as platelets 
became fused during the formation of a platelet plug (Sucker and Borrelli,
1961)• The ability of ADP to induce platelet aggregation both in vivo 
(Bom and Cross 1963c; Davey and Landler, 1964; Uordoy and Chandler,
1964; Regoli and Clark, 1963) and in vitro (Born, 1962b; Hellem et al., 
1963; Mitchell and Sharp, 1964; O’Brien, 1962a; Ollgaard, 1961;
Zucker and Borrelli, 1962) is now firmly established. Furthermore, it 
has been shown that aggregation by ADP is inhibited by AMP, adenosine and 
2-chloro-adenosine and that this inhibition is competitive and highly 
specific(Born, 1964; Bora and Cross, 1963a; Born et al., 1965; Clayton 
et al., 1963; Skalhegg et al., 1964). The inhibition of ADP induced 
aggregation by adenosine has also been demonstrated to operate in vivo 
(Regoli and Clark, 1963). In addition, adenosine can inhibit 
aggregation brought about by other agents; eg>the actions of thrombin,
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serotonin and adrenaline can be blocked by adenosine (O’Brien, 1964).
These observations support the hypothesis that ADP plays a key role in 
the formation of platelet aggregates and implies that aggregation brought 
about by substances other than ADP is mediated by ADP. Evidence to 
substantiate this view has been found by Haslam (1964) who has shown that, 
in the presence of an enzyme system which catalyses the phosphorylation 
of ADP to ATP, neither thrombin nor fatty acids are able to induce 
platelet aggregation.
Platelet aggregation is dependent on viable platelets, calcium 
(Born and Cross, 1963b; Hellem 1964; Mitchell and Sharp, 1964) and on the 
presence of a plasma factor (Born and Cross, 1964). The plasma factor has 
characteristics in common with fibrinogen and with the factor deficient 
in the plasma of patients with Von Willebrand’s disease (Born and Cross, 
1964; McLean et al., 1964; Skalhegg et al., 1964). These various factors 
involved in platelet aggregation have led to the development of two 
hypothetical models for the mechanisms of platelet aggregation. The 
first hypothesis is based on the contention that ADP participates in a 
binding reaction, by means of hydrogen bonds, through the 6-amino group 
of the nucleotide,to a specific receptor molecule on the surface of the 
platelet and that calcium ions and the plasma factor are necessary for 
forming bridges between the negatively charged phosphate groups of two 
molecules of ADP (Born, 1965; Clayton et al., 1963; Gaarder and Laland,
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1964; Skalhegg et al., 1964). This suggestion has been extended by 
Gaarder and Laland (1964) who have pointed out that all the nucleotides 
so far known to bring about aggregation have, at physiological pH, an 
uneven number of negative charges, whereas the inhibitors have no charge 
at all or an even number of charges. Because of the double charge of 
the calcium ion, nucleotides with an uneven number of negative charges would, 
when attached to the platelets, provide more opportunities for calcium ion 
bridges between the nucleotides. The second hypothesis stems from recent 
studies with radioactive labelled ADP which have shown that ADP induced 
platelet aggregation is accompanied by dephosphorylation of the 
nucleotide (Kerby, 1966; Salzman et al., 1966). It has been suggested 
that this process releases energy, necessary for unidentified binding 
reactions and that the protein factor is involved in a secondary bridging 
phenomenon (Salzman et al., 1966; Spaet and Lejnieks, 1966).
According to this scheme, platelet clumping by ADP is a metabolic reaction 
dependent on energy transfer.
Thus, although the precise mechanism of platelet aggregation has 
not been fully elucidated the importance of the phenomenon in coagulation 
is well recognised.
Platelets and Fibrinolysis.
Platelets have been shown to possess antiplasmin activity (Alkjaersig, 
1961; Holemans and Gross, 1961; Johnson and Schneider, 1953;
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Stefanini and Murphy, 1956) and indeed, it has been demonstrated that 
intact platelets may concentrate the protein,antiplasmin, from plasma 
(Stefanini and Murphy, 1956). However, platelets have also been shown to 
possess a protein which exhibits proactivator activity (Holemans and 
Gross, 1961; Lewis et al., 1962) and which has been identified in washed 
platelets, by immunological methods, with plasminogen (Uachman, 1966), 
and it would appear that platelets possess enzymes whose activity can either 
inhibit fibrinolysis or enhance the process.
One hypothesis proposed to account for the maintenance of vascular 
integrity suggests that a dynamic balance between coagulation and 
fibrinolysis exists within the vascular tree (Astrup, 1958? Flute, 1965; 
Luscher, 1967; Sherry et al., 1959). Fibrinolytic agents have been demon­
strated to be capable of dissolving thrombi both in vivo (Douglas and 
KcNicol, 1964) and in vitro (Flute. 1965; McMicol, et al., 1965). It has 
been shown, however, that in the process of destruction of a thrombus by the 
digestion of fibrin, platelet emboli are released which appear to be 
resistant to further fibrinolytic activity (McNicol et al., 1965). Platelets 
may play a role in maintaining the dynamic balance between fibrinolysis and 
coagulation by influencing the rate of fibrinolysis although there is still 
some controversy as to whether the presence of platelets inhibits or 
enhances the lysis of plasma clots formed by thrombin (Alkjaersig, 1961;
15.
Bickford and Taylor 1963).
Fibrinolytic Agents.
Stre-ntokina.se - Streptokinase is present in culture filtrates of certain 
strains of haemolytic streptococci. The enzyme first acts 
stoichiometrically with blood proactivator (Troll and Sherry, 1955).
The activator so formed may then convert plasminogen to plasmin (Alkjaersig 
et al., 1958).
Urokinase. Urokinase is the physiological activator of plasminogen which 
has been isolated from human urine (Ploug and Kjeldgaard, 1957; Sobel 
et al., 1952). The activation of plasminogen by urokinase has been shown 
to be an enzymatic reaction (Alkjaersig et al., 1958; Kjeldgaard and 
Ploug, 1957).
Plasmin is the proteolytic enzyme which can be produced from its inactive 
precursor, plasminogen, by various activation procedures (Sherry et al., 
1959) which can hydrolyse arginine-lysine linkages (Sheriy et al., 1959).
In vitro the enzyme has been shown to have equal affinity for fibrinogen 
and fibrin (Ratnoff and Colopy 1953). Other plasma proteins susceptible 
to digestion by plasmin are prothrombin (Alagille and Soulier, 1956), 
factor V (Greenwalt and Triantaphyllopoulos, 1954) and antihaemophilic 
globulin (Lewis et al., 1949). Platelets have also been shown to be a
substrate for plasmin activity. Unlike trypsin, plasmin does not remove
clottable protein from the platelet or cause release of serotonin and ATP 
(Morse et al., 1965). The enzyme does appear to remove clottable protein
from the platelet surface, however, since plasmin treated platelets
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cannot be aggregated by thrombin (Morse et al., 1965). Platelet factor 
4, the factor which exhibits antiheparin activity (Marcus and Zucker, 
1965b), can be inactivated by plasmin^ (Uiewiarowski et al.-, 1963). 
Trvnsin. Trypsin is an enzyme present in pancreatic juice which can 
hydrolyse peptide linkages involving the carboxyl groups of the basic 
amino acids lysine and arginine (Dixon and ¥ebb 1960a). This enzyme 
can digest the plasma proteins fibrinogen (Mihalyi and Godfrey, 1963a) 
and fibrin (Fletcher et al., 1962) and it has been shown to activate 
plasminogen in vitro (Alkjaersig et al., 1958). In addition to its 
fibrinogenolytic and fibrinolytic activities, trypsin may enhance blood 
coagulation by participating in the conversion of prothrombin to thrombin 
(Ferguson et al., 1960; Stormorken, 1956; Yin, 1964). Furthermore low 
concentrations of the enzyme have been shown to promote platelet 
aggregation (Haslam, 1964). It has been shown, however, that high 
concentrations of trypsin abolish the ability of platelets to aggregate 
by thrombin (ocbmid et al., 1962) or by ADP (Haslam, 1964). This may be 
accounted for by the observations that platelets or factors associated 
with platelets, may act as substrates for the proteolytic activity of the 
enzyme. Trypsin can remove clottable protein from the platelet (Morse 
et al., 1965) and, like thrombin, can cause release of serotonin and 
ADP from platelets (Grette, 1962; Morse et al., 1965). Platelet factor 
1 (adsorbed plasma factor V) can be destroyed by the enzyme (Hjort et al.,
1955) which can also inactivate platelet factor 4 (Deutsch and Kain,
1961).
Chvmotrypsin. Chymotrypsin, like trypsin, is present in pancreatic juice 
and can hydrolyse peptide linkages but, unlike trypsin, its preferred 
linkages are those involving aromatic amino acid residues (Dixon and 
Webb 1960a). Its direct action on the platelet appears to be similar 
to that of plasmin in that it does not remove clottable protein from the 
platelet or cause the release of serotonin and ATP (Morse et al., 1965).
Picin. Ficin is an enzyme obtained from fig latex which can, like 
trypsin and plasmin, hydrolyse arginine-lysine linkages (Dixon and 
Webb 1960b).
As has been mentioned, the work for this thesis has involved the 
investigation of the effect of fibrinolytic agents and the effect of 
products of their fibrinogenolytic activity on platelet aggregation in vitro. 
The two agents principally investigated were streptokinase and trypsin.
As discussed above streptokinase is a cofactor involved in the conversion 
of plasminogen to plasmin which is the naturally occurring proteolytic 
enzyme of the fibrinolytic system. Plasmin is difficult to prepare in 
a form free from contaminating plasma proteins. Consequently, trypsin 
was selected as a suitable substitute since ia vitro it exhibits 
similar substrate specificity to plasmin and it has the advantage of 
being commercially available in a purified form.
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CHAPTER 3  
MATERIALS AMD METHODS 
In this chapter is presented an account of the materials r^id 
methods used in the work for this thesis. Experiments designed to 
clarify some detail of the work in a particular chapter are described 
in the relevant chapter. A brief outline of the basis of each method 
and a short discussion of some of the possible sources of error in 
interpretation of results are discussed for the major assay systems.
Standard methods are described for the assessment of platelet 
aggregation and platelet adhesiveness. These include a technique for 
the estimation of the ability of platelet clumps to form in a recalcified 
plasma system, a turbidimetric method for the detection of platelet 
clumps in plasma on the addition of a stimulant of platelet aggregation 
and a method which can utilize whole blood for the estimation of platelet 
adhesiveness. A short outline of the historical background to these 
techniques is also presented.
A method is described for the preparation of proteolysis products 
of the plasma protein, fibrinogen. Various methods used for the 
characterization of the fibrinogen degradation products are outlined, 
namely, ultracentrifugation, electrophoresis and reaction kinetic studies. 
Mention is also made of a method for the detection of defective fibrin 
polymerization caused by some of these products.
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The biochemical assay techniques used to estimate the plasminogen 
and fibrinogen content of plasma and the concentration of streptococcal 
antibodies present in the plasma are presented. Other biochemical 
methods discussed include a method for the estimation of protein 
content of a sample and an enzymatic assay for the estimation of 
adenosine - 51 - diphosphate and adenosine - 5* - monophosphate in blood 
and plasma.
Some details of the methods of collection and handling of blood 
specimens used during the work for this thesis are described.
Measurement of platelet aggregation in vitro.
There are a number of terms which are currently in use to describe 
various stages in the process of platelet clumping in thrombus formation. 
In this thesis, the term platelet adhesion refers to the initial stage 
in haemostasis, in which platelets adhere to damaged endothelium and which 
is mimicked in vitro by the interaction between platelets and a foreign 
surface. The process of platelet to platelet interaction or cohesion of 
platelets which occurs during the enlargement of the platelet plug is 
referred to as platelet aggregation. The term viscous metamorphosis is 
used to describe the stage in the sequence of reactions leading to 
thrombus formation, which precedes fibrin formation, when platelet 
aggregation is irreversible and the platelets have fused to form an 
impermeable plug.
Platelet adhesion. One of the first successful methods for measuring 
platelet adhesiveness in vitro was devised by Wright in 1941 and was 
dependent on the ability of platelets to adhere to a glass surface. 
Anticoagulated blood was rotated in a glass chamber and serial platelet 
counts performed at various time intervals. The percentage of platelets 
lost during the rotation process was assessed from the difference between 
the platelet counts before and after rotation. The principle of this 
method was applied to a more rapid test by Moolten and Vroman (1949). 
Anticoagulated blood was passed through a length of glass wool, the 
residual blood removed with saline and platelet counts performed on the 
blood before and after passage through the filter. Hellem (i960) also 
used this principle to develop an elegant method of measuring platelet 
adhesiveness by performing direct counts on anticoagulated blood before 
and after it passed through a column of glass beads. A number of 
modifications of this technique have been devised (Hirsh et al., 1966a; 
O'Brien, 1961; Salzman, 1963) and one of these (Hirsh et al., 1966a) is 
outlined in this chapter and discussed in chapter 6.
Platelet aggregation. By comparing the adhesiveness of whole blood 
and platelet rich plasma, Hellem (i960) demonstrated that a factor, 
present in erythrocytes, was essential for platelet adhesion to glass 
beads. The subsequent identification of this factor as ADP has led 
to the development of a method of estimating platelet aggregation in
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platelet rich plasma (Bom, 1962a; Cuthbertson and Mills, 1963a»
OfBrien, 1962b). The method depends on the observation that platelet 
aggregation may be induced when ADP is added to platelet rich plasma 
which is being stirred (Born, 1962a). The progress of platelet 
aggregation can be followed quantitatively by recording changes in light 
transmission through the plasma sample as the platelet clumps form (Born,
1962a)• This method is outlined in this chapter and described more fully 
in Chapter 5. Platelet aggregation in platelet rich plasma can also be 
measured using an artificial circulation system (Cunningham et al., 1965). 
This method depends on the ability of platelets to clump together to form 
macroscopic aggregates before fibrin formation occurs and a thrombus 
forms as recalcified platelet rich plasma is rotated in a loop. The 
method is described in this chapter and in Chapter 4.
Materials.
Adenosine -5* - diphosphate was used in the foim of the sodium salt 
as supplied by the Sigma Chemical Company, St. Louis. This compound was 
prepared at regular intervals by dissolving the salt in a barbitone - 
saline buffer, pH 7*2 and was stored at - 20°C in small amounts. Each 
aliquot was used once only.
Barbitone - Salipft buffer. The barbitone - saline buffer was made up as 
follows:- 0.1 M barbitone sodium, 57 ml; 0.1 N HC1, 43 ml; sodium
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chloride, 0.56 g; 0.9 per cent sodium chloride to 200 ml.
Fibrinogen. Grade L (humantlyophilized) fibrinogen was obtained from 
A.B. Kabi, Stockholm. It was stored in the powdered form at - 20°C and 
was reconstituted in 0.1 M phosphate buffer, pH 7.6 immediately before use. 
Phosphate buffer. The phosphate buffer of 0.1 molar, pH 7®6 was made up 
as follows:- NaH2P04, 2.028 g; Na2HP04, 14 .964 g; NaC1, 9*0 g; distilled 
water to 1,000 ml.
Streptokinase was used in the purified form, Kabikinase, supplied by 
A.B. Kabi, Stockholm. The enzyme was reconstituted with 0.9 per cent 
sodium chloride to give a solution containing 10,000 N.I.H. units/ml which 
was then divided into small amounts and stored at - 20°C. A fresh aliquot 
was used for each assay.
Trypsin. Trypsin was used as the preparation of twice recrystallized, 
salt free powder supplied by Koch-Light Laboratories Ltd. The enzyme 
was dissolved in 0.9 per cent sodium chloride to give solutions of the re­
quired concentrations of protein per ml solution. The enzyme was stored 
at 4°C.
Soybean Trypsin Inhibitor. Type 1 - S, was obtained from the Sigma 
Chemical Company, St. Louis. The powder was dissolved in 0.9 per cent 
sodium chloride and was used at concentrations comparable to those of 
the various trypsin solutions studied. The enzyme was stored at 4°C. 
Adenosine was obtained from British Drug Houses Ltd. The compound was
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dissolved in distilled water as required and the solutions stored at 4°C. 
Thrombin was used in the form of Thrombin Topical (Parke, Davis and Co., 
Detroit). A stock solution of concentration 100 H.I.H. units per ml was 
stored in 50 per cent glycerol - saline at - 20°C and diluted in saline to 
the required strengths.
Carbonate Buffer. The carbonate buffer of 0.1 molar, pH 8.9 was made up as 
follows:- Ha^ 00^, 10.599 g; distilled water to 1,000 ml; pH adjusted to 
8.9 with CO^. A fresh buffer solution was made up for each experiment.
Casein solution was prepared as described by McHicol and Douglas (1964c).
25 g of casein (L. Light and Co., Ltd.) were boiled for 20 minutes in 500 ml, 
0.1 II phosphate buffer, pH 7.6 while still hot. The solution was then 
dialysed for 24 hours at 4°C with constant stirring against 4 litres of 
0.1 M phosphate buffer, pH 7.6. The dialysate was changed once. The casein 
solution was stored at 4°C.
Tubing. Portex transparent vinyl tubing MT/1 3 and HT/1 7  was supplied by
Portland Plastics Ltd., Kent. Esco (Rubber) Ltd.,(LondoiJ) supplied translucent
silicone rubber tubing.
131Radioactive Iodine. I^ was supplied by the Radiochemical Centre, Amersham,
England.
131Tagged. Fibrinogen was prepared with human fibrinogen and I2 by the
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method of Clement and McNicol (1959) as described by McNicol and Douglas 
(I964b)e
1 31
Radioactive iodine ( I^) was prepared from 1 mcu carrier-free
radioactive iodine (as Mai) in 0.1 ml dilute sodium thiosulphate solution
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by the addition of one drop of in methanol and one drop of 0.01 N H2S04.
One drop of heparin (25 units/ml) was added to the radioactive iodine followed 
by 5 nil of human fibrinogen in citrate saline solution (4mg/ml). The 
fibrinogen iodine mixture was then passed through a C1 phase resin column 
(Amberlite IRA 400 C1) with 5 ml, 0.1 M phosphate buffer, pH 7»6. The 
fibrinogen was stored in small aliquots at -20°C.
Methods.
(a) Estimation of platelet aggregation and adhesiveness.
Chandler Tube technique- This method is based on the observation that, 
when whole blood is made to flow round a closed plastic loop, a thrombus 
forms which exhibits the same histological features as a thrombus formed in 
vivo (Chandler, 1958)0 The histological appearance of a Chandler thrombus 
is shown in figures 5 and 4. VJhen platelet rich plasma replaces whole 
blood in this system, in the presence of a physiological concentration of 
calcium ions, a ‘snowstorm* of platelet aggregates becomes visible before the 
appearance of fibrin strands and the formation of a white thrombus 
(Cunningham et al., 1965)-
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The method used liras a modification of that described by Cunningham 
et al., (1965). The transparent vinyl tubing, 12.3 mm bore, 71 cm in 
length was made into a loop by means of a nylon adaptor. The loop was 
washed in cold water and rinsed in 0.9 per cent NaC1. 6 ml of platelet 
rich plasma was added to the loop and the volume made up to 15 ml with 
0.9 per cent ITaC1. The system was then recalcified with one-tenth 
plasma volume, i.e. 0.6 ml, 0.25 M CaCI^, and the loop and contents rotated 
on the turntable of a blood cell suspension mixer, (Matbum Ltd.,
London), rotating at 28.5 rpm in a glass fronted incubator at 37°C.
Platelet aggregation was assessed by the length of time taken for the 
1 snowstorm* of platelet aggregates to appear after recalcification.
The method was designed to resemble as closely as possible the in vivo 
conditions for blood coagulation. Unfortunately, the method fails to 
achieve this ideal situation. The flow round the loop is laminar whereas, 
in vivo blood flow is turbulent in nature. The divergence from in vivo 
conditions is further increased by the use of platelet rich plasma.
During centrifugation, it has been shown that some of the platelets most 
susceptible to aggregation appear to be lost (stormorken et al., 1965). 
Consequently the platelet rich plasma sample may not contain the full 
platelet population of the initial sample. In addition, the red cells 
contain adenosine-di-phosphate (ADP) which is a potent initiator of platelet 
aggregation (Gaarder et al., 1961 ). Any hemolysis of the red cells which
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may occur during the process of centrifugation will release ADP into 
the system. This may cause the aggregation and consequent loss of a 
number of platelets from the plasma sample.
The Chandler tube method involves the estimation of platelet aggregation 
in a recalcified plasma system in which platelet clumping is followed by 
fibrin formation. It may be assumed, therefore, that this method is assessing 
the first visible stage, but relatively late stage of the haemostatic 
process and that any alteration in the rate of formation of the platelet 
aggregates may indicate either, a true change in platelet aggregation ability 
or, may reflect some change in an earlier stage of haemostasis.
The limitations inherent in this technique have to some extent been 
overcome or minimized by the limited use and rigid standardisation of the 
method, (Chapt. 4). Each plasma sample examined was divided into two 
equal portions. One portion was treated with the compound under investigation 
and the second portion with saline so that the dilution of both the test and 
control plasma samples was the same. The plasma samples were added to 
identical Chandler tubes, recalcified simultaneously and rotated together on 
the mixer. In this way it was possible to compare the effect of the compound 
on the rate of formation of platelet aggregates with that for an identical 
control sample.
Turbidimetric Method. (Bom, 1962 a, b; B o m  and Cross, 1963b; O’Brien,
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1962b). The basis of this method for the assay of platelet aggregation 
was the observation (Bom, 1962a) that platelets can be induced, by 
chemical stimulants, to form platelet aggregates in a platelet rich plasma 
system when the plasma is kept in motion. The apparatus used in this study 
consisted of an EEL titrator connected to a galvanometer (EEL type 20,
Evans Electroselenium Ltd., England). A perspex cuvette was fitted onto 
the titrator above a magnetic stirrer and in the light path from the 
photoelectric cell. 2 ml, platelet rich plasma were added to the cuvette 
together with a small stirring rod. Once the stirring rod was rotating 
at a uniform speed ^  the optical density reading of the plasma sample on the 
galvanometer scale was adjusted to an arbitrary value of 0.600. As platelet 
aggregation occurs in the plasma, the light transmission through the sample 
is increased and is recorded as a fall in optical density on the galvanometer 
scale. Before the addition of the platelet aggregation inducing agent, the 
plasma was agitated for at least 60 seconds to ensure that no change in 
optical density occurred. If a change was observed, indicating that 
spontaneous aggregation was occurring in the plasma, the sample was 
discarded. Changes in light transmission, at a wavelength of 492 myu 
were recorded at 30 second intervals over a period of ten minutes from 
the time of addition of the stimulating agent.
There are a number of sources of possible error embodied in this 
method. The use of platelet rich plasma introduces similar discrepancies
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as were considered above for the Chandler tube system. In the 
titrator magnetic stirrer system there is no accurate gauge of the 
speed at which the stirring rod rotates. As it has been demonstrated 
(O’Brien, 1962b), that the degree of agitation of the plasma influences 
the extent to which platelet aggregation occurs, this is an important 
disadvantage of the system as used in the work for this thesis. In the 
present system, the photoelectric light beam was not shielded from 
incident light under the experimental conditions used. This may result 
in some discrepancy in the readings of optical density recorded during a 
period of months.
As with the Chandler tube system, some of the drawbacks of the assay 
system were overcome by rigid standardization in the use of the system.
Two titrators and galvanometers were used simultaneously for each experiment. 
Each platelet rich plasma sample was divided, one portion treated with a 
volume of the test substance and a second portion with an equal volume of 
0.9 per cent saline as a control. The platelet aggregation occurring 
in the control and test samples was assayed simultaneously, the two 
samples being randomly allocated between the two sets of instruments. It 
was only possible to standardize the speed of rotation of the stirring rod 
in the plasma by observation. A minimum fixed volume of plasma, 2 ml, 
was selected so that the meniscus of the fluid in the cuvette lay immediately 
above the light path. As the stirring rod rotated, a vortex formed in 
the plasma and the speed of rotation was arbitrarily fixed as the
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maximum speed which produced a vortex just insufficient to interfere 
with the light path through the plasma sample.
Glass Bead Column Method. Hellem (1960) has shown that when whole
blood, containing an anticoagulant, is pumped through a column of glass
beads, a number of platelets adhere to the surface of the glass beads and
to each other. The technique used in this thesis was a modification of Hellem1 s
original method (Hirsh et al., 1966a). The glass bead column was made
by filling a length of vinyl tubing (MT/13, Portland Plastics, Kent)
with 2.5 g Ballotini glass beads (0.57 mm diameter) to give a column 6 cm
in length. The glass beads were held in the column by a filter of fine
nylon gauze fitted at each end of the column. 2 ml of citrated whole
blood were drawn into a graduated plastic syringe which was then fitted
to an electrically operated mechanical pump. The blood was pushed
through the standardized column of glass beads at a constant rate. The
rate was assessed by the time taken for the leading edge of the column
of blood to pass through the column of glass beads. The pump and glass
bead columns used in the present study gave a mean contact time between blood
and glass of 30 - 1 seconds. Any observation lying outside this range was
discarded. Platelet counts were performed on the blood samples before and
after passage through the column. The difference between the two counts
was expressed as a percentage of the initial platelet count and this value
was taken as an index of platelet adhesiveness in the sample.
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With his original technique Hellem (i960) has shown that platelet 
adhesiveness increases as the glass surface area increases, as the contact 
time between the blood and the glass surface increases and as the packed 
cell volume of the blood sample increases. With the method described above 
the glass surface area and the contact time have been standardized and only 
the packed cell volume can vary. For most of the experimental work in this 
thesis it has not been necessary to make allowance for this in the final 
analysis of the results since each blood sample has been divided into two 
portions each of 2 ml, one portion treated with a volume of the substance 
under test and the second with an equal volume of 0.9 per cent saline.
Each sample was treated identically and the percentage adhesiveness of 
each sample compared. Where this procedure was not used allowance was made 
for the packed cell volume of the sample as described in Chapter 7.
The main source of error with this technique stems from the fact that 
the result is dependent on accurate platelet counting. In an attempt to 
minimize this, four independent platelet counts were performed on each 
blood sample before and after passage through the column and the percentage 
platelet adhesiveness calculated from the mean of the four readings.
Platelet counts were performed using formol citrate as the diluting fluid 
(Dacie, 1956c). 10 ml, freshly filtered diluting fluid was added to a
clean glass test tube together with 0.1 ml blood. The tube was inverted 
gently until the contents were thoroughly mixed. A sample was then run
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onto a Meubauer improved counting chamber and allowed to stand in a damp 
atmosphere for twenty minutes before the platelets were counted with a 
microscope using a white light source.
(b) Preparation of fibrinogen degradation -products.
Pour degradation products were prepared, three by tryptic digestion 
of fibrinogen and one by the enzymatic action of urokinase-activated 
plasminogen. The tryptic fibrinogen degradation products were each 
prepared by incubating 0.3 ml of the various trypsin solutions with a solution 
containing 200 mg fibrinogen dissolved in 4 ml, 0.1 M phosphate buffer, pH 
7.6 at 37°C for 10 minutes. At the end of incubation, 0.3 ml of the 
appropriate concentration of soybean trypsin inhibitor was added to the 
system. The urokinase degradation product was prepared by incubating 0.1 ml 
of the enzyme preparation with a solution composed of 200 mg fibrinogen 
dissolved in 4 ml, 0.1 M phosphate buffer, pH 7.6 and 1.0 ml of plasminogen 
solution containing 17.5 Hgouris units per ml.
Column Ch-rnmatnp-raphv of the fibrinogen degradation products was carried out 
by a modification of the method of Nussenzweig et al*, (1961). A separate 
column was prepared for each degradation product. The mixture obtained by 
incubating fibrinogen with the enzyme preparation was layered onto a DEAE 
cellulose column, 37.5 cm long and 2.5 cm in diameter (DE II, Whatman,
W. & R. Balston Ltd., England). The fibrinogen incubation mixture was
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eluted with a linear concentration gradient within the limits of 0.1M 
carbonate buffer, pH 8.9 to 0.1M carbonate buffer, pH 8.9 plus 0.2 14 
sodium chloride in a total volume of 800 ml. The chromatography was carried 
out at 4°C and the flow rate for each column lay within the range 80-100 ml 
per hour. The eluate was collected in 10 ml amounts using an Aimer 
fraction collector with a drop counter attachment. The eluate samples 
were screened for protein content by estimations of optical density 
measurements at 280 m/u on a spectrophotometer (3P 500>Unicam Instruments, 
Cambridge). The samples found to contain protein were concentrated with. 
Sephadex G - 25 (coarse) using Seitz filters and the precise protein 
concentrations estimated by the method of Lowry et al., (l951)«
(c) Biochemical Assays.
Streptokinase Sensitivity Test. This assay was carried out by the 
method of Johnson et al., (1957) as described by McNicol and Douglas 
(1964c). This test is designed to determine the concentration of 
streptokinase required to neutralise both plasma antibody to streptokinase 
and other inhibitors of the enzyme.
Streptokinase was added to 0o2 ml plasma in a series of test tubes 
at concentrations ranging from 100 - 500 N.I.H. units per ml plasma. The
plasma - streptokinase mixture was then clotted with 0.1 ml thrombin 
(20 N.I.H. units/ml) and the samples incubated at 37°C. The time of clot 
lysis was recorded. The concentration of streptokinase used in subsequent
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experiments was the concentration which produced maximum lytic activity. 
Thrombin Clotting Time* This test is used as an index of defective fibrin 
polymerization.
The method used was that described by Fletcher et al., (1959)• To 
0.1 ml plasma was added 0.3 ml of a 'thrombin titration mixture1 (Seegers 
and Smith, 19421 as described by McNicol and Douglas, 1964ai 0.1 ml
thrombin (10 N.I.H. units/ml) was added and the clotting time at 37°C 
recorded. The 'thrombin titration mixture1 was made as follows 
0.9 per cent sodium chloride, 6 ml; 0.7 per cent calcium chloride, 2 ml;
15 per cent acacia, 2 ml; 0.1 M tris buffer, pH 7.5, 1 ml.
Fibrinogen Assay. The method used was that of Ratnoff and Menzie (1951 )
as described by McNicol and Douglas (1964a). In this method plasma
fibrinogen is converted to fibrin by thrombin. The fibrin is washed free 
of contaminating proteins and then subjected to alkaline hydrolysis.
The tyrosine released is estimated colorimetrically. The initial con­
centration of fibrinogen is calculated from the assumption that the ratio of 
tyrosine residues to each fibrinogen molecule is constant and is 11 „7 to 
1.0 .
Into a 15 ml test-tube were placed '0.2 ml1 glass beads (diameter 
not more than 0.15 mm); 6 ml,0.9 per cent saline; 0.2 ml, 2.5 per cent
CaOl^; 0.2 ml, plasma and 0.1 ml, thrombin (100 N.I.H. units/ml). The
Q
contents of the tube are thoroughly shaken and allowed to stand at 4 C
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for 3 0  minutes. The tube was then shaken and centrifuged at 1,000 g
for 10 minutes. The supernatant was discarded and the glass beads
washed three times with 0.9 per cent saline with centrifugation and 
decantation of the supernatant between each wash. 0.4 ml, 10 f o  sodium 
hydroxide were then added to the glass beads and fibrin and the tube 
boiled for 20 minutes, the top of the tube being sealed with tin foil 
to minimize evaporation. After cooling the tyrosine released was 
estimated by the addition of 2.0 ml, 0.5N sodium hydroxide, 0.6 ml,
5 per cent trichloroacetic acid and 0.6 ml, Folin Ciocalteu reagent 
diluted 1:2 with distilled water. The mixture was thoroughly shaken and 
allowed to stand for 10 minutes to permit maximum colour development.
The optical density was read at 650 myt on a spectrophotometer ( SP 500, 
Unicam Instruments) against a reagent blank.. Optical density readings 
were converted to mg fibrinogen per 100 ml plasma from a standard 
tyrosine curve.
Pi npgen Assay. The method used was the caseinolytic assay of 
Remmert and Cohen (1949) as modified by Alkjaersig et al., (1959). The 
initial steps of the assay involve the destruction of plasma antiplasmin 
with acid, the neutralization of the plasma with alkali and buffer, and 
the conversion of plasma plasminogen to plasmin by the addition of 
streptokinase. Casein is ussd as a substrate for the plasmin0 The
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enzyme reaction is stopped by the precipitation of the proteins with 
trichloroacetic acid (TCA). The tyrosine residues released remain in 
the supernatant and are measured colormetrically. The amount of tyrosine 
released from the casein is a measure of the amount of plasmin present.
0.5 ml, plasma was incubated with 0,5 ml, 1/6 IT HC1 for 15 minutes 
at room temperature. 0.5 ml, 1/6 IT ITaQH was then added followed by 
1.0 ml, phosphate buffer, 0.1 molar, pH 7.6 and 0.5 ml streptokinase 
(2,000 units/ml). 2.0 ml of a 5 per cent casein solution were added 
and the mixture thoroughly shaken. After the addition of casein the 
mixture was incubated at 37°G for 62 minutes. 2 ml samples were removed 
from the incubation mixture at 2 minutes and 62 minutes and each added to 
2 ml of a 10 per cent TCA solution. The supernatant was obtained by 
centrifugation at 1,000 g for 10 minutes and the tyrosine measured by the 
addition of 1 ml supernatant to 5*0 ml, 0.5 H UaOE and 1.5 ml, 5 per cent 
TCA. After the addition of 1.5 ml Folin Ciocalteu reagent (diluted 1:2 
with distilled water) the tubes were allowed to stand for 20 minutes to 
allow for the maximum colour development. The optical density was 
recorded at 650 m/u on a spectrophotometer ( SP 500, Unicam Instruments 
Ltd.) using the 2 minute sample as blank for the 62 minute sample.
The optical density was equated to tyrosine release from a standard curve. 
One casein unit of plasminogen released 180 mg tyrosine per hour. 
Estimation of Protein. The method used was that devised by Lowry et al.,
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(l95l)« This test is based on the reaction between the phenolic residues 
ox a protein moiety and Folin Ciocalteufs reagent and may be used over the 
range of protein concentration 20 to 400 mg/ml.
A volume of protein solution not exceeding 1 ml was added to a test
tube and the final volume made up to 1 ml with distilled water. 5 ml
of the alkaline copper reagent were then added to the test tube and the
mixture allowed to stand at room temperature for at least 10 minutes.
After the addition of 0.5 ml, Folin Ciocalteu reagent (diluted 1:1 with 
distilled water) the tube was allowed to stand for 30 minutes to allow the 
maximum colour development to occur. The optical density was read on a 
spectrophotometer (SP 500, Unicam Instruments Ltd.) at 750 nyu against a 
reagent blank. The optical density was equated to protein concentration 
from a standard curve. The standard curve was prepared with bovine 
albumin (Armour Pharmaceutical Co. Ltd., Eastbourne) over a range of 
concentration 0-400 mg/ml.
Alkaline Conner reagent was prepared as follows:- 1 ml, 1 per cent Cu30^. 
5H20 solution; 1 ml, 2 per cent Na,K tartrate; 2 per cent IfegCO in 
0.1 II KaOH to 100 ml.
Adenosine-di-nhosohate (ADP), and adenosine-mono-ohosnhate (am£. were 
estimated enzymatically using a commercially prepared assay kit (TCK - 
Art. No. 15980, C.F. Boehringer and Soehne, Mannheim, Germany).
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In this procedure ADP is phosphoiylated with phosphoenol pyruvate 
and pyruvate kinase. The pyruvate formed in this reaction is reduced to 
lactate with diphosphopyridine nucleotide and lactic acid dehydrogenase.
The change in adsorption spectrum which occurs as the diphosphopyridine 
nucleotide is oxidized is followed at 366 myu on a spectrophotometer and 
is used to monitor the reaction. After the ADP in the solution is consumed 
and the reaction stopped, the AMP present in the solution is measured by 
the addition of myokinase which phosphorylates ASAP to ADP with the ATP which 
was formed in the first reaction. The ADP formed in this reaction is 
estimated in the same way as that formed in the original reaction.
The preparation of the extracts for assay was carried out in the
manner described by Holmsen et al., (1965) and the samples analysed for
/DP and AI-IP by the enzymatic method given with the Boehringer test kit.
0.5 ml of the whole blood or plasma was added to 2.0 ml, 0.5 M perchloric
acid at 4°C. After thorough mixing, the sample was centrifuged at 1,600 g
for 5 minutes at 4°C and 2.0 ml of the supernatant added to 1.0 ml, 1.3 M
K GO in 1,0 M triethanolamine hydrochloride at 4°C. The solution was 
2 3
maintained at 4°C for at least 5 minutes, thoroughly mixed and again 
centrifuged at 1,600 g for 5 minutes. If not immediately required for 
assay the supernatant was stored at -20°C for not more than 3 days.
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For the determination of ADP and AMP, 2.0 ml of the supernatant was diluted 
with 4.0 ml, distilled' water. 2.0 ml of this mixture was added to a glass 
cuvette (1 cm light path, 4 ml capacity) together with 0.15 ml, 0.01 M 
phosphoenolpyruvate containing 1.3 M KC1 and 0.4 M %  SO.. 0.10 ml, 0.009
nr
II diphosphopyridine nucleotide and 0.02 ml, lactic acid dehydrogenase
(l mg/ml) were also added to the cuvette. The solution was thoroughly
mixed, allowed to equilibrate at room temperature for 5 minutes and the
optical density recorded at 366 nyu on an 3P 500. The optical density was
recorded at 30 second intervals until three consecutive readings were constant
(E^. 0.02 ml, pyruvate kinase (l mg/ml) was then added to the solution
in the cuvette. After thorough mixing and 5 minutes equilibration at
room temperature the optical density was recorded. The recordings were
repeated at 1 minute intervals until three consecutive readings were obtained
(E ). The difference between E^  and E^ was used to calculate the concentration
of ADP in the solution (Adam, 1965). To determine the concentration of
AMP in the solution, 0.02 ml, myokinase (2 mg/ml) was added to the reaction
mixture in the cuvette and after thorough mixing the solution'was allowed to
stand at room temperature for 10 minutes. The optical density was recorded
at minute intervals until a constant value was obtained (E )^. The
difference between E_ and E_ was used to calculate the concentration of
d  3
AMP present in the solution (Adam, 1965)*
weight determinations. The approximate molecular weights of
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some of the fibrinogen degradation products were estimated and compared 
to that of the pure fibrinogen preparation with a sucrose density gradient 
technique. Linear sucrose density gradients over the range 15 per cent 
to 1 per cent sucrose solution were prepared with the Buchler Density 
Gradient Sedimentation System (Buchler Instruments Inc., H.J.). when 
protein is layered onto the surface of the sucrose solution and the system 
centrifuged, the protein moves through the sucrose solution until it reaches 
a point of equilibrium, approximately equivalent to its sedimentation value, 
with the sucrose solution. By careful elution of the resulting gradient 
the position of the protein in relation to the density of the sucrose 
solution may be determined by examination of the absorption spectrum of the 
gradient at 280 myu. 0.2 ml of the protein sample, of approximate concen­
tration 5 mg per ml, was layered onto the surface of a freshly prepared 
gradient which was then centrifuged at 38,000 rpm for 6 hours at 4°C on a 
Spinco Model L Ultracentrifuge (Beckmann Instruments Inc., California) 
using head No. S W 39. After centrifugation the gradient was analysed by 
eluting samples from the bottom of the gradient with a Buchler 1piercing 
unit1. The samples were collected in a series of tubes, 8 drops per tube 
and after the addition of 0.5 ml, distilled water to each tube, the 
samples were screened for protein content by analysis at 280 myu on an 
SP 500.
Reaction p.h . The rate of the reaction between trypsin and fibrinogen
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was followed on a pH stat consisting of titrator (Type TTIc) connected 
to an autoburette (Type ABUlb) and a titrigraph (Type SBR 2c),
(Radiometer Electronic Measuring Instruments, Copenhagen) • As trypsin 
digests fibrinogen, peptide bonds are broken with the release of protons.
Nhen the reaction is carried out in the pH stat a volume of alkali, sufficient 
to neutralize the free protons in the system, is added to the reaction 
mixture. The amount of alkali required to maintain a constant pH is 
recorded on the titrigraph and under carefully standardized conditions this 
volume may be equated to the number of peptide bonds broken during the 
reaction.
20 mg Kabi human fibrinogen dissolved in 1 ml, 0.9 per cent saline were 
transferred to the reaction flask surrounded by a water bath at 37°C and 
allowed to equilibrate for at least ten minutes. TThen equilibration had 
occurred, 0.2 ml of trypsin (at an appropriate concentration) was added, a 
stop watch started and a stream of nitrogen passed over the reaction 
mixture. The reaction was followed for 10 minutes on the titrigraph,
0.0335 M I'laOH being transferred from the autoburette to the reaction flask 
to maintain a constant pH of 8.5. Since the rupture of one hydrogen bond 
utilizes 0.998 meq alkali, and the volume of alkali used during the reaction 
was known, it was possible to calculate the number of peptide bonds broken 
during the reaction process.
Electrophoresis. Electrophoretic studies were performed by horizontal
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paper electrophoresis for 17 hours at 200 volts using a Shandon electro­
phoretic tank and power pack (Shandon Scientific Company, London) (Smith,
196C). The buffer used was 0.1 M barbitone buffer, pH 8.6 (Flynn and 
De Mayo, 1951)» and the strips (2.5 cm x 20 cm) of Whatman filter paper 
(No. 1) were soaked in the buffer and blotted before the application of the 
protein samples. 20yul samples of the protein solutions were applied to the
paper with the current passing through the paper. Six strips were run during 
each experiment. The strips were stained with Bromophenol blue, destained 
with 1 per cent acetic acid and the colour of the dried strips developed by 
exposure to ammonia vapour.
Barbitone buffer., The barbitone buffer of 0.1 molar, pH 8.6 was made up 
as follows:- 10.3 g, sodium diethyl barbitone; 1.84 g ,  barbitone; distilled 
water to 1,000 ml.
(d) Collection of Blood.
All blood samples used in this thesis were collected by clean venepuncture 
with plastic disposable syringes. The samples were collected from three 
groups of donors (a) healthy colleagues, (b) hospital outpatients and (c) 
hospital inpatients. The patients were suffering from a variety of 
diseases, none of which are known to affect blood coagulation or platelet 
aggregation.
With the minimum delay, the blood was transferred from the syringe to 
siliconed glass centrifuge tubes containing 3.8 per cent sodium citrate, 
the relative proportions of blood to citrate being 9 to 1.
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Siliconed glassware was used for all experiments which involved the examination
of platelets. Two methods were used to siliconize the glassware. The
first method used a water insoluble commercial silicone preparation,
Silicone M441 (imperial Chemical Industries Ltd.) as described by facie
(l956d)• For the later work in this thesis a water soluble commercial
silicone preparation was used, Siliclad (Clay Adams Inc., N.J.).
Platelet rich plasma was prepared from citrated whole blood by centrifugation
o_
at 600 g for 5 minutes at 4 C.
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CHAPTER 4
STUDIES OH THE EFFECT OF STREPTOKINASE AND TRYPSIN 
OH PLATELET AGGREGATION IH THE CHANDLER 
TUBS SYSTEM
In this chapter is presented the results of the investigations of the 
effect of two enzymes, streptokinase and trypsin on platelet aggregation in 
the Chandler tube system. Some of the factors influencing platelet aggregation 
in this system have been investigated and are discussed.
The possibility of the existence of a haemostatic balance mechanism has been 
discussed in chapter 2. Previous work reported from this laboratory on the 
effect of anticoagulant drugs on the formation of artificial thrombi and on the 
effect of fibrinolytic enzymes on the lysis of artificial thrombi appeared to 
offer a means of investigating the possible role of such a mechanism. The 
anticoagulant drugs, phenindione and warfarin, and heparin have been shorn to 
cause significant prolongation for the time taken for platelet aggregates to 
form in vitro (Cunningham et al., 1965). It lias also been shown that perfusion 
of an artificial thrombi with the fibrinolytic enzyme, streptokinase, results 
in the lysis of the thrombi but with release of platelet emboli into the 
system which are resistant to further destruction by the enzyme (McNicol et al., 
1965). Accordingly, the effect of streptokinase on the formation of 
artificial thrombi was investigated in the Chandler tube system.
Streptokinase owes its proteolytic and fibrinolytic activity to its
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ability to activate the fibrinolytic enzyme system by bringing about the 
conversion of plasminogen to plasmin (Sherry et al., 1959). Plasmin, a 
proteolytic enzyme, can digest many proteins, including fibrinogen, fibrin, 
antihaemophilic globulin, factor V and prothrombin. Under physiological 
circumstances in vivo its preferred substrate is fibrin, but in the presence 
of excess plasmin, fibrinogen is also readily digested (oherry et al., 1959).
The effect of streptokinase on the lysis of artificial thrombi is caused by the 
production of plasmin in close association with fibrin which is digested.
Trypsin can also digest fibrinogen and fibrin (Fletcher et al., 1962; 
Iiihalyi and Godfrey, 1963a), and since trypsin is readily available commercially 
in a purified form, it was also selected for investigation of its effect on the 
formation of platelet aggregates in the Chandler tube system.
Materials.
Platelet -poor -pl.arana was obtained from platelet rich plasma by centrifugation 
at 1600 g for 15 minutes at 4°C.
0.25 M CaCl, was made up from anhydrous calcium chloride (Analar, British Drug 
Houses Ltd.) and was titrated against 0.02M potassium thiosulphate (ivCNS) 
before use (Douglas, 1962e). A few grains of ferric alum were added to 1 ml 
of the calcium chloride solution. After the addition of 3 ml, 0.05N Ag N0^ 
in concentrated HNCL the solution was run under a cold water tap and shaken 
until the solution was milky white. The solution was titrated with 0.02M KCUS
until a red end point was obtained. A reagent blank containing no calcium
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chloride was treated similarly.
Human fibrinogen. This was prepared by the phosphate buffer method of Jaques 
(1943) as described by Biggs and Macfarlane (1962b) to give a product which 
contained 90-95 per cent coagulable protein.
Human nrothrombin was prepared by adsorption with alumina and elution with 
phosphate buffer pH 8.C as described by Biggs and Macfarlane (1962c).
Details of the preparations of streptokinase, trypsin, ADP, adenosine, 
thrombin and radioactive fibrinogen are described in chapter 5.
Methods.
Platelet rich plasma. 36 ml of venous blood were withdrawn from a volunteer 
by clean venepuncture into a plastic syringeand 9 ml added to four siliconed 
glass centrifuge tubes, each containing 1 ml of 3.8/i sodium citrate at 4°C.
Hith minimum delay, the tubes were centrifuged at 600 g for 5 minutes at 4°0
m Onand the resulting platelet rich plasma pooled. The plasma was maintained at 4 0 
until the experiment was started. It has been shown that cooling increases 
the tendency of platelets to aggregate (Born, 1962b). However, without a 
constant temperature laboratory this was found to be the most satisfactory 
method of handling the plasma samples to obtain reproducible results.
Estimation of platelet aggregation. Two identical Chandler loops were prepared 
as described in Chapter 3. 6 ml, platelet rich plasma were added to each
loop, to one loop was added a volume of the compound under investigation and 
to the second loop an equal volume of 0,9 per cent saline. The volume in
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both loops was made up to 15 ml with 0.9 per cent saline and both loops 
and their contents incubated at 37°C for 10 minutes. At the end of the 
incubation period, both loops were recalcified with 0.6 ml of 0.25 M CaCl2 and 
the time for the appearance of the 'snowstorm1 of platelet aggregates to 
occur was recorded.
Fibrinogen clotting times. The ability of the proteolytic enzyme, trypsin, to 
convert plasma prothrombin to thrombin was assayed by the following method.
0.3 ml, human prothrombin and 0.3 ml of the enzyme preparation were incubated 
together at 37°C for 10 minutes. 0.2 ml of the incubation mixture was then 
added to 0.2 ml of human fibrinogen (4 mg/ml) at 37°C and the clotting time 
recorded. 0.3 ml, distilled water replaced the enzyme preparation in the 
control experiment.
Pla^ inQ recalcification times. The effect of the enzymes trypsin and strepto­
kinase on plasma recalcification times was estimated by the following method. 
Blood was collected by clean venepuncture and added to centrifuge tubes 
containing O.O77II sodium EDTA in the ratio: of 9*25 volumes of blood to 0.75 
volumes of EDTA. Plasma was obtained by centrifugation at 600g for 10 
minutes. 0.1 ml of the enzyme preparation was added to 0.2 ml plasma.
After 10 minutes incubation at 37°C the mixture was recalcified with 0.2 ml, 
M/4 0  CaCl and the clotting time recorded.
The incorporation of fibrinogen into the Chandler thrombus was investigated 
with radioactive iodine tagged fibrinogen. 0.5 ml of the fibrinogen solution
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was added to 6 ml, platelet rich plasma in the Chandler loop and the 
final volume made up to 15 ml with 0.9 per cent saline. The test loop 
was treated similarly. Both loops and their contents were incubated 
at 37°C for 10 minutes. A 1.0 ml sample of the fluid in each loop was 
taken and the samples counted for radioactive content on a scintillation 
counter (Scaler 1700, Isotope Developments Ltd.). The remaining samples 
in both loops were recalcified simultaneously with 0.56 ml, 0.25 E CaCl^. 
After platelet aggregation and any subsequent fibrin formation had occurred 
the fibrin clot or the platelet clumps were separated from the supernatant 
and washed twice with 0.9 per cent saline. The material remaining was 
then counted. A 1.0 ml sample of the supernatant from each loop was 
also counted at the end of the experiment. The results were expressed 
as percentages of the radioactivity present in the initial 15 ml sample.
The one stP_ge -prothrombin time assay was performed by the method of Quick 
(1935) as described by Douglas (l962d). 0.1 ml, human brain extract, 0.1
ml, plasma and 0.1 ml, adenosine or distilled water were incubated at 
37°G for 10 minutes. The system was recalcified by the addition of 0.1 ml, 
fl/ 4 0  CaCl2 and the time for clot formation to occur recorded. The 
preparation of brain was made from a human brain by saline extraction as 
described by Douglas (l962f).
The tfrmnrtvip time assay was carried out as described in chapter
3.
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The streptokinase sensitivity test was carried out as described in chapter 
3.
Results.
Effect of Streptokinase^ The effect of streptokinase on platelet aggregation 
was investigated with eleven plasma samples. A streptokinase sensitivity- 
test was performed on each sample before platelet aggregation was assayed. 
Streptokinase was used in the Chandler loop at the concentration which produced 
maximum lytic activity. It was found that, at this concentration, streptokinase 
produced a marked acceleration of platelet aggregation in every plasma sample 
investigated. The results are illustrated in figure 5 and are tabulated in 
table 26. The mean time for platelet aggregation to occur in the control 
loops was 382 - 110 seconds and in the test loops 276 - 81 seconds { t =  6.602, 
p<£0.001). It was also noted that streptokinase caused a marked decrease in 
fibrin formation, with in some cases, complete failure of fibrin formation to 
occur as a sequel to platelet aggregation.
Effect of Trypsin. The effect of trypsin at a concentration of 10yug/ml 
plasma was investigated with seven plasma samples. As with streptokinase, 
trypsin produced significant acceleration of platelet aggregation in every plasma
sample investigated. The meantime for platelet aggregation in the control
+* 4“
loops was 457 - 115 seconds and in the test loops 151 - 41 seconds
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(t = 7 o764, p^ 0.001; figure 6, table 27)* Trypsin did not appear to 
be as effective as streptokinase in preventing fibrin formation since a 
fibrin clot formed in every plasma sample. This difference was eliminated 
when the concentration of trypsin was increased to 1 mg/ml. Re calcification 
was carried out in both the test and control loops immediately after the 
addition of trypsin to the test loop. Under these conditions, trypsin 
produced marked acceleration of platelet aggregation in each of the seven
plasma samples investigated. The mean time for platelet aggregation in
4* 4*
the control loops was 666 — 64 seconds and in the test loops, 49 - 20
seconds ( t = 26.491» P< 0 .001; figure 7» table 28). In addition it was
noted that, as with streptokinase, trypsin caused impaired fibrin
formation to such an extent that fibrin formation failed to occur in some
of the trypsin treated plasma samples.
To further investigate the observation of defective fibrin formation,
1310.5 ml, I tagged fibrinogen was added to the plasma in both the 
test and control loops in a series of four plasma samples, and equilibration 
allowed to proceed at 37°C for 10 minutes. 0.3 ml, trypsin was added to 
the test loop to give a concentration of 1 mg/ml plasma, 0.3 ml, 0.9 
per cent saline added to the control loop, the contents of each loop 
thoroughly mixed and a 1.0 ml sample taken from each loop. The loops 
were immediately recalcified and the experiment carried out as described 
above. The results were expressed as percentages of radioactivity present
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in the initial 15 ml samples in each loop and are shown in table 1. The 
figures confirm the qualitative observation of impaired fibrin formation in 
the presence of trypsin; in the control samples the major portion of the 
radioactivity was incorporated into the thrombus, while in the trypsin treated 
samples the bulk of the radioactivity remained in the supernatant and only 
a small percentage was incorporated into the platelet clumps.
An important activity of trypsin in plasma has been shown to be the 
conversion of prothrombin to thrombin (Ferguson et al., 1960; Ferguson and 
Ennis, 1963; Stormorken, 1956; Yin, 1964). Thrombin is the highly specific 
proteolytic enzyme which brings about blood coagulation by the conversion of 
fibrinogen to fibrin and in addition it has been shown that trace quantities of 
thrombin are sufficient to promote platelet aggregation (Haslam, 1964; Schmid 
et al., 1962; and Shermer et al., 1961)« To further investigate the effect 
of trypsin on platelet aggregation the following experiments were carried out.
The effect of trypsin, at a concentration of 10^ig/ml, on platelet 
aggregation in a non-recalcified plasma system was investigated with two 
plasma samples. As the diluted plasma in the loops was rotated at 37°C the 
plasma took on a ’ground glass' appearance but no overt platelet snowstorm 
effect was seen. Microscopic examination revealed small platelet clumps 
consisting of approximately 10 to 50 platelets to be present in both the 
control and trypsin treated plasma specimens. There appeared to be no
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significant difference between the control and the trypsin treated .plasma 
specimens, an observation suggesting that during the incubation of trypsin and 
plasma, under the experimental conditions of the system, no significant 
conversion of prothrombin to thrombin occurred. In an attempt to substantiate 
this hypothesis, the effect of trypsin on human prothrombin was investigated with 
a fibrinogen clotting time assay system. Human prothrombin and trypsin were 
incubated at 37°C for 10 minutes and the presence of any thrombin generated 
during this time was detected by the ability of a sample of the incubation 
mixture to convert human fibrinogen to fibrin. The results are shown in table 
2. It would seem that trypsin at a concentration of 10yUg/ml does not cause 
significantly greater conversion of prothrombin to thrombin than that which 
occurs in the saline control. From the results it would seem that trypsin at a 
concentration of 1 mg/ml is causing some inhibition of the formation of thrombin. 
An explanation for the grossly prolonged clotting time observed would be that 
sufficient trypsin is being carried over from the incubation mixture to cause 
the digestion of fibrinogen. In view of these findings, the effect of trypsin 
in promoting platelet aggregation cannot be convincingly explained solely on 
the basis of its action on the conversion of prothrombin to thrombin.
Consequently further clarification of the results was sought by the examination 
of the effect of trypsin on platelets.
The effect of trypsin on platelets was investigated by comparing the
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alteration in the speed of formation of platelet aggregates resulting from 
the incubation of trypsin and platelet poor plasma with that produced by 
incubation of trypsin and platelet rich plasma. In this series of experiments 
platelet rich plasma was divided into two equal portions. One sample was 
centrifuged at 1600 g for 15 minutes to yield platelet poor plasma which was 
divided into two, 3 ml samples. Each sample was added to a Chandler loop, 
to one sample was added 0.3 ml, trypsin to give a final concentration of 10yug/ 
ml plasma and to the control sample was added 0.3 ml, 0.9 per cent saline.
After 10 minutes incubation at 37°C, 0.3 ml, soybean trypsin inhibitor (to give 
a final concentration of 10yug/ml plasma) was added to each loop together 
with 3 ml of the initial platelet rich plasma sample. The final volume in 
both loops was made up to 15 ml with 0.9 per cent saline and the loops recal­
cified in the usual way. The experiment was performed on seven plasma samples 
and the results are shown in figure 8 and table 29. Incubation of trypsin 
with platelet poor plasma appeared to produce no significant enhancement of 
platelet aggregation. The mean time for platelet aggregation in the control
j_ -f- /
loops was 504 - 236 seconds and in the test loops 307 - 124 seconds vt = 2.970, 
< 0.025). The experiment was repeated with a further seven plasma samples 
but with the timing of addition of platelet rich and platelet poor plasma 
reversed* There appeared to be significant acceleration of platelet 
aggregation produced by the incubation of trypsin with platelet rich plasma 
(figure 9, table 30). The mean time for platelet aggregation in the control
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loops was 462 — 114 seconds and in the test loops 208 -  122 seconds 
(t = 4,500, p^O.Ol). These observations would seem to suggest that 
platelets themselves make some contribution to the effect of trypsin on 
platelet aggregation.
Though in the Chandler tube system of estimating platelet aggregation, 
platelet aggregation is followed by fibrin formation, the results 
presented above seem to indicate that the appearance of platelet aggregates 
can be accelerated in the absence of direct enhancement of the initial enzy­
matic reactions which promote fibrin formation and hence the clotting of 
plasma. Further suggestive evidence for this view was obtained by the 
examination of the effect of trypsin and streptokinase in a recalcification 
system. Plasma was incubated with the enzyme preparation for 10 minutes 
at 37°C, the system recalcified and the clotting times recorded. The 
results are presented in table 3 and show that as the concentration of 
trypsin increased the recalcification time became longer; the higher the 
concentration of trypsin added to the system, the less effect it had on the 
system. This is the reverse of the situation found in the Chandler tube 
system where higher concentrations of trypsin produce greater acceleration 
in the rate of formation of platelet aggregates. The effect of 
streptokinase (2,000 N.I.H. units/ml) was particularly striking. At a
concentration which can enhance platelet aggregation (Chapt. 5)> 
streptokinase produced gross prolongation of the time taken for clot
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formation to occur.
Of the many phsiological compounds studied, adenosine-di-phosphate 
(ADPj appears to be the most potent stimulator of platelet aggregation both 
in vitro (Born, 1962b; Gaarder et al., 1961; Hellem, 1960; Hellem et al., 
1963; Mitchell and Sharp, 1964; O'Brien, 1962a; Ollgaard, 1961; Zucker 
and Borrelli, 1962) and in vivo (Bom and Cross, 1963c; Davey and handler, 
1964; Regoli and Clark, 1963). ADP has also been shorn to produce transient 
platelet thrombi in rats (Hordoy and Chandler, 1964). Thus it was considered 
likely that ADP might influence the formation of platelet aggregates in 
the Chandler tube system.
Effect of Adenosine-di-phosphate. The effect of ADP on platelet aggregation 
was investigated with ten plasma samples. 0.3 ml of ADP (10yog/ml) was 
added to the test loop and 0 .3 ml, 0 .9 per cent saline added to the control 
loop immediately before recalcification. ADP produced a marked acceleration
of platelet aggregation in every sample. The mean time for platelet
-j-
aggregation to occur in the control loops was 655 - 152 seconds and in the 
test loops 583 - 117 seconds, (t = 4 .824, p < 0 .001; figure 10 and table 31)«
In the test loop, to which ADP had been added, small discrete platelet 
clumps became visible some time before the actual 'snowstorm' effect was 
apparent. This result suggested that platelet aggregation could be 
accelerated by a biochemical pathway not dependent on the enzymatic cascade 
sequence (Biggs and Macfarlane, 1962a), which leads to the formation of
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thrombin and fibrin clot formation® Corroborative evidence was obtained 
when the effect of ADP was examined in recalcified and non-recalcified 
plasma specimens. ADP (0.5yug/ml plasma) was added to plasma in both the 
test and the control loops but only the control loop was recalcified.
In the seven plasma samples investigated no significant difference was 
found between the rate of formation of platelet aggregates in the recalcified 
and non-recalcified samples (figure 11 table 52). The mean time for 
platelet aggregates to form in the control loops was 85 1  66 seconds anH in 
the test loops 59 - 20 seconds, (t = 0.958, p<0.4)# Further confirmation 
of the suggestion that the appearance of platelet aggregates in the Chandler tube 
is to some extent at least independent of the forces promoting clot formation 
came from the investigation of adenosine, a specific inhibitor of the 
adenine nucleotides.
Effect of Adenosine. The effect of adenosine was investigated with seven 
pl.asma samples. 0 .6 ml, adenosine ( 1 mg/ml) was added to the test loop,
0 .6 ml, 0 .9 per cenl^ added to the control loop and both loops incubated for 
10 minutes at 57°C before recalcification. As was anticipated, adenosine 
was found to cause retardation of platelet aggregation in every plasma sample 
(figure 12 and table 35). The mean time for platelet aggregation to occur
*4"
in the control loops was 377 - 62 seconds and in the test loops 460 - 65 
seconds, (t = 6.606, p < 0.001). It was noted that in some of the adenosine 
treated samples the normal Snowstorm1 of platelet aggregates did not occur 
but a large clump of platelets appeared immediately before fibrin formation
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occurred.
The effect of adenosine on the conversion of prothrombin to thrombin 
and on the reaction between thrombin and fibrinogen was investigated in a 
one stage prothrombin time assay and in a thrombin clotting time assay.
In the one stage prothrombin time assay, adenosine was incubated with tissue 
thromboplastin and plasma at 37°C for 10 minutes before the system was 
recalcified. Table 4 shows that adenosine,over a range of concentration 
100yug/ml plasma to 1 mg/ml plasma, caused no inhibition of the conversion 
of plasma prothrombin to thrombin. Similarly, in the thrombin clotting time 
assay, incubation of adenosine, over the range of concentrations 100yug to 
1 mg per ml plasma, with plasma and ’thrombin time mixture’ (Chapt. 3) at 
37°0 for 10 minutes produced no inhibition of the thrombin fibrinogen reaction 
(table 5). These results suggest that in the Chandler tube system, platelet 
aggregation per se and not the complete coagulation process, is being inhibited 
by adenosine.
In view of the results which suggested that the action of trypsin on 
platelet aggregation might be mediated through a pathway which did not 
involve thrombin, it was considered pertinent to investigate the possibility 
that the ADP mechanism of platelet aggregation might be involved.
Effect of trypsin and ADP. The effect of the combined action of ADP and 
trypsin on platelet aggregation was investigated in a series of seven plasma 
samples. For this experiment 54 ml of blood were withdrawn from each
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subject. Three Chandler loops were prepared, 6 ml of platelet rich
plasma added to each loop, 0 .3 ml, trypsin (200 yog/ml) added to one loop,
the volume in each loop made up to 14.7 ml with 0 .9 per cent saline and all
the loops incubated at 37°C for 10 minutes. After the addition of 0.3 ml,
0.9 per cent saline to the control loop, 0.3 ml ADP (10yUg/ml) was added to
the other two loops and each loop was recalcified. The results are shox-m in
figure 13, table 34. The combined action of trypsin and ADP appeared to be
more effective in promoting acceleration of platelet aggregation than the
action of ADP alone. The mean time for aggregation to occur in the control
loops was 590 - 194 seconds, in the ADP treated loops 349 - 67 seconds and in
the ADP plus trypsin treated loops 137 - 70 seconds. The results of
statistical analysis of these differences were, for the control and ADP treated
loops, t = 2.970, p<0 0.025 and for the ADP and ADP plus trypsin treated loops,
t = 8.194, p < 0.001. During this experiment the time betxreen the appearance of
platelet clumps and of fibrin strands was recorded in the ADP and ADP plus
trypsin treated loops. There was found to be no significant difference between
the two loops (table 6). The mean time interval between platelet aggregation
+
and fibrin formation in the ADP treated loops was 46-16 seconds and in the 
ADP plus trypsin treated loops 58 - 31 seconds, (t = 1.704, p^0.20).
Additional evidence in support of the suggestion that the ADP mechanism 
for platelet aggregation might be involved in the enhancement of aggregation 
by trypsin w a s  obtained from the investigation of the combined action of
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trypsin and adenosine.
Effect of trvnsin and adenosine. The effect of the combined action of 
trypsin and adenosine on platelet aggregation was investigated with sixteen 
plasma samples. 0 .3 ml of trypsin (200yug/ml) was added to 6 ml plasma in 
two Chandler loops, 0.6 ml of adenosine (l mg/ml) was added to the test loop 
and the volume in both loops made up to 15 ml with 0 .9 per cent saline.
After 10 minutes incubation at 37°0, both loops were recalcified„ The results 
are shown in figure 14 and table 35- At the concentrations of trypsin and 
adenosine used there appeared to be only slight inhibition of platelet aggregation 
in the adenosine treated sample. The mean time for platelet aggregation to occur 
in the control loops was 96 - 28 seconds and in the test loops 139 - 71 
seconds, (t = 2.284, p<0.05)o The experiment was repeated with a further 
series of seven plasma samples in which the concentration of trypsin was kept 
at 10 yug/ml plasma but the concentration of adenosine was increased to 2 0 0yUg/ml 
plasma. In every plasma sample, platelet aggregation was significantly re- 
tarded in the adenosine treated loop (figure 15, table 36). The mean time for
platelet aggregation to occur in the control loops was 96 - 35 seconds and 
in the adenosine treated loops 135 - 42 seconds, (t = 4.289, p < 0 .0l).
Discussion.
The investigation of the effect of the enzymes trypsin and streptokinase 
shows that these enzymes can cause acceleration of platelet aggregation and,
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in consequence, acceleration of the rate of formation of a thrombus in an 
artificial circulation. This observation together with results of the 
investigations of the effect of the adenine nucleotides on platelet 
aggregation in vitro suggest that the formation of the thrombus in the 
Chandler tube system is not solely dependent on the generation of thrombin 
in the system.
Platelet aggregation and fibrinolytic enzymes.
Trypsin has been shown to promote blood coagulation in plasma (Douglas 
and Colebrook, 1916; Eagle and Harris, 1937; Northrop and Kunitz, 1932; 
otormorken, 1956). The coagulative action of trypsin has been demonstrated 
to be due to its ability to convert prothrombin to thrombin (Ferguson et al., 
1960; Ferguson and Ennis, 1963; otormorken, 1956; Yin, 1964). Many workers 
have demonstrated the ability of thrombin to promote platelet aggregation 
(Bounameux, 1956 and 1957; Haslam, 1964; Uuscher, 1956; O'Brien, 1964;
Schmid et al., 1962; Shermer et al., 1961; Zucker and Borrelli, 1959).
Thus, it might be supposed that the effect of trypsin on platelet aggregation 
is an effect which is secondary to its action on prothrombin. The results 
presented above, however, indicate that the action of trypsin cannot be 
accounted for solely on this basis and that its activity as a fibrinogenolytic 
agent may also be of considerable importance. This view is supported by the 
similarity of the results obtained for the fibrinolytic enzyme, streptokinase 
which possesses both fibrinolytic and fibrinogenolytic activities but has no 
coagulation properties.
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The examination of the effect of trypsin in a re calcification system 
(table 3) indicates that coagulation can be enhanced even in the absence of 
calcium ions, a result in agreement with the findings of Stormorken (l 956) 
who has also shown that the effect of trypsin on coagulation is increased as 
the concentration of calcium is increased. The action of trypsin on platelet 
aggregation, however, appears to be independent, at least within the 
physiological range, of the concentration of calcium ions since no difference 
could be detected between the effect of trypsin on platelet aggregation in 
citrated platelet rich plasma in a recalcified and non-recalcified system.
A further difference between the effect of the enzyme on coagulation and on 
platelet aggregation becomes apparent when its actions over a range of 
concentrations are compared. As the concentration of trypsin is increased 
so its effect on the acceleration of platelet aggregation is increased (table 
27 and table 28) but its effect on the recalcification time is decreased 
(table 3). Thus, platelet aggregation may be enhanced by trypsin under 
conditions in which the coagulative properties of the enzyme are diminished.
The two systems are not directly comparable, however, since in the recalcification 
system after 10 minutes incubation at 37°C with trypsin (lOyug/inl) a clot 
formed in the plasma but was not observed to form in the Chandler loop until 
after recalcification. This difference may, at least in part, be accounted 
for by the use of non-siliconed glass tubes for the collection of the blood 
and the assay of the plasma in the recalcification system as opposed to the
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use of siliconed glassware and ' non-wet table1 surfaces in the Chandler tube 
system.
In addition to its coagulative properties, trypsin may act as a 
fibrinogenolytic enzyme (Fletcher et al.f 1962 and Mihalyi and Godfrey, 1963a). 
As the concentration of trypsin is increased in plasma, its fibrinogenolytic 
activity may gain ascendency over its coagulative properties. Some evidence 
to support this view is obtained from the investigation of the fate of 
radioactive tagged fibrinogen in the Chandler tube system (table l).
Additional evidence is also obtained from the investigation of the ability of 
trypsin to convert prothrombin to thrombin (table 2). In this experiment 
clear cut conclusions may not be drawn from the results, however, since while 
trypsin may be carried over from the incubation mixture which may then rapidly 
digest the fibrinogen, trypsin may also digest thrombin (Eagle and Harris,
1937) formed in the reaction mixture.
The evidence obtained from the experiments in which the effect of trypsin 
on platelet aggregation after incubation with platelet poor plasma was compared 
to that after incubation with platelet rich plasma (figures 8 , 9 and tables 
29, 30), suggests that platelets make some contribution to the tryptic effect. 
Several workers have studied some of the effects of trypsin digestion of 
platelets. Schmid et al., (1962) have demonstrated that the treatment of 
washed platelets with high concentrations of trypsin (50yug per ml platelet 
suspensions) abolished the ability of platelets to aggregate with thrombin and
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caused irreversible damage to the platelets. Haslam (1964-) has shown that 
treatment of washed platelets with high concentrations of trypsin (0 .2 m g/ml) 
abolished their ability to aggregate with ADP while low concentrations of 
trypsin (0 .2 ^ig/ml) resulted in the rapid and complete aggregation of platelets 
in the presence of calcium ions. Prom the results presented above it would 
appear unlikely that incubation of trypsin with platelet rich plasma produces 
irreversible damage to the platelets since not only is there no visible 
diminution of the 'snowstorm* of platelet aggregates but also the formation 
of the platelet clumps is accelerated. This contention is also supported by 
results presented in Chapter 5.
One possible explanation of the enhancement of platelet aggregation by 
trypsin may be found by consideration of the observations of Grette (1962) who 
has shown that the treatment of platelets with trypsin may result in a release of 
phospholipid, serotonin and ADP from the platelet, an effect which is similar 
to that produced by the action of thrombin on platelets. Since trypsin can 
promote the acceleration of platelet aggregation under conditions in which 
coagulation is not enhanced, it is unlikely that phospholipids or serotonin 
play a primary role in the action of the enzyme on platelet aggregation.
Hence it is possible that the effect of trypsin may, at least in part, be 
mediated through ADP. This hypothesis is substantiated by the evidence for the 
additive effect of ADP and trypsin produced by their combined action on platelet 
aggregation (figure 13 and table 34) and by the observation that the effect
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of trypsin can be blocked by adenosine, the specific inhibitor of the 
adenine nucleotides (figure 15 and table 36).
Platelet Aggregation in the Chandler tube system.
The Chandler tube system assesses platelet aggregation by virtue of the 
ability of platelets to adhere to each other with the formation of platelet 
clumps in an artificial circulation system. The mechanism by which the 
phenomenon of platelet aggregation occurs in this system has not been 
fully elucidated but some factors which may contribute to thrombus formation 
are known.
The results presented above for the action of streptokinase on plasma 
coagulation in a simple recalcification system and on thrombus formation 
in the Chandler tube (figure 5 tables 3, 36), offer strong circumstantial 
evidence that the stimulus to the formation of platelet aggregates is not 
due solely to the generation of thrombin. Supporting evidence is found in the
similar observations for trypsin in both coagulation systems and in the 
Chandler tube system (figures 6 , 7, tables 3, 27, 28). Further, it has been 
shown that the appearance of platelet aggregates in this system may be 
enhanced by ADP (figure 10, table 31) and inhibited by adenosine (figure 12, 
table 32). Gaarder and Laland (1964) have proposed a hypothesis to account 
for the ability of ADP to enhance platelet aggregation. They suggest that 
ADP may stimulate the adhesion of platelets to each other by the formation of 
hydrogen bonds between the platelets and ADP molecules. It is possible that 
a similar mechanism operates in the Chandler tube system. The initial
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molecules of ADP necessary to promote the first steps in the adhesion of 
platelets may come from the plasma by virtue of ADP released from any red 
cells hemolysed during the centrifugation process to produce the plasma 
or from any platelets damaged during the subsequent handling process.
Hovig and Holmsen (l 963) have shown that collagen fibres may release ADP from 
the platelets. The mechanical stress produced by the rotation of plasma 
in contact with a foreign surface may also be sufficient to promote ADP 
release from platelets. It has been demonstrated that during the process of 
platelet adhesion further ADP is released from the platelets (Born, 1956b;
Zucker and Borrelli, 1961) which enables a large platelet clump to form.
Hence, once the initial stimulus to platelet aggregation is present the chain 
reaction of formation of platelet clumps and thrombus formation (Hellem and 
Owren, 1964) follows. Thus it is possible that, in the Chandler tube system, 
the initial stimulus to platelet aggregation may be ADP.
Conclusions.
From the results presented in this chapter it would appear that the 
enzymes streptokinase and trypsin possess the ability to accelerate the formatior 
of platelet aggregates in the Chandler tube system. The effect of trypsin 
cannot be accounted for solely by its coagulative action or its action 011 
platelets per se. However, its action does appear to be mediated in some 
way through the ADP mechanism of platelet aggregation. It would also 
appear that the formation of platelet aggregates in the Chandler tube system 
cannot be accounted for solely on the basis of thrombin generation and that 
the ADP mechanism is implicated in the generation of platelet aggregates.
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CHAPTER 5.
STUDIES OH THE EFFECT OF STREPTOKINASE ADD TRYPSIIT OH 
PLATELET AGGREGATION IN THE TUHBIDB1ETRIC SYSTEM.
In this chapter are presented the results of the investigations of the 
effect of the enzymes, streptokinase and trypsin, on platelet aggregation 
in platelet rich plasma.
One of the disadvantages encountered in the artificial circulation system 
(Chapter 4), is that fibrin formation invariably occurs as a sequel to 
platelet aggregation. As a result, it is sometimes difficult to define 
whether a compound under investigation in this system, is acting specifically 
on platelet aggregation or is causing some alteration of the general 
haemostatic process since both reactions could be reflected by a change in 
the rate of formation of platelet aggregates. Trypsin has been demonstrated 
to be able to promote coagulation by its ability to convert prothrombin to 
thrombin (Ferguson et al., 1960; Ferguson and Ennis, 1963; Stormorken, 1956; 
Yin, 1964). From the results presented in Chapter 4 it was concluded that the 
apparent ability of trypsin to cause acceleration of the rate of formation 
of platelet aggregates in an artificial circulation might be mediated through 
the action of ADP. Consequently, in an attempt to further elucidate the 
relationship between trypsin and platelet aggregation, the action of 
trypsin on ADP induced aggregation was investigated under conditions in
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which fibrin formation does not normally occur.
In the Chandler tube system (Chapter 4) it was demonstrated that 
streptokinase appeared to be able to enhance platelet aggregation and 
it was suggested that this effect might be mediated through its 
ability to activate plasminogen with the formation of plasmin (Troll 
and Sherry, 1955). This has been further investigated in the 
turbidimetric system.
Trypsin is a proteolytic enzyme and although streptokinase is not 
itself directly proteolytic, plasmin which is produced by its activity 
can digest many proteins. In an attempt to determine whether the 
ability of trypsin and streptokinase to enhance platelet aggregation 
is specific to these enzymes or is common to other proteolytic enzymes, 
the effects of urokinase, ficin and chymotrypsin on ADP induced platelet 
aggregation have also been investigated.
Heparin, although not a fibrinolytic agent, has been included 
with the proteolytic enzymes because it can influence the dynamic 
balance between coagulation and fibrinolysis. It can suppress 
coagulation by interfering in the interaction of thrombin and 
fibrinogen and by the prevention of the conversion of prothrombin to 
thrombin by the blood thromboplastin system (Douglas, 1962a).
Heparin was first isolated from liver by Howell and Holt (191Q) and
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has been identified as an acidic mucopolysaccharide consisting,
of a polymer of D-glucuronic acid and D-glucosamine (Douglas, 1962b).
This compound has also been shown to affect the behaviour of platelets. 
Large doses of heparin administered intravenously prevent platelet plug 
formation in cut vessels (Zucker, 1947) but high concentrations of 
heparin applied locally are not as effective (Hugues, 1959) and will 
not prevent platelet clumping induced with mesenteric fibres (Hugues, 
1962; -Spaet and Zucker, 1964). In vitro heparin also inhibits thrombin 
induced platelet clumping (Clayton and Cross, 1963; Cuthbertson and 
Mills, 1963b; Zucker and Borrelli, 1959) and can delay thrombus 
formation in vitro by causing an inhibition of the initial stages of 
the process which involves platelet aggregation (Cunningham et al.,
1965)o The effect of this anticoagulant drug on ADP induced platelet 
aggregation in vitro has been investigated and the results are 
presented in this chapter.
Materials.
ITor-Adrenaline was obtained in the form of bitartrate from Koch Light
Laboratories Ltd. It was made up to the required concentration with
o_
0.9 per cent saline and stored at 4 C,
Chyrnntrypgin was used in the formed chymotrypsin, type II, prepared
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from bovine pancreas as supplied by the Sigma Chemical Company,
St. Louis. The enzyme was dissolved in 0.9 per cent saline to the 
required concentration and stored at 4°C.
Ficin prepared from fig latex was obtained from Koch Light Laboratories 
Ltd. The enzyme was diluted with 0.9 per cent saline to the required 
concentration and stored at 4°C.
Urokinase was supplied by Leo Pharmaceutical Products, Denmark. The 
enzyme was dissolved in distilled water to give a concentration of 
2,000 Sgouris units per ml and this stock solution was stored at-20°C. 
The preparation was further diluted as required.
Heparin. The preparation of heparin used was supplied by Weddel 
Pharmaceuticals, London at a concentration of 50 mg per ml (5,000 
units per ml). It was diluted with 0.9 per cent saline to the required 
concentrations.
Fibrinogen in the form of human lyophilized, Grade L, was supplied by 
A.B. Kabi, Stockholm. The protein was dissolved in 0.9 per cent 
saline to the required concentrations and was stored at-20°C.
Details of the preparations of streptokinase, trypsin, ADP, adenosine, 
thrombin and radioactive fibrinogen are described in Chapter 5.
Calcium Chloride was made up to give solutions of 0.25 M, 0.11 M,
69o
0.01 M and 0.0025 K and the molarity of these solutions was checked 
by titration before use as described in Chapter 4 .
Phosuhate 3-uffer. Phosphate buffer of 0.1 molar and pH J 0 6  was
prepared as described in Chapter 3®
Barbitone saline was prepared as follows:- 0.9 g, HaCl; 0.1 g, HaHCO 
made up to 1,000 ml with distilled H^O.
Bicarbonate saline citrate was prepared as follows:- 0.9 g ,  HaCl; 0.1 g, 
ITaHCO • 2.94 g, Bacitrate; distilled water to 1,000 ml.
Tris buffers. Tris buffer, 0.1 PI and pH 7.5 was made up as follows:- 
25 ml, 0.2 II tris (hydroxy-methyl) aminomethane (24®2 g per litre); 20 ml, 
0.2II HCl made up to 100 ml with distilled H^0.
Tris buffer, 0.154 H and pH 7®2 was prepared as follows:- 
25 ml, 0.308 I-I tris (hydroxy-methyl) aminomethane (37.3 g per litre);
22.1 ml, 0.308II HCl made up to 100 ml with distilled H^O.
Tris buffer, 0.154 II and pH 8.2 was prepared as follows:- 
25 ml-, O.3O8 M tris (hydroxy-methyl) aminomethane (37*5 g per litre);
11 ®0 ml, O.3O8II HCl made up to 100 ml with distilled H^O.
’Platelet suspension mixture* was prepared by the addition of sodium
"J
chloride (1.4X10 M), potassium chloride (2.3 x 10 M) and calcium
70.
chloride (l .7 x 10 ) to 0.114 tris buffer, pH 7 .5.
It was made up as follows:- I'TaCl, 0.817g; KC1, 0.0164g; CaCl^, 
0.0l82g; 0.1M tris buffer, pH 7 .5 to 100 ml.
Potassium chloride was prepared at a concentration of 0.154 molar by- 
dissolving 1 „15g, KC1 in 100 ml distilled H^O.
Magnesium Sulphate was prepared by dissolving 1.85 g % S 0^ in 100 ml 
distilled water to give a concentration of 0.154 molar.
Sodium chloride was prepared at a concentration of 0.154 molar by 
dissolving 0.836 g HaCl in 100 ml distilled H^0.
Sodium HDTA of 0.077M was prepared from 2.867g» ethylene diaminotetra- 
acetic acid, disodium salt and distilled water to 100 ml.
Platelet rich -plasma was prepared and stored as described in Chapter 
4 except that only 18 ml of blood were collected from each 
volunteer.
Platelet noor -plasma was prepared as described in Chapter 4 .
Methods
Estimation of -platelet aggregation. Two EEL titrator and galvanometer 
systems were used simultaneously in all the experiments described 
in this chapter. Each platelet rich plasma sample was divided, to one
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ml sample was added the substance under investigation and to a second 
2 ml sample an equal volume of 0.9 per cent saline as a control. The 
control and test plasma samples were randomly allocated between the two 
titrator systems. Unless otherwise stated, the cuvettes containing 
the control and test plasma samples were incubated with a volume of 
saline and an equal volume of test substance respectively, at 37°C for 
10 minutes before being transferred to the titrators. The actual 
estimation of platelet aggregation was carried out simultaneously on 
each plasma sample at room temperature.
Preparation of washed platelet suspensions. The first method used was 
that described by Born and Cross, (1964-). 12 ml of citrated platelet rich 
plasma was prepared as described in Chapter 4 and from this platelet poor 
plasma obtained by centrifugation at 1 ,500 g at 4°C for 15 minutes. The 
platelet pellet was resuspended in 6 ml of bicarbonate saline citrate and 
centrifuged once more at 1,600 g for 15 minutes. This procedure was 
repeated once with bicarbonate saline citrate and once with bicarbonate 
saline. The platelets were finally resuspended in 6 ml of the ’platelet 
suspension mixture' at 4°C and were maintained at 4°C until the assay 
of platelet aggregation was performed.
The second method used was that described by Haslam, (1964). Bor 
this experiment 92.5 ml of blood were withdrawn by clean venepuncture 
from a volunteer and anticoagulated by addition to 0,077 ^ sodium SDTA
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in siliconed glass centrifuge tubes at 4°C in the ratio, 9.25 ml of 
blood to 0.75 ml EDTA. The blood was centrifuged at 300 g for 15 
minutes at 4°C to obtain platelet rich plasma which was then centrifuged 
at 750g for 15 minutes at 4°C. The platelet pellet was resuspended in 
a volume, equal to that of the initial platelet rich plasma, of a washing 
mixture composed of 90 vol$ 0.154 U UaCl : 8* vols, 0.154 H tris buffer, 
pH 7.2: 2 vols,0.077 m HDTA. This platelet suspension was then 
centrifuged at 250g for 12 minutes at 4°0 and the washed platelets finally 
resuspended in approximately 20 ml of a solution composed of 9 vols,0.154
M ITaCl : 1 vol, 0.154 U tris buffer, pH 7.2, to give a platelet count of
3 3 othe order of 5 x 10 per mm . This platelet suspension was stored at 4 0
until platelet aggregation was assayed. For the assay of platelet
aggregation, to each cuvette was added 1.76 ml of the platelet suspension
and 0.2 ml, 0.154 K KCl, 0.02 ml, 0.154 M %30, and 0.02 ml, 0.11 M CaCl .
4 2
This mixture was then incubated with either saline or the compound under 
investigation at 37°C for 10 minutes before the cuvette containing the 
sample was transferred to the titrator and ADP added to the system. 
Platelet counting was carried out as described in Chapter 3.
StreptokiTy-yqfi sensitivity tests were performed as described in Chapter, 3. 
Urokinase sensitivity tests were carried out in a similar manner with
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urokinase in place of streptokinase.
Destruction of the antinlasmin content of plasma was carried out by 
acid-alkali treatment of the plasma (-Alkjaersig et al., 1959). Platelet 
rich plasma was centrifuged at 1,600 g for 15 minutes at 4°0 and the 
platelet poor plasma obtained decanted from the platelet pellet. 5 ml 
of the platelet poor plasma were treated with 5 ml, 0.167 ^ HC1 at room 
temperature for 15 minutes to destroy the acid labile plasmin inhibitor, 
antiplasmin. 5 ml, 0.167 A ITaOH was then added to neutralize the acid 
and the plasma was rebuffered by the addition of 5 ml, 0.1 M phosphate buffer, 
pH 7.6. The platelets were then resuspended in 5-6 ml of this acid - alkali 
treated plasma to give a platelet count of the same order as that of the 
initial platelet rich plasma sample.
Radioactive iodine labelled fibrinogen was used to monitor the digestion
of fibrinogen occurring in the presence of streptokinase and trypsin.
1310.1 ml, ^  fibrinogen was added to the plasma samples in the
control and test cuvettes before incubation at 37°C. After thorough mixing
0.2 ml samples were removed from the control and test cuvettes and clotted 
with 0.1 ml thrombin (lOQ N.I.H. units per ml). The clot which formed was 
transferred with a clean wooden spatula to a test-tube and the radioactive 
content assessed on a scintillation counter (Scaler 1700, Isotope 
Developments Ltd.). 0.2 ml samples were again removed from the control
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and test cuvettes after platelet aggregation in the samples had been 
monitored for 10 minutes and treated similarly. The clottable protein
present after incubation and platelet aggregation was expressed as a 
percentage of that present in the initial sample.
Fibrinogen clotting times were used to assay the ability of ficin and 
chymotrypsin to convert human prothrombin to thrombin. The method used 
is described in Chapter 4.
Results.
Effect of Streptokinase. The effect of streptokinase on ADP induced 
platelet aggregation was estimated on ten plasma samples in the turbidimetric 
system. Streptokinase was studied at the concentration which produced 
maximum lytic activity as determined for each plasma sample in the 
streptokinase sensitivity test. The results are shorn in figure 16 and 
table 37. It would appear that at this concentration, incubation of plasma 
with streptokinase before the examination of platelet ADP reactivity can 
cause a significant decrease in the degree to which platelet aggregation 
occurs. 4-2 minutes after the addition of ADP to the plasma samples the 
mean optical density reading of the control samples was 0.366 - 0.203 and 
of the streptokinase treated samples 0.499 - 0.129, (t = 2.413 p^O.05).
This result is contrary to the observations made for the effect of a
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similar concentration of streptokinase on platelet aggregation in the 
Chandler tube system (Chapter 4)0 Two possible explanations for these 
converse observations may be found if the mechanism by which platelets 
aggregated differed in the two systems or if streptokins.se was made to 
exert its enzymatic action under different sets of conditions.
From the observations made for the effect of ADP and adenosine in 
the Chandler tube system, (Chapter 4), it was concluded that ADP is involved 
in the formation of platelet aggregates in this system. In Chapter 4 
it was also suggested that the action of the proteolytic enzyme trypsin 
on platelet aggregation might, at least in pert, be mediated through 
the action of ADP. It was therefore, considered most improbable that the 
different actions of streptokinase observed in the two systems could be 
accounted for by the postulation of the operation of two different 
mechanisms of platelet aggregation.
In the Chandler tube system, streptokinase was incubated with 
plasma diluted in the ratio 1 volume plasma to 1.5 volumes, 0.9 per cent 
saline, whereas in the turbidimetric system streptokinase was incubated 
with undiluted plasma. In chapter 4 it was suggested that streptokinase 
might exert its action on platelet aggregation by virtue of its ability 
to activate.plasminogen to plasmin. Plasma contains a protein,
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antiplasmin, which is the specific inhibitor of the enzyme plasmin 
(Sherry et al., 1959)» In the diluted plasma the relative concentrations 
of the enzyme and its inhibitor may become less Important and antiplasmin 
may be less effective in inhibiting the action of any plasmin formed in the 
presence of streptokinase. Thus, in an attempt to explain the unexpected 
observation for the effect of streptokinase in the turbidimetric system the 
action of this enzyme was re-examined with diluted plasma.
Streptokinase at a concentration of 100 H.I.E. units per ml plasma 
was added to seven plasma samples which were diluted with 0.9 per cent saline 
in the proportions, 1 ml plasma to 1.5 ml saline. After 10 minutes 
incubation at 37°C, ADP was added to the samples and the platelet aggregation 
which ensued followed by monitoring the changes of optical density of the 
plasma samples. Under these conditions no pattern emerged for the action of 
streptokinase on platelet aggregation in diluted plasma, figure 17 and 
table 38. There was no statistically significant difference between the 
optical density readings in the control and test samples. 3 minutes after 
the addition of ADP the mean optical density reading of the control samples 
was 0.266 - 0,119 and of the test samples 0.298 - 0 .077, (t = 1.122, p < 
0.40). This result would seem to suggest that, while the effect of 
streptokinase on platelet aggregation is not in statistical agreement with 
that for the Chandler tube system, there is some support for the concept
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of antiplasmin playing a role in the apparent inhibition of platelet 
aggregation by the enzyme in undiluted plasma; in two of the seven 
plasma samples investigated, platelet aggregation was enhanced by 
streptokinase. Another factor which must contribute to the interpretation 
of the results is the use of a fixed concentration of streptokinase for 
all the plasma samples. From the previous experiments in which 
streptokinase sensitivity tests were carried out, 100 N.I.E. units of 
streptokinase per ml of plasma was accepted as the average concentration 
of the enzyme which produced maximum lytic activity. Thus in the above 
experiment this concentration of enzyme might be insufficient to 
neutralize all the streptococcal antibodies present in the sample and 
hence the action of streptokinase could be inhibited not only by antiplasmin 
but also by non-neutralized antibodies. In an attempt to clarify the 
situation, the effect of streptokinase, at a very much increased 
concentration, on platelet aggregation in plasma in which the antiplasmin 
had been destroyed was investigated.
The effect of streptokinase at a concentration of 2,000 M.I.H. units 
per ml plasma was studied with 17 plasma samples. Each platelet rich 
plasma sample was centrifuged at 1600 g for 15 minutes, the platelet 
pellet removed and the remaining platelet deficient plasma treated with 
0,167 H HC1 for 15 minutes followed by neutralization with 0.167 k ITaOH
78.
and pH readjustment with 0.1M phosphate buffer, pH 7.6. The 
platelets were then resuspended in a sufficient volume of the antiplasmin- 
free plasma to give a platelet count similar to that of the initial 
platelet rich plasma. One portion of the platelet suspension was 
incubated with streptokinase and a second portion with saline as a control. 
Under these conditions streptokinase caused significant enhancement of 
platelet aggregation (figure 18, table 39)* 10 minutes after the
addition of ADP the mean optical density of the control samples was 
0.499 - 0.066 and of the test samples 0.430 - 0.129> (t = 2.574> p <
0.025). Thus it would appear that, in the turbidimetric system, 
streptokinase can only enhance ADP induced platelet aggregation when used 
in a sufficiently high concentration to neutralize all the streptococcal 
antibodies of antiplasmin deficient plasma.
It has been shown that nor-adrenaline is one of many physiological 
compounds which may induce platelet aggregation in vitro (Mitchell and 
Sharp, 1964; O’Brien, 1963 and 1964) • The view is currently held that 
while physiological compounds, other than ADP, may induce platelet 
aggregation it is likely that their action is mediated through ADP 
(Haslam, 1964). Thus in an attempt to elucidate the physiological 
significance of the effect of streptokinase on platelet aggregation, the 
effect of the enzyme at a concentration of 100 E.I.H. imits per ml
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plasma on nor-adrenaline induced aggregation was investigated in 10 
plasma samples. At this concentration streptokinase appeared to have 
no significant effect on nor-adrenaline induced platelet aggregation 
(figure 19, table 40). 10 minutes after the addition of nor-adrenaline
(1.0 yug per ml plasma), the mean optical density reading of the control 
plasma was 0.371 - 0.224 and of the test plasma 0.351 - 0.219, (t =
0.623, p<0.60).
In the Chandler tube system some evidence was obtained to suggest that
during the incubation of plasma and streptokinase, fibrinogen was digested
(Chapter 4). This observation has been confirmed in the turbidimetric
system by the use of radioactive fibrinogen. To five of the plasma
samples used in the investigation of the effect of streptokinase in diluted
plasma and to four of the samples in which platelet aggregation was
131induced by nor-adrenaline, 0.1 ml, I2 tagged fibrinogen was added to 
both the control and test plasma samples before they were incubated with 
saline and streptokinase respectively. 0.2 ml plasma was removed from 
both the test and control samples before incubation and clotted with 
0.1 ml thrombin (100 1J.I.H. units/ml). The clot was then counted for 
radioactive content on a scintillation counter (Scaler 1700, Isotope 
Developments Ltd.). Following incubation and after platelet 
aggregation had been monitored for 10 minutes, further 0.2 ml plasma
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samples were removed and treated similarly. The percentage clottable 
protein present after aggregation was calculated from the two results.
The figures are presented in table 7. It can be seen that, unlike the 
Chandler tube system in which fibrinogen appeared to be markedly 
digested in every plasma sample, in the turbidimetric system streptokinase 
appeared to have little effect on the fibrinogen molecule in some plasma 
samples. This observation supports the suggestion that, in some of the 
plasma samples, the action of streptokinase may be inhibited and that this 
may account for the inconsistent results obtained with streptokinase in 
this system.
Thus the effect of streptokinase on platelet aggregation appears to be 
due to its ability to activate plasminogen to plasmin. In the Chandler 
tube system the effect of the proteolytic enzyme trypsin was investigated 
as an alternative to further investigation of plasmin because of the 
difficulties in obtaining plasmin sufficiently free from contaminating 
plasma constituents. The effect of trypsin on platelet aggregation was 
studied in the turbidimetric system.
Effect of Trvps^n. The effect of trypsin, at a concentration of 10yug 
per ml, was investigated with ten plasma samples. At this concentration, 
the enzyme not only failed to enhance platelet aggregation but in some 
samples appeared to cause inhibition of aggregation.(figure 20 and
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table 41 )® One minute after the addition of ADP (0.5 yug per ml 
plasma) the mean optical density reading of the control plasma was 
0.513 - 0.061 and of the test plasma 0.544 - 0.053? (t = 2.119? P<
0.10). This result does not agree with the observations made with the
Chandler tube system (Chapter 4) in which trypsin, at a similar 
concentration produced an acceleration of platelet aggregation in every 
plasma sample investigated. However, the same ten plasma samples were 
used to examine the effect of trypsin at a concentration of 1C0yug per 
ml plasma. At this concentration trypsin treatment of plasma caused 
enhancement of aggregation in every sample (figure 20 and table 4 2).
1 g- minutes after the addition of ADP (0.5yug per ml plasma) to the system 
the mean optical density reading of the control samples was 0.529 - 
0.041 and of the test samples 0.501 - 0.041, (t = 3.925, p < 0 .005).
The effect of trypsin was even more dramatic when it was studied at a
concentration of 1 mg per ml plasma. In a series of seven plasma samples, 
trypsin, at this concentration, was added to the plasma which was 
immediately agitated. Under these conditions trypsin produced a 
marked enhancement of aggregation in every plasma sample even although 
the plasma and enzyme had not been incubated together at 37°C for 10 
minutes and no ADP was added to the system (figure 21 and table 43)•
2 minutes after the onset of agitation the mean optical density readings
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of the control samples was 0.540 - 0.041 and of the test samples 
0.263 - 0 .204, (t = 3«080, p <0.025). In three of the trypsin treated 
plasma samples small fibrin strands appeared towards the end of the 10 
minute period during which platelet aggregation was monitored. This 
may have been due to the fact that in the trypsin treated plasma samples 
no platelet disaggregation was observed and thrombus formation was 
occurring following the formation of irreversible platelet aggregates.
In an attempt to determine whether trypsin could cause enhancement of 
platelet aggregation in the absence of fibrin formation and in the absence 
of added ADP, the experiment with trypsin (l mg per ml plasma) was repeated 
with seven plasma samples which were incubated at 37°G for 10 minutes with 
streptokinase (l,000 H.I.H. units per ml plasma) before the addition of 
trypsin. Under these conditions the addition of trypsin again resulted 
in platelet aggregation as soon as agitation was commenced (figure 22, 
table 44). Thirty seconds after the onset of agitation the mean optical 
density of the control samples was 0.525 - 0.009 and of the test samples 
0.345 - 0.060, (t = 6.485, p < 0.001)„ ho fibrin strands were visible 
in any of the plasma samples investigated.
As with streptokinase, it was thought that the difference between 
the effects of trypsin, at a concentration of 10yug per ml, on platelet 
aggregation in the Chandler tube and turbidimetric systems might be due
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to the different conditions under which the enzyme was incubated with 
the plasmao Consequently, the effect of trypsin on platelet aggregation 
in plasma diluted in the same proportions as in the Chandler tube
system was investigated. Trypsin (l O^ug per ml plasma) was added
to seven plasma samples which were diluted with 0*9 per cent saline
in the proportions, 1 ml plasma to 1 .5 ml saline. After 10 minutes
incubation at 37°C, ADP (l , 0  j a g  per ml plasma) was added to the control 
and test samples. 4 minutes after the addition of ADP the mean optical 
density reading of the control plasma was 0.254 - 0.118 and of the test 
plasma 0.273 - 0.110, (t = 0.965, p<0.40). Under these conditions 
no pattern became apparent for the action of trypsin on platelet 
aggregation (figure 17, table 45)®
The action of trypsin is dependent on the presence of calcium 
ions, although the concentration of calcium is not normally critical 
for its proteolytic action. Calcium ions are present in normal 
citrated plasma since the anticoagulant, sodium citrate, does not 
effectively chelate all the calcium ions present in whole blood.
In an attempt to confirm that the action of trypsin, at low concentration, 
on platelet aggregation is independent of the concentration of 
calcium it was decided to investigate the effect, on ADP induced 
platelet aggregation, of incubation of trypsin (10 ng/ml
plasma) and plasma to which calcium had been added at the same 
concentration as used for the Chandler tube system. In order to 
prevent clot formation during the incubation period, heparin was to be 
added to the system. A pilot experiment was carried out to determine 
the minimum concentration of heparin required to prevent clot formation 
in the plasma within the period of the experiment. To 0.5 ml normal 
citrated plasma was added 0 .05 ml heparin solution and 0.05 ml, 0.25 K 
CaCl^. The time for clot formation to occur was recorded and is 
tabulated (table 8). A concentration of 10 units heparin per ml plasma 
was selected as appropriate for the experiment, A second pilot 
experiment was carried out in which heparin (10 units per ml plasma) was 
incubated with plasma at 37°C for 10 minutes before the ADP reactivity 
was estimated in the turbidimetric system. It was found that under 
these conditions heparin appeared to cause enhancement of platelet 
aggregation. The effect of heparin on platelet aggregation has been 
further investigated and will be discussed below. Thus it was not 
possible to investigate the effect of trypsin on platelet aggregation 
in the presence of a relatively high concentration of calcium. As a 
compromise, the effect of trypsin on platelet aggregation in plasma 
to which a low concentration of calcium ions had been added was 
investigated.
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In a series of seven plasma samples calcium chloride (0.25 m mole 
per ml plasma) was added to both the control and test samples and trypsin 
(lOyug- per ml plasma) to the test sample. After 10 minutes incubation 
at 37°C platelet aggregation was induced by the addition of ADP. At 
this concentration the presence of calcium chloride did not substantially 
alter the result from that obtained for trypsin at the same concentration 
in plasma to which calcium chloride had not been added (figure 23, table 
46). The mean optical density readings of the control and test samples 
1 minute after the addition of ADP were 0.372 - 0.115 and 0.331 - 0.118 
respectively, (t = 1 .363, p 0.30). The experiment was repeated with a 
further series of seven plasma samples and a higher concentration of 
calcium. Incubation of trypsin with plasma to which calcium chloride, 
at a concentration of 1.0 m mole per ml plasma, had been added resulted 
in no significant alteration of platelet aggregation from that of the 
control sample (figure 24, table 47)® 3 minutes after the addition of
ADP, the mean optical density reading of the control sample was 0.371 - 
0.196 and of the test sample 0.446 -  0.143, (t = 1 .690, p<0.20). Thus 
in the turbidimetric system the action of trypsin on platelet aggregation 
does not appear to depend on the concentration of calcium in the system.
Certain of the observations made on the action of trypsin on the 
acceleration of platelet aggregation in the Chandler tube system
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(Chapter 4), it was suggested, that the presence of platelets 
enhanced the effect of the enzyme. This possibility has been further 
examined with the turbidimetric system. In a series of seven plasma 
samples, platelet rich plasma was divided and one portion centrifuged 
at I600g for 15 minutes to obtain platelet poor plasma. The platelet 
poor plasma samples were subdivided, one portion used as a control and 
the other portion treated with trypsin (lOOyug per ml plasma) at 37°C for 
10 minutes. After incubation soybean trypsin inhibitor (lOOyug per ml 
plasma) was added to both the control and test samples together with a 
volume of platelet rich plasma equal to that of the incubated platelet 
poor plasma sample. Under these conditions trypsin appeared to have no 
significant effect on platelet aggregation (figure 25, table 48). 10
minutes after the addition of ADP, the mean optical density reading of 
the control plasma was 0.480 -  0.133 and of the test plasma 0.453 - 0.121, 
(t = 1.170, p<0.30). However, when the experiment was repeated with the 
times of addition of platelet rich plasma and platelet poor plasma 
reversed, trypsin at a similar concentration appeared to cause significant 
enhancement of platelet aggregation even in the presence of soybean trypsin 
inhibitor (figure 26, table 4 9). 10 minutes after the addition of ADP
to the system the mean optical density reading of the control samples was 
0.484 - 0.104 and of the test samples 0.448 ^  0.083, (t = 2.768, p < 0 .05)„
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It would therefore appear that platelets themselves or some factors 
closely related to platelets may act as the substrate for trypsin.
In order to determine whether platelets themselves acted as the substrate 
for the enzymatic action of taypsin, the effect of trypsin on platelet 
aggregation in a suspension of washed platelets was investigated.
In a series of seven citrated plasma samples, the plasma was 
centrifuged at I600g for 15 minutes, the supernatant platelet poor 
plasma decanted and the platelet pellet washed twice with bicarbonate 
saline citrate and finally with bicarbonate saline (Bom and Cross,
1964)® The platelet suspension was centrifuged at 1600 g for 10 minutes 
between each wash. After a series of pilot experiments 0.1 M tris 
buffer, pH 7.5 was chosen as a suitable medium for the platelet suspension 
and thus after washing the platelet pellet was resuspended in a volume 
of the buffer, containing additional sodium, potassium and calcium ions, 
sufficient to give a platelet count similar to that of the initial platelet 
rich plasma sample. Trypsin (lOyug per ml) appeared to have little 
effect on platelet aggregation in this platelet suspension (figure 27, 
table 50). 10 minutes after the addition of ADP (0. 5  J i g  per ml suspension)
to the system, the mean optical density of the control samples was O.5O3 - 
0.058 and of the test samples 0.516 - 0.025, (t = 0.291, p<0.80).
This experiment was rather disappointing in that even in the control
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sample platelet aggregation occurred only to a limited extent. This
system could not he improved by resuspending the washed platelet pellet
in a volume of its own platelet poor plasma® This observation together
with the apparent loss of a considerable number of platelets during
the washing procedure seemed to indicate that this was not an ideal
system for the investigation of platelet aggregation in a washed platelet
suspension. Accordingly the experiment was repeated with a different
washing regimen (Haslam, 1964)® Blood was collected from a volunteer
and anticoagulated by the addition of 9.25 ml whole blood to 0.75 ml,
0.077 ^ sodium EDTA, pH 7®2. The blood was centrifuged at 600 g for
5 minutes to obtain platelet rich plasma which was then centrifuged as
above to obtain platelet poor plasma. The platelet pellet was then
washed as set out in the methods section and was resuspended finally in a
medium containing 9 volumes, 0.154 M sodium chloride and 1 volume 0.154
M tris buffer pH 7.2, to give a final platelet count of approximately 
5
5 x 1 0  per cumm. For the estimation of platelet aggregation, 0.2 ml, 
0.154 M KOI, 0.02 ml, 0.154 M %30 and 0.02 ml, 0.11 M CaCl were 
added to 1.76 ml of this platelet suspension. The effects of trypsin 
at the concentrations of I0yug, 10 0  j i g  and 1 mg per ml suspension on 
platelet aggregation in this suspension were investigated. The results 
for trypsin at the concentrations 10/ug and 1 mg per ml suspension are
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shown in figure 28. For clarity, the readings obtained with trypsin 
at a concentration of 100 j a g  per ml suspension have been omitted as they 
lay between the readings for the other concentrations. It would appear 
that trypsin can almost completely inhibit platelet aggregation in this 
platelet suspension. The action of trypsin at 100yug per ml and 1 mg per 
ml was not altered by the addition of fibrinogen (4OO mg per ml) to the 
system (tables 9, 10), although fibrinogen, at this concentration, when 
added alone to the system could produce enhancement of platelet aggregation 
(figure 29)0 The effect of srreptokinase (2,000 H.I.H. units per ml 
suspension) on platelet aggregation in the washed platelet suspension has 
also been investigated. The results are shown in figure 30 and it would 
appear that streptokinase has no effect on platelet aggregation in this 
system. The effect of trypsin and streptokinase on platelet aggregation 
in a washed platelet suspension was unchanged when the pH of the tris 
buffer of the suspension medium was increased to pH 8.2. From the 
results it would seem tha'c the effect of trypsin and streptokinase in 
enhancing platelet aggregation in platelet rich plasma is not mediated 
through a direct action on the platelets.
An attempt was made to investigate the action of thrombin on 
platelet aggregation in a washed platelet suspension. Thrombin (0 .04  
N.I.H. units per ml platelet suspension) was incubated with 2 ml platelets
suspended in medium (tris buffer 0.1 M, pH 7.2 plus additional ions).
Unfortunately platelet aggregation in this sample could not be assayed
since a small fibrin clot had formed before the incubation period was over.
This observation would seem to indicate that the washing schedule carried
out for these experiments did not remove the coagulation factors which
are believed to be closely associated with the platelets in blood
(Adelson et al., 1961; Iatridis and Ferguson, 1965).
From the observations made on the effect of ADP and adenosine on
platelet aggregation in trypsin treated plasma it was suggested that the
action of trypsin might be mediated through the ADP mechanism. Evidence
to support this view has been obtained from the study of the action of
trypsin on ADP induced platelet aggregation. Additional supporting
evidence has been obtained from the investigation of the effect of adenosine
on trypsin treated plasma. In a series of seven plasma samples, one
portion of the plasma was incubated with trypsin (lOO^ug per ml) and a
second portion with trypsin (lOOyug per ml) and adenosine (100 ^ug per ml).
In every plasma sample investigated platelet aggregation was inhibited
in the test sample (figure 31, table 51). One minute after the
addition of ADP (0.5yug per ml plasma) to the system, the mean optical
+
density reading of the control samples was 0.491 - 0.054 and of the
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test samples 0.567 - 0.039, (t = 2.724, p^O.05). The ability of 
adenosine to inhibit the action of trypsin on platelet aggregation 
appeared to be dependent on the relative concentrations of trypsin and 
adenosine. In a series of seven plasma samples, trypsin ( 1 mg per ml) 
was added to the control sample and trypsin (1 mg per ml) and adenosine 
(0.5 mg per ml) to the test sample. At these concentrations adenosine 
was only partially able to inhibit the action of trypsin (figure 21, 
table 53); in three of the plasma samples investigated adenosine caused 
marked inhibition in the degree of platelet aggregation and in the remaining 
four samples aggregation was virtually unchanged from that occurring in 
the absence of adenosine. 4 minutes after the addition of trypsin to 
both the control and test samples the mean optical density reading of the 
control plasma was 0 .177 -  0.182 and of the test plasma O.3O3 - 0.086,
(t = 1.818, p<0.20). In this series of experiments the plasma was not 
preincubated with either trypsin or adenosine before agitation of the 
plasma was commenced and changes in optical density monitored. As ADP 
was not added to the system the partial inhibiting action of adenosine 
would appear to be due to its action at some stage in the sequence of 
changes produced by trypsin during the initiation of platelet aggregation.
During the investigation of the effect of streptokinase on platelet 
aggregation it was observed that the action of streptokinase did not
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appear to be changed if aggregation was induced by ADP or by nor­
adrenaline. A similar observation was made with trypsin. The effect
of trypsin (lOyug per ml) was investigated in a series of 10 plasma 
samples in which aggregation was induced by nor-adrenaline (figure 32, 
table 53)o 2 minutes after the addition of nor-adrenaline (1 .Oyug per
ml) to the system, the mean optical density reading of the control plasma 
was 0.440 i 0.141 and of the test plasma 0.395 - 0 .207, (t = 1.691, p<
0„20). Thus, just as in the series of experiments in which aggregation 
was induced with ADP, trypsin at a concentration of 1 Cyug per ml plasma 
appeared to have no significant effect on nor-adrenaline induced aggregation.
The effect of trypsin at a concentration of 10yug per ml on platelet
aggregation in the turbidimetric system does not agree with the effect
observed for trypsin at the same concentration in the Chandler tube
system (Chapter 4 ). From the use of radioactively tagged fibrinogen in
the Chandler tube system it was observed that as a result of incubation
of plasma with this concentration of trypsin marked digestion of
fibrinogen occurred. In an attempt to determine whether digestion of
fibrinogen also occurred during incubation and platelet aggregation in the
131turbidimetric system, a sample of I fibrinogen was added to the control 
and test plasma samples before incubation in five of the samples used 
for the investigation of trypsin (l0yug per ml) on diluted plasma and in
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five of the samples used in the study of nor-adrenaline induced 
aggregation. 0.2 ml amounts of both the control and test samples 
were removed before incubation and after platelet aggregation, 0.1 ml 
thrombin (100 IT.I.H. units per ml) added and the amount of radioactivity 
present in the clot which formed counted on a scintillation counter 
(Scaler 1700, Isotope Developments Ltd.). The percentage clottable 
protein present after aggregation was calculated from the two results.
The figures are presented in table 7. It would appear that in neither 
the undiluted nor in the diluted plasma samples is there any significant 
reduction in the amount of clottable protein present before and after 
treated with trypsin at this low concentration. This is in complete 
contrast to the results obtained from the use of radioactive fibrinogen 
in the Chandler tube system and may in part explain the different results 
obtained for the effect of trypsin, at this concentration, on platelet 
aggregation in the two systems.
From the results presented above it may be concluded that the 
proteolytic enzymes, trypsin and streptokinase, can, under certain 
conditions, result in enhanced platelet aggregation in plasma samples 
with which they have been incubated. In an attempt to determine 
whether platelet aggregation could be enhanced by other proteolytic 
enzymes, the effect of urokinase, chymotrypsin and ficin on ADP
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induced platelet aggregation was investigated.
Effect of -proteolytic enzvmes. The effect of urokinase on ADP 
induced aggregation was investigated in a series of ten plasma samples. 
Urokinase was studied at the concentration which produced maximum lytic 
activity as determined for each plasma sample in a urokinase sensitivity 
test. The results are shorn in figure 33 and table 54. It would 
appear that at this concentration, incubation of plasma with urokinase 
results in some inhibition of platelet aggregation. 3 minutes after
the addition of ADP (0.5yug per ml plasma), the mean optical density
“4“ +
of the control plasma was 0.400 - 0.264 and of the test plasma 0.499 -
0.128, (t = 3.134, p<.0.02). Urokinase, like streptokinase, is an
activator of plasminogen (Sherry et al., 1959) and it would seem that at
an equivalent concentration these enzymes have a similar effect on
platelet aggregation in the turbidimetric system.
Chymotrypsin and ficin were studied as enzymes with which the action
of trypsin could be compared. Both these proteolytic enzymes have pH
optima in a similar range to that of trypsin but as shown in table 2,
neither of these enzymes appeared to be able to convert prothrombin to
thrombin.
Chymotrypsin like trypsin is a pancreatic enzyme and like trypsin it 
is able to hydrolyze tyrosylglycine linkages. Its effect on platelet 
aggregation was studied in a series of seven plasma samples. The results 
are shown in figure 34 arid table 55. If would appear that chymotrypsin
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at a concentration of 10 0 j a g  per ml plasma has no effect on ADP
induced platelet aggregation. 5 minutes after the addition of ADP, the
mean optical density reading of the control samples was 0.364 - 0.156 and
of the test samples 0.377 ^ 0.144, (t = 0.412, p<0„070).
Ficin is a proteolytic enzyme obtained from fig latex and is able to
hydrolyze certain synthetic esters such as benzoylarginine amide. The
enzyme was incubated, at a concentration of 10yug per ml plasma, with a
series of 12 plasma samples. It would appear that ficin at this concentration
has no significant effect on ADP induced platelet aggregation (figure
35, table 56). 5 minutes after the addition of ADP, the mean optical
"1"
density reading of the control plasma was 0.360 - 0.160 and of the test 
sample 0.335 - 0.165, (t = 0.996, p<0.40).
Further experiments with higher concentrations would have to be 
carried out before it would be possible to assess the full significance 
of the effect, if any, on platelet aggregation of the proteolytic enzymes 
chymotrypsin and ficin.
During a pilot experiment described above it was observed that 
heparin at a concentration of 10 units per ml plasma appeared to cause 
enhanced aggregation. This observation was further investigated together 
with the effect of heparin on ADP induced aggregation at the concentrations 
0 .05 units per ml and 500 units per ml.
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Effect of heparin. Following the single observation with heparin 
(10 units per ml) a further seven plasma samples were investigated.
The incubation of plasma with heparin at this concentration appeared to 
result in some enhancement of aggregation (figure 36 table 57). 4
minutes after the addition of ADP to the system the mean optical density 
reading of the control plasma was 0.196 -  0.146 and of the test plasma 
0.096 - 0.091, (t = 2.594, p ^ 0„05). This result was contrary to the 
effect of heparin on platelet aggregation in the Chandler tube system 
observed by Cunningham et al., (1964). However, these workers had used 
heparin at a concentration of 0.1 to 0.2 units per ml plasma. Thus the 
effect of heparin at a concentration of 0.05 units per ml plasma on ADP 
induced aggregation was investigated in an attempt to demonstrate the 
anticoagulant action of heparin, in therapeutic concentrations, on 
platelet aggregation. The effect of heparin (0.05 units per ml) was 
investigated in a series of 14 plasma samples. Heparin, at this 
concentration, appeared to cause marked enhancement of platelet 
aggregation, figure 37 and table 58. 10 minutes after the addition of
ADP, the mean optical density of the control plasma was 0.436 - 0.139, 
and of the test plasma 0.376 -  0.167, (t = 3.297, p^O.010). Thus the 
effect of heparin on the enhancement of platelet aggregation appeared to 
be even greater at a concentration of 0 .05 units per ml than at 10 units
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per ml. Z'hus it was observed that, contrary to expectations, at low 
concentrations heparin appears to enhance platelet aggregation in the 
turbidimetrie system. The effect of heparin, at a high concentration, 
on ADP induced aggregation was investigated. Heparin (500 units per 
ml plasma) was incubated with a series of 8 plasma samples before 
platelet aggregation was induced by the addition of ADP (0.5yug per ml). 
In every sample investigated heparin appeared to cause some inhibition 
of platelet aggregation (figure 38, table 59). 10 minutes after the
addition of ADP the mean optical density reading of the control plasma 
was 0.422 - 0 .184 and of the test plasma 0.508 -  0.140, (t = 2.563, p 
0.05)o It would seem, therefore, that heparin must be present in a 
relatively high concentration before it can inhibit ADP induced platelet 
aggregation.
A series of experiments was described above in which the action of 
trypsin on platelet aggregation in a suspension of washed platelets in 
tris buffer, pH 7 .5. The same series of seven bicarbonate-citrate 
solution washed platelet suspensions was used to determine whether 
heparin caused enhancement of platelet aggregation by direct action on the 
platelet. Over the series of experiments heparin (10 units per ml) 
appeared to have no significant effect on platelet aggregation in this 
suspension (figure 27, table 60). 10 minutes after the addition of ADP
the mean optical density reading of the control plasma was O.5O3 -
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0.058 and of the test plasma 0.512 -  O.O53, (t = 0.756, p < 0 .50).
Thus it would appear that heparin does not enhance platelet aggregation 
by direct action on the platelet and that some plasma factors must there­
fore be essential for its 1 coagulant‘ action.
Discussion.
The investigations of the effect of the enzymes streptokinase 
and trypsin in the turbidimetric system show that under certain conditions 
these enzymes appear to be able to enhance the extent to which platelet 
aggregation can occur in platelet rich plasma. It would appear, however, 
that these enzymes do not exert their action directly on the platelets 
but their ability to enhance platelet aggregation depends on the alteration 
of one or more plasma constituents of which one may be fibrinogen since 
the results seem to indicate that the effect of the enzymes on platelet 
aggregation may be related to their fibrinogenolytic activity.
Effects of Streptokinase and Trypsin. The turbidimetric system for the 
measurement of platelet aggregation appears to be less sensitive to the 
action of streptokinase and trypsin, at low concentrations than the 
Chandler tube system. The results of the investigation of some of the 
differences in the conditions under which the enzymes react with the 
plasma in the two systems suggest that the apparent different effects of 
the enzymatic action on platelet aggregation cannot be explained solely
on a difference in experimental conditions. When trypsin and 
streptokinase were incubated with plasma, diluted in the same proportions 
as for the Chandler tube system, there was no significant difference 
in the effects observed compared to those for the undiluted samples.
The effect of trypsin, at the relatively low concentration of lOyug per 
ml plasma, did not appear to be influenced by the concentration of 
calcium ions present in this system (figures 23 and 24). Consequently, 
some other explanation must be sought for the apparent difference of the 
effect of low concentrations of trypsin and streptokinase on platelet 
aggregation when measured in the Chandler tube and the turbidimetric 
systems.
As discussed in chapter 2, during the process of thrombus 
formation a sequence of reactions, involving platelets, occurs (Glynn 
et al., 1966; Hellem and Owren, 1964; Kaser-Glanzmann and Luscher, 1962 
Luscher, 1967; Mustard et al., 1964a; Poole and French, 1961; Roskam, 
1961; Sharp, 1961). It is thought that after the adhesion of one 
or more platelets to the damaged tissue, ADP, which is released from the 
adhering platelets, stimulates the adhesion of more platelets leading 
to the formation of a permeable platelet plug. At this stage in the 
reaction sequence it has been shown that platelets maintain their 
morphological integrity (Hellem and Owren, 1964; Sharp, 1964) and
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aggregation is thought to he reversible (Hellem and Owren, 1964).
During the formation of a thrombus, however, the platelets in this 
permeable platelet plug gradually undergo viscous metamorphosis with 
the loss of morphological integrity and the formation of a platelet 
plug impermeable to blood flow. The turbidimetric method estimates 
reversible platelet aggregation (Bora, and Cross, 1963b). This is 
confirmed by the examination of the mean control curves in which 
plasma was incubated with saline before ADP was added to the system and 
it can be seen in figures 16 and 20 that after the initial aggregation 
in response to the challenge by ADP the platelet aggregates are rapidly 
dispersed. with the turbidimetric system, microscopic platelet 
aggregation is sufficient to alter the turbidity of the plasma which is 
recorded as a change in optical density on the galvanometer scale but 
with the Chandler tube system, the appearance of macroscopic platelet 
aggregates is taken as the end point of the effect of the substance 
under investigation on the rate of formation of platelet clumps. In 
addition, in the Chandler tube system, the appearance of platelet clumps 
is followed by fibrin formation. Thus, it is likely that in the 
Chandler tube system the end point of the reaction is assessed at a 
point at which platelet aggregation has become irreversible and hence 
the Chandler tube and turbidimetric systems are measuring different 
stages in the reaction sequence. This may, at least in part, account
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for the apparent different effect of low concentrations of trypsin
and streptokinase on platelet aggregation in the two systems since it
would appear that the enzymes do not act directly on the platelets
(figures 2 8  and 30 ) hut on certain of the plasma proteins. Evidence
20
to support this view may he drawn from figure/ in which it would appear 
that when platelet aggregation is enhanced hy the action of the 
enzymes on the plasma, platelet disaggregation is impaired over that 
observed in the control samples.
Recently it has heen shown that a wide range of physiological 
compounds can induce platelet aggregation in vitro of which one is 
nor-adrenaline (Mitchell and Sharp, 1964, O'Brien, 1963b and 1964).
The effects of streptokinase and trypsin at low concentrations are 
shown in figures 19 and 32 and it can be seen that, as for ADP induced 
aggregation, these enzymes ezert no significant effect on nor-adrenaline 
induced aggregation. Platelet aggregation initiated by nor-adrenaline 
is similar to that induced by ADP in that it is reversible (Mitchell 
and Sharp, 19643. Consequently, this observation tends to support the 
view that the apparent conflict in the results obtained for the action 
of low concentrations of the enzymes streptokinase and trypsin in the 
Chandler tube and turbidimetric systems is dependent on the stage in the 
reaction sequence of the formation of platelet aggregates that is measured
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by the system rather than on the experimental conditions under which 
the enzymes react with the plasma in the two systems.
A further point, which may be relevant to the consideration of 
results obtained with the Chandler tube and turbidimetric systems is 
the different stimuli causing aggregation in the two systems. The 
Chandler tube system reflects the speed of platelet aggregation in an 
artificial circulation in which fibrin formation occurs. As discussed 
in chapter 4, the explanation for the appearance of platelet aggregates 
in this system is not clear but aggregation may be initiated by trace 
amounts of ADP released into the system during the procedure of 
centrifugation to obtain platelet rich plasma and the subsequent handling 
of the samples. On the other hand, in the turbidimetric system, 
relatively large amounts of ADP are added to plasma to initiate platelet 
aggregation. The concentration of ADP is probably much greater than 
that actually required to cause the initial stimulation of platelet 
aggregation and consequently there may be masking of the effect of low 
concentrations of streptokinase and trypsin on platelet aggregation in 
this system.
In chapters 2 and 4, it was suggested that, as in the fibrinolytic 
enzyme system, the action of streptokinase on platelet aggregation may 
be mediated through its ability to convert plasminogen to plasmin.
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Some evidence which would seem to support this has been obtained from 
the investigation of streptokinase and antiplasmin in the turhidimetric 
system. IJhen plasma was incubated with streptokinase, at a concentration 
which produced maximum lytic activity, ADP induced aggregation appeared 
to be impaired (figure 16); when the plasma was diluted and streptokinase 
added, at a concentration of a similar order, the enzyme appeared to 
have little effect on aggregation (figure 17); but when the enzyme, 
at a relatively high concentration was incubated with plasma in which the 
antiplasmin had been destroyed, streptokinase appeared to produce a 
significant increase in the extent to which aggregation occurred (figure 
18). Thus, it may be concluded that streptokinase is not able to 
produce enhancement of platelet aggregation in the presence of anti­
plasmin, indicating that the effect of the enzyme is mediated through 
plasmin.
The effect of trypsin at the relatively high concentrations of 
100yug/ml and 1 mg/ml on ADP induced platelet aggregation appears to be 
similar to that observed for the effect on the initial stages of thrombus 
formation as measured in the Chandler tube system, (figures 6, 7, 20 
and 21). As in the Chandler tube system in which trypsin (1 mg/ml) 
could cause significant acceleration of platelet aggregation without 
prior incubation of the enzyme and plasma, so trypsin (1 mg/ml) could 
induce aggregation in the turbidimetric system without either prior
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incubation before the plasma was stirred or the addition of ADP 
to the system (figure 21). In this series of experiments, however, 
the enhancement of aggregation cannot be accounted for solely by the 
action of trypsin since in three of the plasma samples investigated, 
small fibrin strands appeared towards the end of the ten minute period 
during which platelet aggregation was monitored. In these three 
plasma samples at least, thrombin generation may have been a 
contributory factor. This concentration of trypsin (l mg/ml) could be 
made to enhance platelet aggregation in the absence of fibrin formation 
by prior incubation of the plasma samples with streptokinase (2,000 
S.I.E. units/ml) before trypsin was added to the system (figure 22). 
ho fibrin strands became visible in any of the seven plasma samples 
during the period of the experiment, perhaps because the clottable 
protein had been digested by plasmin, formed under the action of 
streptokinase, before the addition of trypsin to the system. Some of 
the prothrombin present in the plasma may also have been digested but 
as data is not available on the rate of destruction of prothrombin under 
these particular experimental conditions, the possibility that thrombin 
was being generated in this system cannot be excluded. The in vitro 
investigations of the effect of trypsin on the coagulation system 
described in chapter 4 (tables 2 and 3) seemed to suggest, however, 
that the effect of trypsin on platelet aggregation was not entirely
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due to its action on coagulation as estimated by its ability to convert 
prothrombin to thrombin but that its fibrinogenolytic activity was 
also involved in the process.
The results obtained in the investigation of the clottable protein 
present after ADP and nor-adrenaline induced aggregation in streptokinase 
and trypsin treated plasma support the hypothesis that fibrinogenolysis 
is critical to the action of streptokinase and trypsin in enhancing 
platelet aggregation (table 1 ). In this system, in which these enzymes 
had no significant effect on platelet aggregation (figures 17, 19 and 
32), the percentage clottable protein did not appear to differ 
significantly between the control and enzyme treated plasma samples.
In the Chandler tube, however, similar concentrations of these enzymes 
not only produced marked acceleration of platelet aggregation (figures 
5 and 6) but also appeared to cause a significant decrease in the amount 
of clottable protein incorporated into thrombi (table l).
In chapter 4 it was suggested, from the results of the investigations 
of the effect of incubation of trypsin with platelet poor plasma and 
platelet rich plasma in the Chandler tube system, (figures 8 and 9), 
that the presence of platelets appeared to enhance the tryptic effect. 
Similar results have been obtained with the turbidimetric system 
(figures 25 and 26). During this investigation, soybean trypsin
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inhibitor was added to the trypsinized plasma before platelet 
aggregation was assayed. The results suggest that trypsin is not 
acting directly on the platelet aggregation mechanism but that the enzyme 
produces some change either on the plasma proteins or the platelets 
themselves which can subsequently influence platelet aggregation.
However, from the investigation of the effect of streptokinase and 
trypsin on a washed platelet suspension it would appear that the 
enhancement of platelet aggregation apparently produced by these enzymes 
is not mediated through direct enzymatic action on the platelets.
Incubation of streptokinase (2,000 h.I.H. units/ml) with a washed 
platelet suspension appeared to have little effect on ADP induced 
platelet aggregation in the sample (figure 30) • Morse et al., (1965) 
have demonstrated that incubation of washed platelets with streptokinase 
alone, unlike the results with trypsin, plasmin or thrombin, produced no 
detectable alterations in the platelets. Hence, it seemed unlikely 
that the apparent slight enhancement of the aggregation of washed 
platelets produced by streptokinase could be explained on the basis of 
the enzyme causing any alteration of the platelets themselves. The 
action of streptokinase on fibrinolysis has been demonstrated to be 
due to its ability to convert plasminogen to plasmin (Sherry et al.,
1959) and it has also been shown from the results presented above that
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its effect on platelet aggregation may also be mediated through the 
same reaction. Thus, if this mechanism were to operate in washed 
platelet suspensions, either exogenous plasminogen would have to be 
added to the system or plasminogen, or a precursor, which had not been 
removed by the washing procedure would have to be present in association 
with the platelets. It has been demonstrated that platelets are 
surrounded by an atmosphere, sometimes referred to as the 'plasmatic 
atmosphere', which contains a number of coagulation factors (Adelson 
et al., 1961; Iatridis end Ferguson, 1965). However, not only may 
plasminogen be present, but antiplasmin may also be adsorbed onto the 
platelet surface and in addition platelets themselves possess relatively 
high antiplasmin activity (Johnson and Bchneider, 1953; Alkjaersig,
1961). In the present system it is unlikely that platelet antiplasmin 
may play a significant role since, presumably, some rupture of the 
platelet membrane would have to occur before it could be released into 
the system. On the basis of one experiment it is not possible to draw 
more than tentative conclusions from the result. Plasma factors may 
be present in the washed platelet suspension since incubation of the 
suspension with thrombin resulted in the formation of a fibrin clot. 
However, with the present limited available information it is not 
possible to define whether the fibrinogen was present in association
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with the platelet membrane or, since it has been shown that thrombin 
can release aniinactivate clottable protein from platelets (Morse 
et al., 1965; Schmid et al., 1962),was released from the platelets 
by thrombin.
The results of the investigations of trypsin, at the concentrations 
10 yug, 100^ i g  and 1 mg per ml platelet suspension, show that the enzyme 
appears to cause impaired aggregation of ADP induced platelet aggregation 
in a washed platelet suspension (figure 28). This result does not 
agree with the effect of trypsin on washed platelets observed by Haslam 
(1964). The discrepancy may be explained by the fact that Haslam used a 
lower concentration of trypsin (2 yug per ml platelet suspension) and that 
he did not incubate the trypsin and washed platelet suspensions together 
before investigating platelet aggregation. Schmid et al., (1962) have 
shown that washed platelets treated with trypsin (50yug per ml) remain . 
morphologically intact although clottable protein had been removed from 
the platelets and they cannot subsequently be aggregated by thrombin.
This result has been confirmed by Morse et al., (1965) who further demon­
strated that platelets treated with trypsin, at concentrations less than 
2yug per ml, retain clottable protein and can be aggregated by thrombin. 
Fibrinogen has been demonstrated to be an integral part of the platelet 
structure (Castaldi and Caen, 1966; Gokcen and Tunis, 1963; Grette,
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1562; Morse et al., 1965; Machman et al., 1964; and Schmid et al.,
1962), and it has also been shown to be closely associated with the 
platelet surface (Adelson et al., 1961; Iatridis and Ferguson, 1965).
In addition, fibrinogen has been shown to be an important factor in ADP 
induced platelet aggregation (McLean et al., 1964)- It would appear that 
the addition of fibrinogen alone to a washed platelet suspension is 
sufficient to promote enhancement of ADP induced platelet aggregation 
(figure 29). This result is in agreement with the observations for the 
effect of fibrinogen on platelet aggregation in platelet rich plasma 
(Cross, 1964; Solum and Stormorken, 1965) and of Kopec (1966) for 
washed platelet suspension, and gives support to the concept of the involve­
ment of fibrinogen in the mechanism of platelet aggregation. The 
marked impairment of aggregation caused by trypsin could not be reversed 
by the addition of fibrinogen to the system although Schmid et al.,
(1962) have been able to demonstrate that the addition of fibrinogen to 
trypsinized platelet suspensions restored Their ability to aggregate in 
the presence of thrombin. In the present experiment, however, trypsin 
and fibrinogen were present together in the washed platelet suspension 
during the incubation of the mixture so that the possibility exists that 
fibrinogen itself was digested before platelet aggregation was assayed.
In order to make the investigations of the effects of streptokinase 
and trypsin on washed platelets more comparable to the investigations in
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platelet rich plasma, lower concentrations of the enzymes should be
used to allow for the presence of antiplasmin (Sherry et al., 1959)
and antitrypsin (Wu and Laskowski, 1960) present in plasma. Nevertheless,
it may be concluded from the experiments that the apparent ability of
the enzymes streptokinase and trypsin to enhance aggregation is not
mediated through their direct action on the platelet but requires the
presence of one or more plasma factors.
It was suggested from the results of the investigations of the
combined action of trypsin and ADP and trypsin and adenosine in the
Chandler tube system (figures 13 and 15) that the effect of trypsin was 
mediated through the ADP mechanism of platelet aggregation (Gaarder and 
Laland, 1964; Salzman et al., 1966). This has been confirmed with the 
turhidimetric system in which not only can trypsin be made to cause
significant enhancement of ADP induced aggregation (figure 20), but also
it would appear that adenosine can inhibit the action of trypsin in 
both the presence and absence of ADP (figures 31 and 21 ).
Effects of proteolytic enzymes. At the concentrations studied, neither 
urokinase, ficin nor chymotrypsin appear to cause any enhancement of ADP 
induced platelet aggregation. Urokinase, at an equivalent concentration 
to streptokinase, appeared to exert a similar effect on ADP induced 
aggregation in that aggregation appeared to be impaired in some of the
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samples investigated (figures 16 and 33). Urokinase is an activator 
of plasminogen (Astrup and Eterndoff, 1953; Sobel et al., 1952;
Williams 1951), and consequently it is conceivable that its action in 
plasma like that of streptokinase, is mediated through the formation 
of plasmin.
Ficin and chymotrypsin, at a concentration of 100yug per ml plasma, 
produced no apparent effect on ADP induced aggregation (figures 34 and 35)» 
Table 2 shows that at this concentration, these proteolytic enzymes did 
not appear to be able to convert any plasma prothrombin to thrombin.
Morse et al., (l965) have shown that papain and chymotrypsin, like thrombin, 
trypsin and plasmin, are able to bring about inactivation of the clottable 
protein of washed platelets with the release of serotonin and ATP into 
the system; such platelets are not then susceptible to aggregation by 
thrombin. However, the concentrations of papain and chymotrypsin 
required to produce a similar effect on washed platelets appeared to be 
somewhat greater than that for plasmin and trypsin. Consequently, the 
concentrations of ficin and chymotrypsin studied in the present series of 
experiments may be comparable to trypsin at a concentration of 10 yug/ml 
rather than at a concentration of 100yug/ml. The effects of ficin and 
chymotrypsin at higher concentrations would have to be examined before 
reaching a conclusion that streptokinase and trypsin have a specific
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effect not produced by other proteolytic enzymes.
Effect of Heparin. From the results presented in figures 36, 37 and 33 
it would appear that the effect which heparin eserts on ADP induced 
platelet aggregation depends on the concentration of heparin in the 
system. At the relatively low concentrations of 0.05 units/ml and 10 
units/ml plasma heparin appears to cause marked enhancement of ADP 
induced aggregation and that at a high concentration (500 units per ml) 
heparin may cause marked inhibition of platelet aggregation. These 
observations are in agreement with those of hellem et al., (1963) on 
the action of heparin on platelet adhesiveness in platelet rich plasma. 
These workers demonstrated that platelets were more adhesive and more 
sensitive to ADP in the presence of low concentrations of heparin (4»5 
- 180 units per ml) and that platelet adhesiveness was only inhibited by 
the presence of heparin at concentrations greater than 180 units per ml. 
Mustard et al., (1964b) have, however, demonstrated that heparin at a 
concentration of 100 units per ml plasma appears to cause no inhibition 
of ADP induced platelet aggregation. Thus it would appear that heparin 
has a coagulant action at low concentrations and an anticoagulant effect 
at high concentrations in vitro when platelet aggregation in the absence 
of fibrin formation is investigated. Cunningham et al., (1965) have shown 
that heparin at a low concentration (0.1 to 0.2 unit per ml) caused 
significant prolongation of the rate of formation of platelet aggregates
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in an artificial circulation in which fibrin formation occurred, as 
a sequel to platelet aggregation.
The results described for the action of heparin on ADP induced 
aggregation are not in agreement with observations made for the action of 
heparin on thrombin induced aggregation since it has been shown that 
heparin inhibits platelet aggregation in the presence of thrombin (Clayton 
and Cross, 1963; Mustard et al., 1964b; Zucker and Borrelli, 1959).
The anticoagulant action of heparin in a system in which clot formation 
can occur may be accounted for by the observation that heparin can inhibit 
the action of thrombin on fibrinogen (Howell, 192b) and can also inhibit 
the conversion of prothrombin to thrombin (Howell and Holt, 1918; Howell, 
1925).
From the series of experiments in which the effect of heparin, at a 
concentration of 10 units per ml, on washed platelets was examined it would 
appear that heparin does not cause enhancement of platelet aggregation 
by direct action on the platelets. Unfortunately, it would appear that 
the platelets had been damaged during the washing process since only 
minute traces of aggregation occurred in the control samples (figure 27) 
and so no conclusions may be drawn from this experiment. Hampton and 
Mitchell (1966) have shown that heparin appears to be able to alter the 
surface charge of human blood platelets as measured by their electrophoretic 
mobility. Heparin at concentrations up to 50 units per ml plasma 
appears to prevent the change in platelet electrophoretic mobility 'which
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is usually observed, after the ad.cl.ition of ADP and. nor-adrenaline.
'.‘Jith the evidence at present available it is not clear why heparin 
appears to exert different effects on ADP induced aggregation depending 
on the concentration present in the system. The strong electronegative 
charge of heparin (Douglas, 1962c) may contribute to its antithrombotic 
properties since platelets themselves possess a strong negative surface 
charge (Abramson, 1928) and in addition it has been shown that dextrans 
exert a protective effect against thrombosis (Borgstrom et al., 1959).
Conclusions.
From the results presented in this chapter it would appear that the 
fibrinogenolytic agents streptokinase and trypsin exert an 'anticoagulant' 
effect on ADP induced aggregation when present in low concentrations but 
their effect becomes 'coagulant' when they are present in relatively 
high concentrations. This observation is in contrast to the effect of 
the anticoagulant agent, heparin, which appears to exert a 'coagulant' 
effect on ADP induced platelet aggregation at low concentrations and 
becomes 'anticoagulant' only at high concentrations.
From the investigations of the actions of trypsin and streptokinase 
on washed platelets, it appears that the enzymes do not exert their 
effect on aggregation by direct action on the platelets but require the 
presence of certain plasma factors. It would seem that the ability of 
streptokinase to enhance ADP induced platelet aggregation depends on the 
production of plasmin.
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CHAPTER 6.
STUDIES OH THE EFFECT OF STREPTOKINASE AMD TRYPSIN 
OH PLATELET ADHESIVENESS.
In this chapter are presented the results obtained from the investigations 
of the effect of streptokinase and trypsin on platelet adhesiveness.
Platelet adhesiveness was assessed by the ability of platelets to adhere 
to glass beads and to each other in either citrated whole blood or platelet 
rich plasma during passage through a standard column of glass beads. The 
concentrations of ADP present in whole blood and plasma before and after the 
samples came into contact with the glass beads have been determined together 
with the apparent influence of trypsin digestion of whole blood and plasma 
on the concentration of nucleotide present in the samples.
The effect of the enzymes streptokinase and trypsin on platelet 
aggregation in platelet rich plasma has been described in chapters 4 and 
Neither the Chandler tube system nor the turbidimetric system, however, is 
suitable for the investigation of platelet aggregation in the presence of 
red cells. This is a considerable disadvantage when an attempt is made to 
correlate in vitro findings with in vivo conditions. Hellem (i960) has 
devised a method for the investigation of platelet adhesiveness in the 
presence of red cells. A modification of this method (Hirsh et al., 1966a) 
has been used to investigate the effect of streptokinase and trypsin on 
platelet adhesiveness in both the presence and absence of red cells.
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Materials.
Trypsin and Streptokinase were used as described in chapter 3.
Platelet rich -plasma was prepared from citrated whole blood by centrifugation 
at 600g for 5 minutes at room temperature (approximately 20°C) and was kept 
at 2C°C until platelet adhesiveness was assayed.
Glass Beads» These were Ballotini beads of 0.57 mm diameter.
The beads were prepared for the columns by thoroughly washing with chromic 
acid followed by rinsing in 20 per cent sodium carbonate solution and finally 
in tap water. After the glass beads had been thoroughly rinsed in distilled 
water they were dried in a hot air oven.
Tubing. Portex transparent tubing (il.T. 13) was cut into lengths of 7.0 cm, 
the Esco translucent silicone tubing (3.0 mm bore, 2.0 mm wall) was cut into 
lengths of 1.5 cm and 1.0 cm and the Esco translucent silicone tubing (2.0 
mm bore, 1.0 mm wall) was cut into lengths of 2.0 cm. All the lengths of 
tubing were prepared for use by thorough washing in tap water, followed by 
rinsing in distilled water and finally the tubing was thoroughly dried in a 
hot air oven.
Methods.
Estimation of platelet adhesiveness. The method was used as described in 
chapter 3. Citrated whole blood was allowed to stand at room temperature and 
was tested 30 to 60 minutes after collection. Platelet rich plasma was 
prepared from citrated whole blood which had been standing for 30 minutes at 
room temperature and was tested 40 to 60 minutes after collection. The
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samples were pumped, through, a column of glass beads, 6 cm in length, containing’
2.5 gm washed glass beads, with a transit time lying between 29 - 30 seconds; 
observations lying outside this range were discarded. Duplicate platelet 
counts were set up on the samples before and after passage through the 
column and two platelet counts were read on each sample so that a total of four 
platelet counts were performed on each blood sample before and after passage 
through the column. The percentage platelet adhesiveness was calculated 
from the mean platelet counts.
Platelet counting was performed by the method of Dacie C1956c) as described 
in chapter 3.
White cell counts were performed as described by Dacie (1956b) 0.05 nil blood 
was added to 0.95 ml diluting fluid and the solution thoroughly mixed by 
gentle inversion. The counts were performed on an improved Neubauer 
counting chamber with a white light source. The diluting fluid was 2 per 
cent (V/VJ acetic acid coloured pale violet with crystal violet.
ADP/aMP assays were carried out as described in chapter 3 with a commercially 
prepared test kit. The extracts of blood and plasma were prepared for 
analysis by the method of Eolmsen et al., (1965) as described in chapter 
3. The optical density readings , E^ and obtained during the 
oxidation of diphosphopyridine nucleotide (DPKH) in the indicator reaction 
were used to calculate the concentrations of ADP and AMP in the sample 
(Adam, 1965).
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Calculation.
Extinction coefficient for DPHE at 25°C at 366 xoyu. is 3*30 (cm^/yumoles )
I S  E ADP x VA x VE = yumoles ADP in extract
£ x d x Vp
and A E  AMP i VA x 7B = nmoles AMP in extract
£ x d x Vp X
Inhere A E  ADP = E. — E_1 2
a e  AMP = E2 - E^
VA = Volume in test mixture = 2.0 ml.
VE - Volume of extract = 0.5 ml.
2
£ = 3 .30 (cm /yumole)
d = light path of the cuvette = 1 cm.
Vp = total volume of extract added to the cuvette
= 0.01106 ml
Under the stated conditions the calculation becomes 
A E ADP x 54«796 = yumoles ADP per ml sample
and
/\E AMP x 27.398 = yumoles AMP per ml sample 
Results.
Effect of StreutnlH naae. The concentration of streptokinase used throughout
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the series of experiments to investigate the effect of the enzyme on 
platelet aggregation was that concentration which produced maximum lytic 
activity. This was determined by performing streptokinase sensitivity 
tests on plasma obtained from a portion of each citrated blood sample 
before platelet adhesiveness in the sample was assayed. The citrated 
whole blood was divided into two samples, each of 2 ml; one sample 
was treated with streptokinase and the second sample with an equal 
volume of 0.9 per cent saline to act as a control. After incubation at 
37°C for 10 minutes, the blood was pumped through a glass bead column 
and the percentage of platelets lost during the process calculated from 
the difference between the platelet counts before and after passage 
through the column. The value obtained was accepted as representing the 
percentage platelet adhesiveness of the sample. The results are 
shown in figure 39 and table 61 and it would appear that streptokinase 
treatment of blood results in a significant decrease in platelet adhesive­
ness. The mean percentage adhesiveness in the eight control samples 
was 47.9 - 27.2 and in the eight test samples 21.3 - 17.4, (t = 2.402, 
p<0.05). This observation is in agreement with the results obtained 
with a similar concentration of enzyme in the turbidimetric system 
(figure 16) but does not agree with the findings for the effect of 
streptokinase in the Chandler tube system (figure 5). In both the 
Chandler tube and turbidimetric systems the plasma samples and the enzymes
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under investigation were thoroughly mixed during the measurement of 
platelet aggregation; by rotation in an artificial circulation in one 
system and by vigorous stirring in the other system. This procedure may 
facilitate numerous collisions between the enzyme molecules and their 
substrate molecules and hence it may promote some enhancement of the 
enzymatic reaction. In the experimental design outlined above for the 
investigation of the effect of streptokinase on platelet adhesiveness, the 
enzyme and blood were not vigorously mixed. The experiment was therefore 
modified, in order that the conditions under which the enzyme could react 
with the blood were more closely comparable to the conditions in the 
turbidimetric and Chandler tube systems.
In a series of ten citrated blood samples, each sample was divided into 
two portions,each of 2 ml,which were added to small polystyrene stoppered 
containers ^capacity 5 ml). To one sample was added streptokinase, at the 
concentration which produced maximum lytic activity in the sample, and to 
the second sample an equal volume of 0o9 per cent saline. Both test and 
control samples were then rotated, on the turntable of a blood cell 
suspension mixer (Matburn Ltd., London), rotating at 2805 rpm, at 37 C for 
10 minutes before the blood was passed through a glass bead column. Under 
these conditions it appears that streptokinase treatment of blood, results 
in a significant increase in the platelet adhesiveness of the sample 
(figure 40, table 62). The mean percentage adhesiveness of the ten control
"4~ *4* /
samples was 52.0 - 19.5 and of the ten test samples 65.9 - 2 5 . 1 ,  (t =
2.780, p 2.0.025). No visible hemolysis of red cells was apparent in
either the control or test blood samples after rotation and passage through
the column. This result is in agreement with the observations made for the
action of streptokinase on the rate of formation of platelet aggregates in
the Chandler tube system (figure 5). Since it would appear that the action
of streptokinase on platelet aggregation is mediated through plasmin
(Chapter 5) and since trypsin has been selected as a proteolytic enzyme
comparable to plasmin, the effect of trypsin on platelet adhesiveness was
also investigated.
Effect of Trypsin. The ability of trypsin to influence platelet
adhesiveness was investigated with a series of ten blood samples. Bach
sample was divided into two portions each of 2 ml, one of which was treated 
with trypsin (lOyug per ml blood) and the other with an equal volume of 
0.9 per cent saline. Both samples were then incubated at 57°C for 10 
minutes, without rotation, before the blood was passed through the column. 
The results are presented in figure 41 and table 63. Under these 
conditions of incubation of trypsin and blood it would seem that this 
enzyme has some tendency to produce an increase in platelet adhesiveness, 
but since in four of the ten plasma samples investigated, platelet 
adhesiveness was decreased in the presence of trypsin, the overall result 
is not statistically significant. The mean percentage platelet
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adhesiveness of the ten control samples was 48.4 - 30.1 and of the test 
,|
samples 61.5 - 18.6, (t = 1.513* p<.0.20). This result is in agreement 
with the observations for the effect of trypsin, at this concentration, 
on AI)P induced aggregation in the turbidimetric system (figure 20) but 
differs from the findings in the Chandler tube system (figure 6). As 
mentioned above, however, the Hellem glass bead column method for the 
investigation of platelet adhesiveness differs from the other two systems 
used in this thesis to investigate platelet aggregation in that the enzyme 
and blood samples are not thoroughly mixed during the assay procedure. 
Consequently, the experiment was repeated with the modified system whereby 
the enzyme and blood were thoroughly mixed during the incubation period.
dith a series of eight citrated blood samples trypsin (10yug/ml) and 
the blood sample were rotated on the turntable of a blood cell suspension 
mixture for 10 minutes at 37°C before platelet adhesiveness was assayed. 
Control samples were treated similarly. In this system trypsin appears 
to be able to produce a significant increase in the percentage platelet 
adhesiveness of the blood samples investigated (figure 42, table 64).
i •The mean percentage adhesiveness of the eight control samples is 58.9 - 
11.7 and of the test samples 69«7 - 8.9 (t = 3*011, p<0.02). A s  in the 
investigation of streptokinase there was no visible red cell hemolysis 
produced either by the rotation of the blood or passage through the column.
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It has recently been suggested that the Hellem glass bead column 
method of measuring platelet adhesiveness may reflect red cell behaviour 
rather than true platelet behaviour (Harrison and Mitchell, 1966). If 
this is the case, it may be argued that the apparent effect of 
streptokinase and trypsin on platelet adhesiveness may merely be 
indicative of the action of these enzymes on red cells. Consequently 
the effect of trypsin on platelet adhesiveness in platelet rich plasma was 
investigated. In a series of seven platelet rich plasma samples, each 
sample was divided into two portions each of 2 ml. One portion was 
incubated with trypsin (lOyug per ml plasma) at 37°C for 10 minutes and the 
second portion with an equal volume of saline to serve as a control before 
the samples were pumped through the columns. The results are shown in 
figure 43 and table 65. In each of the seven plasma samples investigated, 
platelet adhesiveness was increased in the presence of trypsin. The 
average percentage adhesiveness of the control samples was 10.6 — 12.7 
and of the test samples 44.0 -  36.6, (t = 2.801, p<0.05). It would 
therefore seem that the apparent ability of trypsin to increase platelet 
adhesiveness in citrated whole blood is not mediated through its 
action on red cells.
These experiments suggest that trypsin is less effective in its 
ability to cause an increase in platelet adhesiveness in whole citrated
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blood than in platelet rich plasma since the enzyme and whole blood 
must be thoroughly mixed throughout the period of incubation before a 
significant increase in platelet adhesiveness is detected. The effect 
of red cells and white cells on platelet aggregation in platelet rich 
plasma has been investigated by Harrison et al., C1966), who have shown 
that red cells appear to exert no action on ADP and ATP induced aggregation 
but that white cells enhance disaggregation of ADP induced aggregation 
and cause initial enhancement followed by inhibition of ATP induced 
aggregation; the apparent difference between the effects of trypsin 
in whole blood as contrasted with platelet rich plasma might be 
accounted for by the influence of white cells on adhesiveness in the 
whole blood system.
Bffect of white cells. The effect of the presence of white cells on 
platelet adhesiveness in platelet rich plasma was investigated with two 
samples. Blood was withdrawn from two hospital patients (A and B), 
known to have an elevated red cell sedimentation rate, citrated in the 
usual way allowed to stand at room temperature until a minimum of 4 
ml of plasma could be separated from the red cells. In neither sample 
did this take longer than 30 minutes. The white cell count in the 
platelet rich plasma samples was 1,530 per cu mm for subject A and 2,145 
per cu mm for subject B. One portion of the platelet rich, white cell 
rich plasma was incubated with trypsin (lOyug/ml) at 37°0 for 10 minutes 
and the second portion was incubated with saline before the platelet
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adhesiveness was assayed. The percentage white cell adhesion in the 
control and trypsin treated samples was also estimated by performing 
white cell counts on the plasma before and after passage through the 
glass bead column. The results are shorn in table 11. Platelet and 
white cell adhesiveness was assessed in a citrated whole blood sample 
from subject B treated with both saline and trypsin and the results are 
also shown in table 11. It can be seen that, as demonstrated above, 
trypsin appears to be able to cause an increase in platelet adhesiveness 
in the presence of platelets and white cells but that this effect is not 
always produced when red cells are also present in the system. The 
incubation of whole blood or plasma with trypsin also appears to result 
in an increase in the number of white cells lost during the passage of the 
sample through the column of glass beads. On the present experimental 
evidence, the apparent difference in the action of trypsin on platelet 
adhesiveness in whole blood and platelet rich plasma systems cannot be 
explained on the basis of the interference of white cells in the reaction 
sequence.
Hellem (i960) lias shown that the adhesion of platelets to glass beads 
in whole blood is dependent on a factor released from the red cells.
This factor has been identified as ADP by Gaarder et al«, (1961). Prom 
the observations made concerning the action of trypsin on platelet
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aggregation presented in chapters 4 and 5, it was suggested that the 
action of trypsin might be mediated through the ADP mechanism of platelet 
aggregation (Gaarder and Laland, 1964; Haslam, 1964; Salzman et al., 
1966). This possibility has been investigated with the glass bead column 
method by assaying the concentration of ADP and AMP present in either 
blood or plasma, treated with trypsin, before and after passage through the 
column. Control samples treated with 0.9 per cent saline were assayed 
similarly.
ADP and AMP assays. In a series of eight citrated whole blood samples,
2.5 ml blood were incubated at 37°C for 10 minutes with trypsin (lOyug/ml) 
and 2.5 ml blood with an equal volume of saline. Aliquots (0.5 ml) of 
both the control and test samples were added to 2.0 ml, 0.5M perchloric 
acid at 4°C and the remaining blood was passed through a glass bead column 
and a further 0.5 ml sample added to perchloric acid as soon as all the 
blood hqd passed through the column. The concentration of ADP and AMP 
in the samples was estimated as described above, and the percentage 
platelet adhesiveness was also assayed. The same procedure was carried 
out on a series of seven platelet rich plasma samples. The results are 
shorn in tables 12, 15, 14 and 15. It would appear that over the series 
of experiments there is no significant difference in either ADP or AHP 
concentrations in the control and trypsin treated samples. When citrated 
whole blood was studied, the mean concentration of ADP ^umoles per ml) in 
the control sample before passage was 1 .103 - 0.539 and ax'ter passage
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1.055 - 0.243* (t = 0.242, p < 0 .90) and in the trypsin treated samples 
the values were 1.110 i 0.582 and 1.123 - 0.543 respectively, ( t = 0 .063, 
p < 0 .975). In the series of platelet rich plasma samples, the mean 
concentration of ADP in the control sample before passage was 0.963 -
0.298 and after passage 0.830 -  O .454 (t = 0.860, p<C0.50) and in the
" h  “ t "
trypsin treated samples the values were 0.712 - 0.288 and 0.650 - O .319
respectively, (t = 0.164, p<0.90)„ Further, in the citrated whole
blood sample, the mean concentration of AMP ^umoles per ml) in the control
series before passage was 1.870 - 0.353 and after passage 1.781 - 0 .293,
(t = 0 .930, p<0.40) and in the trypsin treated series the values were
1.976 -  0.282 and 2.072 - 0.337 (t = 2.053, p < 0.10). with the platelet
rich plasma samples the values were,for the control series 0.669 - 0.315
and 0.830 - O .548 (t = 1.196, p < 0 .30) and for the trypsin treated
series 0.654 - 0.263 and 0.595 - 0.156 (t = 0.725, p<0.50). When
the concentration of ADP present in the control samples after incubation
that
was compared to that in the trypsin treated samples it was found/trypsin 
caused no significant change in the citrated whole blood system but 
produced a significant decrease in platelet rich plasma. The mean 
concentration of ADP ^umoles per ml) present in whole blood in the control 
sample after incubation and before passage was 1.103 ~ 0.539 and in the 
trypsin treated samples 1.110 i 0.582 (t = 0 .020, p < 0 .09) but in the
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platelet rich plasma samples the values were 0.963 i 0.298 and 0.712 
i 0.288 respectively (t = 3.153, p <0.025). Different results were 
found when the concentrations of AMP present after incubation in the 
control and trypsin treated samples were compared since in neither the 
'whole blood nor the platelet rich plasma series was any significant difference 
in AMP concentration detected. The mean AMP concentration ^umoles per ml) 
in the whole blood series in the control samples after incubation was 
1.870 i 0.353 and in the test samples 1 .976 - 0.282 (t = 0.786, p<0.50)
*j,‘ ■}■
and in the plasma series the values were 0.b69 - 0.313 and 0.654 - 0.263 
respectively (t = 0.289, p<0.80). In neither the control nor the trypsin 
treated samples did there appear to be any correlation between the 
percentage of platelets lost and the change in ADP concentration as the 
whole blood or plasma was passed through the column (tables 16 and 17).
The percentage platelet adhesiveness of the control and trypsin treated 
samples did not appear to depend on the initial ADP concentration of 
samples (tables 16 and 17).
Discussion.
It has been shown that when platelet adhesiveness in whole blood is 
measured by the glass bead column method, there is a direct relationship 
between the packed cell volume of the sample and platelet adhesiveness in 
that sample (Hellem, 1960; Hirsh et al., 1966a; McClure et al., 1966).
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In the present study no allowance has been made for the packed cell 
volume of the whole blood samples investigated. Since each sample was 
divided and one portion treated with the enzyme while the second was 
treated with saline to act as a control, each sample on which the action 
of either streptokinase or trypsin was examined, had its own individual 
control.
The investigation of the effect of the enzymes streptokinase and trypsin 
on platelet adhesiveness in citrated whole blood shows that these enzymes 
can cause an increase in platelet adhesiveness when they are thoroughly 
mixed with the blood during the period of incubation (figures 40 and 42 and 
tables 62 and 64). ¥hen the enzymes ana whole blood are incubated together 
?rith initial mixing but without continued motion in the sample, trypsin 
appears to cause inhibition of platelet adhesiveness in some samples and 
streptokinase produces a significant decrease in platelet adhesiveness 
(figures 41 and 39 and tables 63 and 61 ). These results are in striking 
contrast to the findings obtained when the effect of trypsin on platelet 
rich plasma is examined. Trypsin can produce a significant increase in 
platelet adhesiveness in platelet rich plasma when the plasma and enzyme 
are incubated together without constant motion in the sample during the 
incubation period (figure 43, table 65). In an attempt to determine 
whether this difference between the apparent action of trypsin in citrated 
whole blood and platelet rich plasma could be accounted for by the
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presence of cellular components present in whole blood but absent in 
plasma, the effect of the presence of white cells and red cells on the 
action of trypsin has been investigated.
It would seem that white cells do not interfere with the action of 
trypsin on platelet adhesion in platelet rich plasma (table 11).
Confirmation for the suggestion that a factor other than white cells is 
involved in the apparent inhibition of the tryptic effect in whole blood was 
obtained from the observation that trypsin appeared to cause a decrease in 
platelet adhesiveness in a sample of citrated whole blood but could produce 
an increase in platelet adhesiveness in a sample of platelet plus white 
cell rich plasma prepared from the same citrated whole blood (table 11 ). 
Consequently the effect of the presence of red cells on the action of 
trypsin on platelet adhesiveness was investigated.
ADP has been shorn to have a unique position in platelet aggregation 
in vitro (Born 1962a; Gaarder et al., 1961; Haslam, 1964; Hellem and 
Owren, 1964; Hovig and Holmsen, 1963; liaser-Glanzmann and Luscher, 1962; 
Inischer 1967; O'Brien, 1964). In addition, ADP may be liberated from 
red cells under certain conditions (apaet, 1964) and it has been shown that 
its liberation from red cells during the passage of whole blood through a 
glass bead column stimulates the adhesion of platelets (Gaarder et al.,
1961; Hellem, 1960). When the effect of trypsin on the concentration
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of ADP present in blood or plasma before and after passage through, a 
column of glass beads was investigated it was found that incubation of whole 
blood with trypsin appeared to cause no significant change in the ADP 
concentrations of the samples (table 12) but there appeared to be a 
significant decrease in the concentration in platelet rich plasma (table 
14j * This may account for the apparent different effect of trypsin on 
platelet adhesiveness in whole blood and plasma* It has been shorn that 
platelets are rich in ATP and ADP (Born, 1956 a and b) and that during the 
process og aggregation the nucleotides are rapidly broken down (Born, 1956b 
and 1958; Salzman et al*, 1966; Spaet 1964; Zucker and Borrelli, 1961), 
Thus the incubation of plasma with trypsin may result in platelet changes 
reflected by a fall in the concentration of ADP in the sample which 
facilitate platelet adhesion to a foreign surface as well as to each other* 
In whole blood, these changes may either be prevented or the action of 
trypsin may be inhibited in some way. The decrease in ADP concentration 
in trypsinized plasma is not reflected by an increase in AMP concentration 
(table 15)o Since AMP is only one of the products of metabolism of ADP 
(Chen and Jorgensen, 1957; Ireland and Mills, 1966) it is not possible 
to draw any conclusion from this observation except that either some of 
the ADP present in the sample may be phosphorylated to ATP or that it is 
being degraded beyond ADP*
During the investigation of the action of trypsin on platelet 
adhesiveness in platelet rich plasma it was observed that in some samples 
a surprisingly high percentage of platelet adhesiveness was estimated in 
the control samples treated with saline* when the ADP concentration of 
of whole blood and plasma were measured, it was found that the mean ADP 
concentrations in both whole blood and platelet rich plasma were very 
similar (tables 12 and 14). This observation is in agreement with that of 
Born (1956 a and b )  who demonstrated that platelets have a very large 
store of nucleotides. Further, when the apparent ADP concentrations of 
whole blood and plasma, in the presence and absence of trypsin, before 
and after passage through the glass bead columns were compared there 
appeared to be no significant difference in the amounts measured (tables 
12 and 14). The percentage platelet adhesiveness observed in the control 
and trypsin treated plasma and whole blood samples did not appear to be 
related to either the initial ADP concentration or to the change in ADP 
concentration found in the samples. This result appeared somewhat sur­
prising since it has been shown that in citrated platelet rich plasma, 
platelet adhesiveness appears to be closely related to the concentration 
of added ADP (Hellem et al., 1963; Holmsen et al., 1965). The concentration 
of ADP required to promote platelet adhesion may be so small that it is not 
detectable by the assay system used in this study. Spaet and Lejnicks
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(1966) have suggested that the function of ADP in platelets is to 
supply energy for platelet aggregation and since ADP is a relatively high 
energy source it is conceivable that minute amounts are required for the 
initiation of and the process of platelet aggregation* It has also been 
suggested that the participation of a heat labile plasma factor is 
essential to the process of ADP induced aggregation (Born and Cross, 1964; 
Castalai, 1966; Skalhegg et al*, 1964). These observations may account 
for the apparent lack of correlation between platelet adhesiveness and ADP 
concentration found in this study.
Jorgensen (1956) found that the breakdown of ATP in whole blood was 
much more rapid than in plasma. This observation may account for the 
findings in the present series of experiments in which the concentration of 
AMP present in whole blood appeared to be much greater than that present in 
plasma (tables 13 and 15). Thus it may be the greater platelet adhesiveness 
observed in whole blood over that of platelet rich plasma may be accounted 
for, not by the concentration of ADP in the system but by its ability to be 
dephosphorylated since this process has been shown to occur as platelets 
aggregate (Bom, 1956 b and 1958; Balzman et al«, 1966; Spaet, 1964;
Mucker and Borrelli, 1961 )* It is therefore difficult to come to any firm 
conclusions from this short series of experiments but it would seem that 
platelet adhesiveness in either whole blood or plasma is not dependent
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solely on the concentration of nucleotide in the sample*
Conclusions.
From the results presented in this chapter it would appear that trypsin 
can increase platelet adhesiveness in platelet rich plasma and that both 
streptokinase and trypsin can produce an increase in platelet adhesiveness 
in whole blood under certain conditions of incubation. The percentage 
of platelets lost during the passage of either whole blood or plasma 
through a glass bead column does not appear to be related to the initial 
concentration of ADP in the sample.
135.
CHAPTER 7.
CQMPARIoOH OF CKAHDLER TUBE. IURBIDB1ETRIC aBD HELLEM 
METHOD FOR THE ESTIMATIuH OF PLATELET AGGREGATION.
In chapter 3 was discussed the outline of the various techniques 
used to measure platelet aggregation and the various aspects of platelet 
aggregation on which each method was based. There is still some doubt
as to the precise function of the platelet which is measured by each test
arid in an effort to determine whether there was any correlation between
the tests used in chapters 4, 5 and 6, a comparison was made of the various
methods of assessing platelet aggregation and adhesiveness.
Materials.
ADP was prepared as described in chapter 3.
Platelet rich plasma was prepared as described in chapter 3.
Chandler loops were prepared as described in chapters 3 and 4.
Glass bead columns were prepared as described in chapters 3 and 6.
Cfl^n.iTirp ch 1 nrirle. C.25K was prepared as described in chapter 4•
Methods.
Platelet aggregation was estimated in the Chandler tube system as 
described in chapters 3 and 4 and in the turbiaimetric system as described 
in chapters 3 and 5«
Platelet adhesiveness was assessed by the Hellem glass bead column method 
as described in chapters 3 and 6.
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Platelet counting was performed, by the method ox Dacie (l 956 c) as 
described in chapter 3.
Packed cell volume. It has been shown that there is a direct 
relationship between packed cell volume and platelet adhesiveness 
(Hellem, 1960; Hirsh et al., 1966a; McClure et al., 1966). In order 
to define the relationship between packed cell volume and platelet 
adhesiveness, the effect of the addition of red cell concentrate to 
platelet rich plasma on platelet adhesiveness was investigated. To 45 
ml blood, withdrawn from a volunteer by clean venepuncture, was added 
5 ml of 3.8 per cent sodium citrate. The citrated blood was then 
centrifuged at 600g for 5 minutes at room temperature and the top two 
thirds of the plasma removed from each centrifuge tube. The red cell 
concentrate was then centrifuged at 150C g for 20 minutes at room 
temperature and the bottom 1 .0 ml of red cell concentrate harvested from 
each tube. The platelet poor plasma from each tube was also collected.
A series of samples was then prepared in which the volume of platelet 
rich plasma was kept constant and the relative concentrations of platelet 
poor plasma and red cell concentrate added to each sample were varied 
so that, while maintaining a uniform dilution of the platelet rich plasma, 
the haematocrit of the samples varied over the range 94 - 43/°» The 
percentage platelet adhesiveness was estimated by the glass bead column
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method, and the results are shown in figure 44.
The racked cell volume of the samples was measured by means of a 
Hawksley microhaematocrit centrifuge.
Fibrinogen assays were performed as described in chapter 3.
Plasminogen assays were carried out as described in chapter 3.
Results.
Twenty five normal control subjects were selected. From each
volunteer, 22.5: ml blood were withdrawn by clean venepuncture and
anticoagulated with 2.5 ml, 3.8^ sodium citrate. 5 ml of the citrated
whole blood was allowed to stand at room temperature for a minimum of 30
minutes and a maximum of 45 minutes while platelet rich plasma was
prepared from the remainder of the blood, and tested simultaneously in the
Chandler tube system and in the turbidimetric system. For the Chandler
tube system 5 ml, platelet rich plasma were made up to 14.5 ml with
0.9 per cent saline and the plasma recalcified with 0.5 ml, 0.25M CaCl^.
For the turbidimetric system 2 ml, platelet rich plasma were added to a
cuvette in the light path of a photoelectric cell, the plasma stirred
for at least 1 minute to ensure that spontaneous aggregation did not
occur and platelet aggregation induced by the addition of ADP (0.5yUg per
ml plasma). The contact time between the citrated whole blood and the
+
glass beads in the Hellem system was 30 - 1 sec.
In addition to the citrated whole blood collected from each patient
a sample was anticoagulated by addition to disodium EDTA and the 
packed cell volume, of each subject, estimated on this sample. From the 
results of the graph of percentage packed cell volume against percentage 
platelet adhesiveness (figure 44) a linear correlation appears to 
exist between the two parameters. From this graph it was estimated 
that a change of one unit of packed cell volume corresponded to an 
alteration of 1.8/units of platelet adhesiveness. The mean value for the 
packed cell volume of the twenty five samples investigated was 40 .3 with 
a standard deviation of - 5.0 (table 18) which lies within the accepted 
range of normal (Dacie, 1956 a). In the present trial, the packed cell 
volume of the individual blood sample was not adjusted to 40 per cent 
by the addition of platelet poor plasma or red cell concentrate to the 
citrated whole blood because the packed cell volume of the samples lay 
within the physiological range of normal.
Mathematical correlation of the results of platelet function as 
assessed by each method, the Chandler tube, the turbidimetric method 
and the glass bead column method, have been determined and the results 
are shown in table 19. The 1 minute and 4 minute optical density 
readings obtained in the turbidimetric system were selected for comparison. 
The 1 minute reading was selected because by this time platelet aggregates
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had begun to form in every sample so that this reading represents the 
initial stages of the reaction between platelets and exogenous aDP.
The 4 minute reading was selected because by this time the maximum aggregation 
had occurred in the majority of the twenty five samples as was indicated 
by a graph dram from the mean values obtained from the optical density 
readings. From the results presented in table 19 there appears to be 
no significant correlation between the results of the three methods 
examined, irrespective of the optical density readings selected for 
comparison. The platelet adhesiveness for each of the samples was then 
adjusted, to allow for the differences in the packed cell volume, from the 
calibration curve described above and the mathematical correlation between 
the results of each technique reinvestigated. The correlation coefficients 
obtained are shorn in table 19. Once again there is no mathematical 
significance between the observations obtained for each of the three 
methods. ho advantage appeared to have been gained by the correction 
of the platelet adhesiveness for packed cell volume since, as shoxm 
in table 18, the mean and standard deviations of the adhesiveness over 
the series of samples investigated was similar before and after adjustment.
The data from forty of the plasma samples examined in the control 
loop of the Chandler tube experiments described in chapter 4 was gathered.
The mathematical correlation between the speed of formation of platelet 
aggregates and the platelet count in each sample was estimated and the 
result is shown in table 20. There appears to be no significant correlation
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between the speed of formation of platelet aggregates and the platelet 
count. similar mathematical treatment was carried out on 53 of the 
control specimens used in the turbidimetric experiments described in chapter 
5. For this series of experiments the optical density reading 2 minutes 
after the addition of ADP to the sample was examined since over the 
series of experiments this was the time at -which maximum aggregation 
invariably occurred. The result is shown in table 20 and indicates that 
there appears to be.no mathematical correlation between the degree of 
platelet aggregation, as estimated from the optical density change 
occurring in the sample, and the platelet count of the sample.
Mathematical correlation was also assessed between the platelet counts of 
the twenty-five citrated whole blood samples used in the trial described 
above and the percentage platelet adhesiveness of the samples. As shown 
in table 20 there appears to be no correlation between platelet count 
and percentage platelet adhesiveness either uncorrected or adjusted for 
packed cell volume.
The concentration of fibrinogen and plasminogen, present in the 
plasma samples used in the Chandler tube series of experiments and 
turbidimetric experiments on which mathematical studies were perfoimed, 
was estimated. As shown in table 21 the results lay within the accepted 
range of normal for this laboratory.
Discussion.
From the results presented above there appears to be no correlation
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between the results obtained from the three techniques used to investigate 
platelet aggregation and platelet adhesiveness (table 19)* This 
observation throws some doubt on the validity of these tests as an 
index of platelet function. As was discussed in chapters 2 and 3> 
however, each of the methods used is based on a different aspect of the 
phenomenon of platelet clumping. The turbidimetric system of Born 
depends on the ability of platelets to react with or metabolise 
exogenous ADP, the Eellem glass bead column method is based on the 
ability of platelets to adhere to a glass surface and the Chandler tube 
system depends on the ability of platelets to form aggregates as a 
precursor to fibrin formation in an artificial circulation. The 
Chandler tube system, as mentioned in chapter 5> probably measures a much 
later stage in the sequence of platelet aggregation than either of the 
other two methods since macroscopic platelet clumping has to occur before 
it is detected in the rotating loop. In addition the platelet clumps 
which form in the Chandler tube system do not disaggregate, whereas, as 
indicated by the control curves in figures 16 and 20, the platelet 
aggregates which form in the turbidimetric system undergo spontaneous 
disaggregation (Born and Cross, 1963b; Mitchell and Sharp, 1964)*
The Hellem glass bead column method possibly measures a stage of 
aggregation intermediate between that of the turbidimetric method and 
the Chandler tube method since platelet adhesion to the glass surface is
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initiated by the release of ADP from red cells damaged during the passage 
of blood through the column (Hellem, 1960; Stormorken et al., 1965).
Thus it is possible that the apparent lack of correlation'between each 
method is probably due to the fact that a different parameter is being 
measured in each case. This view is partially substantiated by the
observation of Hirsh et al., (1966b) that a significant mathematical 
correlation exists between the results of platelet adhesiveness assessed 
in the Hellem glass bead 001x11101 and the Wright ‘rotator1 since with both 
these techniques a similar parameter is being measured, namely, the 
ability of platelets to adhere to a damaged surface. Furthermore, the 
platelet populations xdiich are assayed in the methods involving platelet 
rich plasma and those utilizing citrated whole blood a r e  probably different. 
Stormorken et al., (1965) have shown that the most adhesive platelets within 
a sample are those which are most easily sedimented and accordingly a 
percentage of adhesive platelets within each sample may have been lost 
during the centrifugation procedure to prepare platelet rich plasma.
The Chandler tube method, the turbidimetric method and the Hellem 
method would each appear to measure some inherent property of the 
platelet population of the samples under investigation. I11 none of the 
methods was there any mathematical correlation between platelet count and 
the extent of platelet clumping or the rate of clumping within the sample
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(table 20) „ A lack of correlation between platelet count and platelet 
adhesiveness has previously been reported (Hirsh et al., 1966a). This 
observation is contrary to that of Stormorken et al., (l965) who have shown 
that within a specific platelet population there exists a linear relation­
ship between platelet count and platelet adhesiveness. These workers 
also claim that there is a linear relationship between the amount of ADP 
added to a sample platelet rich plasma and the adhesiveness of that 
sample. This is contrary to the results presented in chapter 6 where the 
data fail to reveal a correlation between the recorded platelet adhesiveness 
of a sample and the initial ADP concentration within the sample. Prom 
these observations it may be concluded that the various methods used in 
this trial measure some, as yet undefined, inherent property of the platelets 
and the results obtained are to some extent independent of the number of 
platelets present.
The difference between the results obtained with the three methods 
may be quantitative rather than qualitative since it would appear that 
alterations, in platelet rich plasma and blood, which influence platelet 
aggregation are reflected in all three methods although the quantitative 
changes are variable. In chapters 4, 5 and 6 have been presented and 
discussed the observations on the effect of the enzymes streptokinase and
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trypsin on platelet function. Both enzymes could be made to enhance 
aggregation in the Chandler tube, turbidimetric and Hellem techniques but 
in some instances the concentration of enzyme required to produce this 
effect is higher than in others. Further investigations will have to be 
performed before the significance of the similarities and the differences 
of the various techniques currently available to investigate the ability 
of platelets to clump in vitro.
Conclusions.
From the results presented in this chapter it would appear that there 
is 110 mathematical correlation between observations made for platelet 
function in the Chandler tube method, the turbidimetric method and the 
glass bead column method. 'There is some evidence to suggest, however, that 
each method measures some inherent property of the platelet population of 
the samples under investigation and that the differences observed between 
each method may be quantitative rather than qualitative.
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CHAPTER 8 .
PREPARATION OF FIBRINQGEH DEGRADATION PRODUCTS.
The observations presented in chapters 4 ,  5 and 6 show that trypsin 
can produce significant enhancement of both platelet aggregation and platelet 
adhesiveness. In the platelet rich plasma systems described in chapters 4 
and 5 it appeared that the effect of trypsin on platelet aggregation could 
not be accounted for wholely on the basis of the coagulative properties of 
the enzyme. In addition, in the Chandler tube system, in which fibrin 
formation occurs as a sequel to platelet aggregation it was found that, the 
presence of trypsin in the system resulted in significant impairment in 
fibrin formation. Further, as discussed in chapter 5> it appears that 
trypsin does not produce enhancement of platelet aggregation by direct 
action on the platelets and that the presence of plasma proteins are 
essential for its action. Accordingly, it was thought worth while to 
investigate the effect of fibrinogen digests on platelet aggregation. The 
fibrinogen digests were purified by column chromatography before appraisal 
of their physical and chemical characteristics and of their effect on 
platelet aggregation.
In this chapter is presented an account of the method of preparation 
of fibrinogen degradation products formed by the action of trypsin on 
fibrinogen or on the action of urokinase activated plasminogen on the protein.
Materials.
Fihrn nngp.n. Human lyophilized fibrinogen, Grade L, was obtained from
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A.B. Aabi, Stockholm. The protein was made up to the required 
concentration with 0o1M phosphate buffer, pH 7 .6 immediately before use. 
Plasminogen. Human lyophilized plasminogen, Grade 3, was obtained from 
A.B„ Kabi, Stockholm. The protein was reconstituted, Immediately before 
use, with distilled water to give a concentration of 17*5 Sgouris units 
per ml.
Urokinase was obtained from Abbott Laboratories, Illinois. Immediately 
before use the enzyme was reconstituted with distilled water to give a 
concentration of 40,000 CTA units per ml.
pj fithvl.sininoethvl cellulose (PBll) was obtained from W. and R. Balston 
Ltd., England. The PEAL cellulose was prepared for column chromatography 
by immersing PE11 in 0.5U HG1, in the proportion of 10 g cellulose to 
150 ml acid, and allowing the suspension to stand for one hour. The 
cellulose was then washed with distilled water before it was Immersed in 
0.5 U, HaOH in the same proportions as with the acid. Finally the 
cellulose was washed with 1 H HaCl until the pH of the washings was 
7 and most of the fine particles had been removed by decantion.
G~25 Senhadex (coarse) was obtained from Pharmacia, Sweden.
The preparations of trvnsin and soybean trypsin inhibitor used 
are described in chapter 3 along with the methods of preparation of 0.1 M 
phosphate buffer. pH 7.6 and 0.1M carbonate buffer, pH 8.9
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Methods.
Preparation of Columns. The columns were packed at room temperature 
with DEAE cellulose in 2 M HaCl. The DEAE cellulose was held in the 
column by a thin layer of glass wool covered with a layer of glass beads 
to give a smooth surface to support the cellulose. The glass columns were 
of heavy duty glass, 45 cm long and 2 .5 cm internal diameter, and were 
specially made to have a negligible dead space. The first few centimetres 
of cellulose were packed into the column under gravity and the rest of the 
column was packed under the pressure of a small hand pump, at approximately 
51bs pressure per sq. in. The final length of the cellulose column was 
37»5 cm. After packing, the column was washed with distilled water until 
the pH of the eluant was 7.0 and then equilibrated with 0.1M carbonate 
buffer, pH 8.9 before a protein solution was eluted from the column. A 
fresh column was prepared for each experiment.
Buffer system. Fibrinogen degradation products -were eluted from the BEAS 
cellulose column with a linear concentration gradient with the range of 
buffer from 0.1k carbonate buffer pH 8.9 to 0.1k carbonate buffer, pH 8.9 
plus 0.2 k HaCl in a total volume of 800 ml. The head of pressure 
between the top of the column and the reservoir was adjusted in each 
experiment so that a flow rate of approximately 90 ml per hour could be 
achieved.
Concentration of .proteins. The samples eluted from the column 
which had been shown to contain protein by measurement of optical 
density at 280 m j i  were concentrated with G-25 Eephadex using oeitz 
filters. 10 ml of the protein solution were concentrated with 4 g 
Sephadex by centrifugation at 1600 g for 15 minutes at 4°C.
Estimation of protein concentration was carried out by the method of 
Lowry et al., U95l) as described in chapter 3. The fibrinogen degradation 
products prepared by column chromatography were stored at -2Q°C in small 
amounts for periods not greater than a few weeks.
Results.
Initial ex-nerlmfints were carried out to study the elution patterns of pure 
fibrinogen, plasminogen, trypsin, soybean trypsin inhibitor and urokinase 
from a DEAE cellulose column.
100 mg pure human fibrinogen dissolved in 2 ml, 0 .1M phosphate 
buffer, pH 7°6 was layered onto the surface of a DEAE cellulose column.
The protein was eluted from the column with the buffer system, 0.1 M 
carbonate buffer, pH 8.9 to 0.11-I carbonate buffer plus 0.5 M HaCl, in a 
total volume of 800 ml with a flow rate of 90 ml per hour. The 
fractions were collected in volumes of 10 ml and the pattern obtained 
is shown in figure 45. Fibrinogen appears to be eluted from the column 
at a sodium chloride molarity of 0.105M. A small shoulder appears on the 
main peak and this may either be an impurity in the fibrinogen solution
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or some denatured protein.
0.5 ml, purified plasminogen solution (17.5 Sgouris units per ml) 
was eluted from a DEAE cellulose column with the buffer system 0.1M 
carbonate buffer, pH 8.9 to 0.1M carbonate buffer plus 0.2 M HaCl, in 
350 ml with a flow rate of 100 ml per hour. The fractions were collected 
in 10 ml amounts and the pattern is shown in figure 46. Plasminogen 
appears to be eluted from the column in two fractions, the major fraction 
being eluted from the column at a sodium chloride molarity of O.G77 M 
and the smaller fraction at 0.159 H HaCl.
A solution composed of 1 ml trypsin (22.2 mg/ml) and 1 ml soybean 
trypsin inhibitor (22.2 mg/ml) was eluted from a column with the buffer 
system, 0.1M carbonate buffer, pH 8.9 to 0.1M carbonate buffer plus 
0.4 k HaCl, in a total volume of 800 ml with a flow rate of 80 ml/hour.
The eluant was collected in 10 ml samples and the pattern is shown in 
figure 47. Within the salt concentration studied, only one protein 
containing fraction appeared to be eluted from the column which is in 
keeping with concept of the formation of an irreversible stoichiometric 
compound in the presence of trypsin and soybean trypsin inhibitor 
(Northrop et al., 1948). The protein was eluted from the column at a 
sodium chloride molarity of 0.314k.
0.5 ml urokinase (40,000 CTA units per ml) were eluted from a
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DEAE cellulose column with the buffer system, 0.1 M carbonate buffer, pH 
8.9 to 0.1M carbonate buffer plus 0.2 M HaCl, in 400 ml with a flow 
rate of 84 ml per hour. The eluant was collected in 10 ml amounts and 
the elution pattern is shown in figure 48. It would seem from the 
elution pattern that the urokinase solution contains a number of components, 
none of which are removed from the column at a sodium chloride molarity 
of less than 0.0751-1. The main component appears to be eluted at a salt 
concentration of 0.120 M NaCl.
Prenaration of degradation products. For the preparation of fibrinogen 
degradation products by tryptic digestion, conditions of incubation were 
selected which were to some extent comparable to those under which 
trypsin and platelet rich plasma were allowed to react. The average 
fibrinogen content of plasma was assumed to be 500 mg per 100 ml plasma.
Thus the incubation of 2 ml plasma with 20 j i g  trypsin would be approximately 
equivalent to incubating 6 mg fibrinogen with 20j a g  trypsin. Similarly, 
incubation of 2 ml plasma with 200 yug trypsin was assumed to be comparable 
to incubating 6 mg fibrinogen with 200 j i g  trypsin.
The first degradation product was made by the addition of 0.3 ml 
trypsin (2 .22 mg per ml) to 200 mg fibrinogen in 4 ml, 0.1M phosphate 
buffer pH 7.6. After incubation at 37°C for 10 minutes, 0.3 ml soybean 
trypsin inhibitor (2 .22 mg per ml) were added to the mixture and the 
resulting solution was layered onto a DEAE cellulose column. The protein
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was eluted from the column with the buffer system described above. The 
flow rate was 88 ml per hour and the elution pattern is shorn in figure 
49® The major portion of the protein appeared to be eluted as a single 
fraction with a much smaller fraction separating at a slightly higher salt 
concentration. The main component was eluted from the column in a 
volume of 50 ml between the HaCl concentrations 0.032M and O.O42M, the 
sample containing the largest concentration of protein (as estimated by 
optical density measurements) being eluted at O.O36M HaCl. The pooled 
samples from this peak were concentrated with G-25 sephadex and the protein 
concentration of the final protein solution estimated by the method of 
Lowry et al., (1951)® This product will be referred to in subsequent 
chapters as product 'a1.
The second fibrinogen degradation product was made by the incubation 
of 200 mg fibrinogen in 4 ml, 0.1 M phosphate buffer, pH 7.6 with 0.3 ml 
trypsin (22.2 mg per ml) at 37°C for 10 minutes. After incubation, 0.3 ml 
soybean trypsin inhibitor (22.2 mg per ml) was added to the incubation
mixture and the products of digestion separated from the mixture by
fractionation on a DEAE cellulose column. The protein was eluted with the 
standard buffer system with a flow rate of 90 ml per hour. The resulting
elution pattern is shown in figure 50. As with the first degradation
product prepared, the major portion of the protein was eluted as a single
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well defined peak in a volume of 60 ml between the HaCl concentrations 
0.033 H and 0.045 H and with a maximum optical density reading at the 
concentration O.O4O M HaCl. The samples forming this peak were pooled, 
concentrated with G-25 sephadez and the protein concentration of the 
resulting solution estimated. This protein will be referred to as 
product 'b1. A second sample of product 1 b* has been made and, as shown 
in figure 51 > the elution pattern is, within the limits of experimental 
error, identical to the first pattern obtained for this product. The 
major portion of the protein was eluted from the column in a volume of 40 
ml between the concentrations O.O4OK and 0.047k HaCl with a maximum at 
0.045M ITaCl.
A third degradation product was made by the incubation of 200mg 
fibrinogen in 4 ml, 0.1M phosphate buffer, pH 7 .6 with 0.3 ml trypsin 
(22.2 mg per ml) at 37°C for 16 hours. After incubation, 0.3 ml soybean 
trypsin inhibitor (22.2 mg per ml) was added and the various protein fractions 
eluted from this mixture by column chromatography. The elution was 
carried out with the usual buffer system, with a flow rate of 95 ml per 
hour and the resulting elution pattern is shown in figure 52. The 
elution pattern is somewhat diffuse but a single well defined fraction 
was separated in a volume of 50 ml between 0o035k HaCl and 0.045 M HaCl 
with a maximum at 0.040M HaCl. The samples in this fraction were pooled,
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concentrated with. G—25 sephadex and the protein concentrations of the 
final solutions estimated. This product will he referred to as product 
’c1.
Trypsin is an e n z y m e  which is not normally found in circulating 
hlood. It has been shown that plasmin digestion of fibrinogen can produce 
a variety of degradation products (Fletcher et al., 1966; Hirsh et al.,
1965; Jerushalmy and Zucker, 1966; Hussenzweig et al., 1961) • Thus, in 
order to compare degradation products prepared by tryptic digestion of 
fibrinogen, a degradation product which could be produced under physiological 
conditions was prepared by digestion of fibrinogen with plasmin formed by the 
activation of plasminogen by urokinase. Fibrinogen, 200 mg in 4 ml, 0.1M 
phosphate buffer, pH 7.6, was incubated with 0.1 ml urokinase (40,000 GTA 
units per ml) and 1 „0 ml plasminogen (17«5 Sgouris units per ml) at 37°C for 
10 minutes. After incubation, the mixture was immediately layered onto a 
DEAE cellulose column and the fractionation process started. The elution 
was carried out with the usual buffer system with a flow rate of 84 ml 
per hour. The elution pattern is shown in figure 53. The major portion 
of the protein was eluted a single broad peak in a volume of 80 ml 
between the HaCl concentrations 0.030M and 0.047k. The central sample 
of this peak was eluted at a HaCl concentration of 0.035 M. The samples 
forming this peak were pooled, concentrated with G—25 sephadex and the 
protein concentration of the final solution estimated. This protein will
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be referred to as product 'd*.
For comparative purposes, in the subsequent study of the effect of 
the degradation products, prepared as described, on platelet aggregation, 
pure fibrinogen incubated at 37° C without the addition of an enzyme was 
fractionated by column chromatography. After incubation of 200 mg 
fibrinogen in 4 ml, 0.1I-I phosphate buffer, pH 7.6 at 37°C for 10 minutes 
the protein was eluted from a column with the usual buffer system at a 
flow rate of 92 ml per hour. The elution pattern is shorn in figure 54. 
Fibrinogen was eluted from the column in a volume of 70 ml between the 
concentrations 0.085M and 0.010 M HaCl. The central sample of the peak 
was eluted with a concentration of 0.091 M HaCl. In view of the different 
concentration gradients used in the initial experiment and in the present 
experiment, the elution patterns for the two fibrinogen solutions are 
essentially similar. The samples comprising the peak were pooled, 
concentrated with G-25 sephadex and the protein concentration in the final 
solution estimated.
Discussion.
The degradation products formed by the digestion of fibrinogen with 
trypsin or plasmin appear to be quite separate and distinct entities from 
the original fibrinogen. The degradation products prepared by plasmin 
digestion and by short trypsin digestion of fibrinogen appear to be somewhat 
similar in that they are all eluted from the DEAE cellulose column
155.
within the sodium chloride concentration r a n g e  o f  0 .030 M and 0 .047 M. 
W i t h  prolonged digestion of fibrinogen by trypsin a diffuse elution 
pattern was obtained (figure 52) but a definite peak of protein was 
visible within this concentration range. These observations would seem 
to suggest that the initial reaction of fihrinogenolytic enzymes on 
fibrinogen involves the formation of a smaller protein moiety which in 
turn may be degraded' by prolonged proteolytic activity. This suggestion 
is supported to some extent by the observations of Mihalyi and Godfrey 
(1963b).
W i t h  the elution system described in this chapter minor variations 
in the elution patterns of the various degradation products may have been 
lost since the eluant samples were collected in the relatively large 
amounts of 10 ml. There is, however, a striking similarity between the 
elution patterns of the degradation products 'a1, 'b1 and 'd'.
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CHAPTER Q.
CHARACTERIZATION OF FIBRINOGEN DEGRADATION PRODUCTS.
In this chapter is presented the results of investigations 
carried out on the various degradation products formed by proteolytic 
digestion of fibrinogen as described in chapter 8. The physicochemical 
parameters chosen to characterize the various protein fragments included 
molecular weight determinations, ultracentrifugation patterns and 
electrophoretic studies. The degree of digestion occurring in the formation 
of two of the products has also been investigated by estimation of the 
number of peptide bonds of the parent fibrinogen molecule ruptured during 
the enzymatic reaction.
Materials.
Sucrose. Analar grade, was obtained from British Drug Houses Ltd.
1 per cent aid 15 per cent sucrose solutions were made up in 0.05M 
sodium phosphate buffer, pH 7 .5.
Phn.qphate buffer. -Sodium phosphate buffer of 0.05 molar and pH 7.5 was 
prepared as follows:- 16.0 ml, 0.2 M NaH^PO (27.80g per litre); 84 
ml, 0.2 M NagHPO (28.54g per litre); distilled water to 200 ml.
Ribonuclease (RNase) was a chromatographically prepared protein obtained 
from Koch Light Laboratories Ltd.
Tubing used for dialysis was Visking tubing 8/32" obtained from E.M.C. 
Scientific Instruments Centre, London.
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Fibrinogen was obtained in the form human, lyophilized Grade L from 
A.B. Kabi, Stockholm.
Trypsin. The preparation used was that described in chapter 3<>
Methods.
Sucrose density gradients were prepared with the Buchler Gradient Sedimentation 
System as described in chapter 3. The gradients were prepared immediately 
before centrifugation was carried out.
Ultracentrifugation studies were performed on a Spinco, Model E, Ultracentrifuge 
equipped with a Schliem optical system. The ultracentrifugal patterns for the 
sedimentation runs were photographed at zero, 8, 16, 24, 32 and 64 minutes 
from the start of the run. For the diffusion runs, the ultracentrifugal 
patterns were photographed 8, 16, 24, 32, 40 and 48 minutes from the start 
of the run.
Electrophoresis was carried out as described in chapter 3«
Reaction 1<i ne t i  p.s - The degree of digestion of fibrinogen occurring during 
the formation of the degradation products 'a' and *b' was investigated as 
described in chapter 3«
Results.
Molecular weight riatp.myinations. The approximate molecular weights of the
fibrinogen degradation products 'a1, *b*, *c' and 'd' were estimated by 
sedimentation in a sucrose solution with a linear concentration gradient.
The proteins were eluted from the density gradient by collection of drops
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from the bottom of the tube and the samples collected screened for protein 
content by measuring the optical density of the solutions at 280 myu.
Pure fibrinogen (molecular weight 340,000) and RNase (molecular 
weight 12,700) were assayed in the sucrose density gradient system as 
references for the estimation of the molecular weights of the degradation 
products. The elution pattern obtained with fibrinogen is shown in
figure 35. Fibrinogen sediments in the sucrose solution as two peaks.
The main peak appeared to be sedimented in the range of sucrose concentrations 
from 9.0 ? o  to 5.0/^  sucrose with a maximum at 6.4/°« The very much smaller, 
secondary peak was eluted with the sucrose solution in the concentration 
range 1.8)0 to 1 ,2>o sucrose with a peak at 1 »5/b sucrose. From this pattern 
it would appear that the fibrinogen solution is not completely homogeneous.
It is possible that the small secondary peak may represent plasminogen which 
is contaminating the fibrinogen preparation. The fractionation of fibrinogen 
on a DEAE cellulose column appears to remove the contaminating protein.
The pattern obtained from the elution of the protein solution, obtained from 
fibrinogen by column chromatography, from the sucrose density gradient is 
shown in figure 56. The protein fraction bears close resemblance to the 
main fraction of the untreated fibrinogen (figure 55). The protein was 
sedimented in the range of sucrose concentrations 7.2)6 to 4 • 7 C/'3  sucrose 
with a maximum at 5.3;<> sucrose. This fraction was used as a reference for 
the degradation products. The second protein studied as a reference for the
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degradation products was RITase. This protein, of known molecular weight, 
was sedimented in the range of sucrose concentrations 4.25$ to 1.4$ 
sucrose with a maximum at 2.5$ sucrose. The elution pattern is shown in 
figure 57»
The elution pattern obtained with product 'a' is shown in figure 58. 
The protein solution appeared to have some denatured protein which was 
eluted from the bottom of the gradient but the bulk of the protein was 
eluted as a somewhat diffuse band between the sucrose concentration of 8.25/° 
and 2.50$ with a maximum at 4.25$ sucrose. There appeared to be a second 
fraction in this solution which was eluted with sucrose at a concentration 
of 2.2/0. The molecular weight of the main fraction was estimated from the 
concentration of sucrose at which the maximum optical density reading of the 
protein fraction was obtained and was calculated as 217,263.
The elution pattern obtained for product 'b1 in the sucrose density 
gradient system is shown in figure 59. The main fraction of the protein 
was removed from the gradient between the sucrose concentrations of 8.25$ 
and 3.2$ with a maximum at 4.6$ sucrose. The molecular weight of the 
fraction, calculated from this point, was 258,175. As with product *a', 
there appeared to be a second protein separated from the solution during 
the sucrose density gradient experiment at a sucrose concentration of 
1.75$ sucrose.
Product ' c1 remained at the top of the sucrose solution and was
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eluted with the sucrose solution at a concentration of 1$. Therefore 
it would appear that the molecular weight of this protein is less than 
12,700 since the protein RMase which has this molecular weight was removed 
from the gradient with 2.5$ sucrose.
Product 1 d1 was eluted from a sucrose density gradient in three 
fractions (figure 60). The main fraction was separated between the sucrose 
concentrations of 8.2$ and 3.25$ with a maximum at 4.9$ sucrose. The 
molecular weight calculated from this point was 293,243. Two smaller 
fractions were visible at sucrose concentrations of 12.1$ sucrose and 2.4/^  
sucrose.
'tfith the sucrose density gradient method, the molecular weights of the 
degradation products ’a1, 'b1 and 'd1 appeared to be similar. The results 
are somewhat unsatisfactory, however, as the proteins separated in the sucrose 
solution as diffuse bands and it was difficult to determine precise 
molecular weights. The molecular weights of the two products 'a' and 'b1 
were further investigated by ultracentrifugation studies.
Ultracentrifugation. The ultracentrifugation studies were performed by
Miss H. Moss and Mrs 3. Beaton of the Biochemistry Department, University 
of Glasgow. Samples of products ‘a1 and *b1 were prepared and concentrated 
with G-25 sephadex until the protein concentration was 10 mg per ml.
Both products were then dialysed overnight at 4°C, each sample against 
1 litre of 0.15 I-i HaCl. The protein solutions were then stored at -20°C 
until they were analyzed on the ultracentrifuge. It was only possible to
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perform one determination of the sedimentation and diffusion coefficients
for each product,, The sedimentation and diffusion patterns obtained for
product 'b' are shown in figures 61 and 62. For product 'a' the
-13sedimentation coefficient was calculated as 6.72 x 10 sec and the diffusion
-7 2
coefficient as 6.62 x 10 cm per sec From these results the molecular 
weight of the product was calculated from the Svedberg equation as 82,427.
-13For product 'b1, the sedimentation coefficient was calculated as 4.37 2 10 
sec and the diffusion coefficient as 1.44 x 10  ^cm per sec. The molecular 
weight of product ‘b1 was calculated from these values in the Svedberg 
equation as 24,642.
Electrophoresis. The degradation products were examined by electrophoretic 
analysis as described in chapter 3« For comparative purposes pure 
fibrinogen and fibrinogen which had been fractionated on a DEAE cellulose 
column were also investigated. The patterns are shown in figure 63. As all 
the proteins moved in diffuse bands it was not possible to draw precise 
conclusions for the eLectrophoretic characteristics of the degradation 
products. All the degradation products studied appear to behave similarly 
during electrophoresis and in a somewhat different fashion to fibrinogen.
The fibrinogen samples tended towards the anode indicating that the molecule 
has a net negative charge while the degradation products remained as 
diffuse bands around the origin. The electrophoretic bands for fibrinogen 
before and after passage through a DEAE cellulose column are identical.
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This suggests that the fractionation of the protein on the column 
does not cause degradation or denaturation of the protein.
An attempt to improve the electrophoretic bands by current reversal 
at the end of electrophoresis was not successful.
Reaction Kinetics. The degree of digestion of the fibrinogen molecule 
which occurred during the formation of products 'a' and 'b1 was estimated 
with a pH stat as described in chapter 3. To simulate the conditions for 
the formation of product 'a1, the reaction between 1 ml fibrinogen (?Qmg per 
ml) and 0.5 ml trypsin (0.1334 mg per ml) was followed at 37°C for 10 
minutes. During this reaction 0.03 ml, 0.0335 H ITaOE were required to main­
tain the pH of the fibrinogen solution at 8.6. This is equivalent to 
—61.005 x 10 moles of alkali and hence the number of moles of alkali required
to maintain 340,000g fibrinogen at a constant pH would be 17.085. Since
0.998 meq of alkali are utilized for every hydrogen bond broken in the
protein molecule, it would appear that 17 peptide bonds in the fibrinogen
molecule are broken during the formation of product 'a*.
For the investigation of the reaction leading to the formation of
product 'b1, the reaction between 1 ml fibrinogen (20 mg per ml) and 0.5 ml
trypsin (l .334 mg per ml) was followed at 37°0 for 10 minutes. To maintain
the pH of the fibrinogen solution at 8.6 during this reaction, 0.08 ml,
—6
0.0335R NaOH were utilized. Since 2.680 x 10 moles of alkali would be 
required for 0.02g fibrinogen, 45.56 moles of alkali would be required for 
340,000g fibrinogen. Thus it would appear that, in the formation of
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product !b', 45 peptide bonds in the fibrinogen molecule are broken.
Discussion.
From the results it would appear that the degradation products formed 
by enzymatic digestion of fibrinogen have different physico-chemical 
parameters from the parent molecule.
The molecular weights of the degradation products, as determined by 
sucrose density studies, indicated that the products were all smaller then 
fibrinogen. It was not possible to detect any significant difference between 
products 'a1, *b' and ‘d*. This may partly be accounted for by the observa­
tion that all the proteins, including fibrinogen, were eluted from the 
gradient within a wide range of sucrose concentration indicating that, in 
addition to sedimentation, 3ome diffusion of the proteins through the 
sucrose solution had occurred. Further, there are a number of sources of 
error in this system; the sampling system from the gradient is empirical 
and minor variations in the size of the drops collected may occur and minor 
variations may also occur in the dilution of the samples.
The ultracentrifuge studies show clearly that the products ’a* and 'b! 
are quite different. Table 22 illustrates the different sedimentation 
and diffusion coefficients and molecular weights for the two products and 
of fibrinogen. The ultracentrifugation data for fibrinogen was obtained 
from Caspary and Ivekwick (1954) as quoted by Scheraga and Laskowski (1957) •
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Although it was not possible to carry out ultracentrifugation analysis on
product ’d1, formed by urokinase-activated plasminogen digestion of fibrinogen,
there are a number of reports which suggest that degradation products formed
by plasmin proteolysis are similar to these formed by tryptic digestion of
fibrinogen (Beck and Jackson, 1966; Fletcher, et al., 1962). It has been
shown that the enzyme plasmin degrades fibrinogen into three classes of
-13fragment: the first has a sedimentation coefficient of 5®27 x 10 sec and
a molecular weight of 88,000; the second has a sedimentation coefficient of 
—133.00 x 10 sec and a molecular weight of 30,000; and the third has a
■"13sedimentation coefficient of 1.4 x 10 sec (Alkjaersig et al., 1962;
Fletcher, 1966; Fletcher et al®, 1966). Similar values have also been 
obtained by Larrieu et al., (1966). These values are comparable to those 
found for the degradation products produced by trypsin digestion of fibrinogen 
(table 22). These observations together with the pattern obtained by sucrose 
density gradient sedimentation of product ' d * would seem to suggest that the 
product formed under the proteolytic action of urokinase-activated plasminogen 
is similar to those produced by tryptic digestion of fibrinogen.
Electrophoresis of the degradation products revealed no distinguishable 
difference between the patterns for the products formed under the action of 
trypsin to that of the product formed by urokinase-activated plasminogen 
although the products gave slightly different patterns to that of fibrinogen. 
Fibrinogen, both before and after passage through a DEAE cellulose column 
was found to be anionic. This is in agreement with the observations of
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several authors using different electrophoretic media (Beck and Jackson,
1966; hihalyi, 1950; Seegers et al., 1945). Further, by means of starch
gel electrophoresis, it has been shown that trypsin digestion products also
have an anodal tendency (Beck and Jackson, 1966) and that this tendency is
also exhibited by plasmin digestion products (Beck and Jackson, 1966;
Bussenzweig et al., 1961 ). The movement of the products towards the anode
during paper electrophoresis was not demonstrated in the present study but
such movement may have been masked by the diffusion of the products during
the electrophoretic run.
The reaction kinetics of the degradation of bovine fibrinogen by trypsin
have been extensively studied by Mihalyi and Godfrey (1963a). These workers
demonstrated that the reaction proceeded in two stages; the first stage
involved the splitting of 12 peptide bonds and the second stage involved
the rupture of 88 peptide bonds. Subsequent examination of the product
formed at the end of the first stage of the reaction showed that the protein
-“ 13had a sedimentation coefficient of 5.22 x 1u sec, a diffusion coefficient
-7 2 ,of 5.12 x 10 cm per sec and a molecular weight of 95,000 Uiihalyi and
Godfrey, 1963b). Further, they suggested that 3 such fragments were formed
from every molecule of fibrinogen. The present results for the action of
trypsin on human fibrinogen are in accord with those of Mihalyi and Godfrey
(1963a and b). The degradation of the fibrinogen molecule results in a
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product with a very much smaller molecular weight than fibrinogen although 
relatively few peptide bonds have been broken. The currently accepted 
concept for the structure of fibrinogen is that the molecule is made up of 
three peptide chains (Blomback and Xamashina, 1958; Blomback et al., 1966; 
Laki and Gladner, 1964-) • Thus it seems probable that the initial action 
of trypsin on fibrinogen is on the bonds between the three chains of the 
molecule since cleavage of the bonds between the peptide chains would result 
in a marked diminution in the molecular weight of the protein moiety. 
Consequently the degradation products may be molecules relatively simple in 
structure as compared to the parent fibrinogen molecule.
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CHAPTER 10.
EFFECT OF FIBHIHOGBN DEGRADATION PRODUCTS ON 
PLATELET AGGREGATION AMD PLATELET ADEESIVBBE8S.
In this chapter is presented an account of the investigations of the 
effect of fibrinogen degradation products on platelet aggregation and platelet 
adhesiveness. The preparation and characterization of the degradation 
products studied, is presented in chapters 8 and 9. The effect of pure 
fibrinogen, from which the degradation products were made, on platelet 
aggregation and platelet adhesiveness has also been studied.
In chapter 4 it was demonstrated that the enzymes streptokinase and 
trypsin, could cause a marked acceleration in the rate of platelet 
aggregation under conditions in which fibrin formation was severely impaired. 
The inhibitory actions of fibrinogen degradation products, formed either 
'spontaneously1 during substrate decay or by the enzymatic action of 
plasmin on the protein, on the conversion of fibrinogen to fibrin under 
the action of thrombin have been recognised for a number of years (Bang 
et al., 1962; Fletcher et al., 1962; Latallo et al., 1962; Latallo et 
al., 1964; Triantaphyllopoulos, 1958, 1959, 1960, 1961;
Triantaphyllopoulos and Triantaphyllopoulos, 1962; 1964). The present
study was undertaken to investigate whether the presence of fibrinogen 
degradation products in the system could account, not only for the 
occurrence of defective fibrin formation, but also for the acceleration of
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the rate of formation of platelet aggregates. To ensure that the 
degradation products, produced hy both tryptic digestion of fibrinogen 
end by the enzymatic action of urokinase - activated plasminogen on 
fibrinogen, behaved in the predicted fashion in the thrombin - fibrinogen 
reaction, the effect of these products on a thrombin clotting time system 
was studied.
Materials.
Fibrinogen was human lyophilized fibrinogen, Grade L, supplied by A.B.
Kabi, Stockholm.
Fibrinogen degradation 'products were prepared as described in chapter 8.
ADP was the same preparation as that described in chapter 3.
Carbonate Buffer of OJ molar and pH 8.9 was prepared as described in 
chapter 3.
Methods.
Turbidimetric Method. ADP induced platelet aggregation was assessed in the 
turbidimetric system as described in chapters 3 and 5*
Chandler tube system. Platelet aggregation in an artificial circulation 
was studied by the method described in chapters 3 and 4.
Platelet adhesiveness was investigated in the modified glass bead column 
method of Hellem (i960) as described in chapters 3 and 6.
Thrombin olott-i^ g times. The effect of fibrinogen degradation products 
was investigated in the thrombin clotting time system described in chapter 
3. To 0.05 ml plasma was added 0.05 ml, degradation product, 0.3 ml
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‘thrombin time mixture1 and finally 0.1 ml thrombin (10 units per ml).
Results.
Effect of -product ‘a*. The effect of fibrinogen degradation product ‘a’ 
on platelet aggregation was investigated in the turbidimetric system and 
the Chandler tube system and its effect on platelet adhesiveness in whole 
blood was studied with the modified Hellem technique.
The effect of the product on platelet aggregation in the turbidimetric 
system was studied in a series of seven platelet rich plasma samples. Each 
plasma sample was divided into two portions each of 2 ml. To one portion 
was added 0.2 ml product ‘a1 to give a final concentration of 10CyUg per ml 
plasma and to the second portion was added 0.2 ml,0.9 per cent saline.
Both samples were then incubated at 37°C for 10 minutes before platelet 
aggregation was induced in the samples by the addition of ADP (0.5yug per ml 
plasma). The results are shorn in figure 64 and table 66. Product ‘a‘ 
appears to have no significant effect on ADP induced platelet aggregation. 
The mean optical density reading of the seven control samples, 1 minute 
after the addition of aDP, was 0.456 - 0.090 and of the seven test samples
0.442 i 0 .103, (t = 1.172 p < 0 .30).
In the turbidimetric system fibrin formation does not normally occur 
as a sequel to platelet aggregation. To study the effect of the 
degradation product in a situation in which platelet aggregation preceded 
thrombus formation, product 'a1 was added to plasma in the Chandler tube
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system. In a series of three plasma samples each sample was divided into
two 5 ml amounts and to one portion was added product 'a* at a concentration
of 200yug per ml plasma while to the second portion was added an equal
volume of 0.9 per cent saline. The volume in both loops was made up to
15 ml with 0.9 per cent saline and both loops incubated at 57°0 for 10 
minutes before recalcification with 0.5 ml, 0.25 M CaCl^. In each of the 
three plasma samples investigated the presence of product 'a1 appeared to 
cause acceleration of the rate of formation of platelet aggregates (table 2 3 ) .  
No visible difference was detected between fibrin formation in the control and 
test loops. There may be some doubt, however, as to the validity of this 
result since the protein was stored in solution for several weeks before its
effect in this sytem was studied and in addition to any spontaneous digestion
which may have occurred some denaturation of the protein may also have taken 
place.
From these observations it would appear that, in platelet rich plasma, 
the effect of product 'a' appears to differ depending on the system used to 
investigate platelet aggregation and perhaps also on its concentration in 
the plasma. Thus, the effect of product 'a1 on platelet adhesiveness has been
investigated at the two concentrations used in the plasma studies, namely
100yug and 200yug per ml blood. With a series of eight citrated whole 
blood samples, each sample was divided into two portions, each of 2 ml.
One portion was incubated at 57°0 for 10 minutes with 0.1 ml product ’a1
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(100yug per ml blood.) and the second with an equal volume of 0 .1M
sodium carbonate buffer, pH 8„9. After incubation, each sample was
passed through a glass bead column and the platelet adhesiveness of each
sample assessed from the number of platelets lost during passage. The
results are shown in figure 65 and table 67« The average percentage
+
platelet adhesiveness of the eight control samples was 41 .9 - 17.4 and of the 
eight samples treated with product ’a’ 33.5 “ 16.7» = 2,149, p< 0 .010).
It would appear that, at this concentration, the presence of product 'a1 
tends to produce a slight decrease in platelet adhesiveness although the 
difference between the control and test samples is not significant, 
when the concentration of product 'a' was increased to 200yUg/inl blood, the 
protein appeared to exert an even less pronounced influence on platelet 
aggregation than at the lower concentration. The effect of product ’a'
(200 yug per ml blood) was investigated with a series of eleven citrated whole 
blood samples the results are shown in figure 66 and table 68. The 
average percentage platelet adhesiveness of the eleven control samples was 
4 3 ,4 i 17.8 and of the eleven samples treated with product 'a' the value was 
4006 - 17.4, (t = 0.826, p<0.50). Hence, at this concentration it would 
appear that product 'a' exerts no significant influence on platelet 
adhesiveness. While this result is in agreement with observations in the 
turbidimetric system it is contrary to those made with the Chandler tube 
system. As discussed in chapter 6, one of the differences between the
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measurement of platelet adhesiveness in the modified Hellem technique and 
the measurement of platelet aggregation is that at no stage during the 
procedure is the blood thoroughly mixed with the substance under investigation 
for any length of time,, With earlier studies on the action of trypsin 
and streptokinase on platelet adhesiveness (chapter 6) this difference was 
partly overcome by agitating the blood and the substance under investigation 
during the period of incubation. This was achieved by rotating the sample 
on the turntable of a blood cell suspension mixer (Mathum Ltd., London) 
sited in an incubator at 37°C, This experimental procedure was carried out 
with-product 'a!. In a series of seven blood samples, blood and the protein 
(lOOytig per ml) were agitated for 10 minutes at 37°G and a second sample of 
blood treated similarly with 0.1H sodium carbonate buffer, pH 8,9. The 
results are shown in figure 67 and table 69« From the results it would 
appear that, even with thorough mixing, product !a' does not produce a 
significant effect on platelet adhesiveness. The average percentage 
platelet adhesiveness of the seven control samples was 72,5 - 12.3 and of the 
seven test samples 70,4 - 15.6 (t = 1.084, p < 0.40)„
Effect of -product *b!. As with product 'a1, the effect of fibrinogen 
degradation product 1 b * on platelet clumping was investigated in the 
turbidimetric system, the Chandler tube system and with the modified Hellem 
technique.
The effect of product 'b1 on ALP induced platelet aggregation in the 
turbidimetric system was studied in a series of seven .platelet rich plasma
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samples. The experimental procedure was similar to that described 
above for product 1 a*. The results are presented in figure 68 and table 
70, From the results it would appear that the presence of product 1 b1, 
at a concentration of 10Gyug per ml plasma, produces a significant enhance­
ment of platelet aggregation. The mean optical density reading of the 
seven control plasma samples, 2 minutes after the addition of ADP (0.5 yUg 
per ml) was 0.378 - 0.140 and the value for the seven test samples to which 
product *b* had been added was 0.341 ~ 0.141 (t = 3.253, p<0.02),
A similar result was obtained for the effect of product 'b' on 
platelet aggregation in the Chandler tube system. The experimental 
procedure was the same as that for product 'a1 as described above. In each 
of the three plasma samples investigated the presence of product 'b1 at a 
concentration of 200yug per ml resulted in an acceleration in the rate of 
formation of platelet aggregates (table 24). The presence of this fibrinogen 
degradation product aid not appear to impede the formation of fibrin 
following platelet aggregation in this system,
when the effect of product ‘b1 on platelet adhesiveness in whole 
blood was investigated the protein did not appear to be as effective in 
influencing platelet adhesion as in the plasma systems. Product fb'
(100 yUg per ml blood) was incubated with blood at 37°C for 10 minutes and 
over the series of eight samples investigated there appeared to be no 
significant difference in the percentage of adhesive platelets in the
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control and test samples (figure 69 and table 71 ). The average percentage
+platelet adhesiveness of the eight control samples was 41*9 - 17.4 and of
the eight test samples to which product *b* had been added the value was 
+
59.6 - 17.6 It = 0.594, p<0.60). Similar results were obtained when the 
concentration of product 1 b * was increased to 200yug per ml (figure 70 
and table 72). The average percentage adhesiveness of the eleven control 
samples was 45.4 - 17.8 and of the eleven test samples treated with product 
!b' (200ytig per ml blood) the average value was 58.5 - 15.7 (t = 1.251, p< 
0 „50). when the conditions of incubation were altered, as described above 
for product 'a1, to make this technique more comparable to the Chandler tube 
and turbidimetric systems the apparent effect of product 1 b1 in this system 
was also altered* In a series of seven samples, blood and product 'b1
(l OOyug per ml) were agitated together at 57°C for 10 minutes before being 
pumped through a glass bead column. Control samples containing 0.1M 
carbonate buffer, pH 8.9 were treated similarly. The results are shown in 
figure 71 and table 75. The average percentage platelet adhesiveness of the 
seven control samples was 72.5 - 12.5 and of the seven test samples 77.6 -
11.7 (t = 5.456, p <10.02). Thus it would seem that the presence of product 
*b* can produce a statistically significant increase in the number of 
platelets lost from a sample during its passage through a glass bead column. 
Effect of -product *0'. The effect of product 'c' on ADP induced platelet 
aggregation in the turbidimetric system was investigated with a series of
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seven plasma samples. The experiments were carried out as described for
product 'a*. The results are shorn in figure 64 and table 74. From
the results it would seem that product 'c1 at a concentration of lOO^ug per
ml plasma does not impair platelet aggregation but produces a marked
increase in the rate of disaggregation of platelet clumps which have formed.
Two minutes after the addition of ADP (G.5yUg per ml), platelet aggregation
is still proceeding in the control plasma samples but disaggregation has
occurred to such an extent in the samples treated with the degradation
product that over the series of seven plasma samples investigated the
difference between the optical density readings in the control and test
plasma samples is statistically significant. At this point, the mean
+
optical density reading of the control samples was 0.445 - 0.121 and of 
the test samples treated with product 'c' UCGyug per ml) the value was
0.475 - 0.105 (t = 5.255, p<0.02).
Effect of -product 'd*. The effect of product ‘d1 on platelet aggregation 
was investigated in both the turbidimetric and Chandler tube systems.
The effect of product ’df on ADP induced platelet aggregation was 
investigated in the turbidimetric system with a series of ten plasma samples. 
The experiments were carried out as described above for product ’a' . From 
the results it would appear that the presence of product 'df (lOOyug per ml) 
can cause a significant increase in the extent of platelet aggregation which 
occurs in the sample following the addition of ADP (figure 72 and table 75).
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The mean optical density reading of the ten control samples, 1-g- minutes 
after the addition of ADP (0.5yog per ml) was 0.305 -  0.159 and in the ten 
test samples to which product ’df was added, the mean value was 0.216 -  
0.112 (t = 2.415, p < 0.05).
A similar result was obtained when the effect of product 'd1 on platelet 
aggregation was studied in the Chandler tube system. This experiment 
was performed by Dr a .E.C. Uttley. The effect of product 'd1 (180yUg per 
ml) was studied in a series of seven plasma samples and the investigation 
was carried out as described above for product 'a1. The results are shown 
in figure 73 and table 76 where it can be seen that every sample investigated 
the presence of product 'd1 resulted in an acceleration of the rate of 
formation of platelet aggregates. The mean time for the formation of 
platelet aggregates to form in the seven control samples was 477 - 168
"i* '
seconds and for the seven test samples 294 - 45 seconds It = 3«874, p<
0 .01).
The results presented suggest that the various degradation products 
obtained by enzymatic digestion of fibrinogen, have slightly different 
effects on platelet aggregation. In an attempt to confirm that these 
observations were produced by the protein moieties added to the various 
systems and were not artefacts produced by the passage of fibrinogen through 
a DEAE cellulose column, the effect of fibrinogen on platelet aggregation
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before and after passage through, the column was investigated.
Effect of fibrinogen. The effect of fibrinogen (as supplied by the 
manufacturers) on ADP induced platelet aggregation was studied in a series 
of seven plasma samples. The experimental procedure was carried out as 
described above. The results are shorn in figure 74 and table 77 and it 
would seem that fibrinogen (lOG^ug per ml) can cause a significant enhancement 
in the extent to which platelet aggregation occurs following the addition of 
ADP. The mean optical density readings of the seven control samples,
1-jr minutes after the addition of ADP (0.5yug per ml), was 0.406 - 0.135 and 
of the seven test samples to which fibrinogen (lOOyug per ml plasma) had 
been added 0.275 - 0.198 (t = 3.162, p<0.025).
The same series of seven plasma samples was used to study the effect, 
on platelet aggregation, of fibrinogen which had been 'purified1 by passage 
through a DEAS cellulose column. The results are shown in figure 74 and 
table 78. It would appear that 'purified' fibrinogen tends to cause 
enhancement of ADP induced aggregation but the difference between the control 
and protein treated samples, over the series of seven samples, was not 
significant since in one of the seven samples the protein appeared to produce 
slight inhibition of aggregation. One and a half minutes after the addition 
of ADP (0.5yug per ml) to the system, the mean optical density reading in the 
seven control samples was 0.406 - 0.135 and the mean value in the seven 
samples treated :-ith 'purified' fibrinogen (100 ug per ml) was 0.312 i
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0.123 (t = 2.361, p<0.10).
The effect of fibrinogen on platelet adhesiveness in citrated whole 
blood was also investigated. In a series of blood samples, blood and 
fibrinogen (iGGyug per ml blood) were incubated together at 37°0 for 10 
minutes. -Control samples to which 0.9 per cent saline had been added were 
treated similarly. The results are shown in figure 75 and table 79.
Under these conditions, fibrinogen did not appear to cause an increase in 
the number of platelets lost during the passage of blood through a glass 
bead column. The average percentage platelet adhesiveness of the seven 
control samples was 37.0 i 9.9 and of the seven samples treated with 
fibrinogen 38.5 - 6.8 (t = 0.359, p< 0 . 3 0 ) . However, when the Hellem 
system was further modified to ensure thorough mixing of the blood and 
protein during incubation, fibrinogen appeared to exert a different effect 
on platelet adhesiveness. The same seven blood samples were used to 
investigate the effect of fibrinogen (lOOyug per ml) on platelet adhesiveness 
following thorough mixing during the 10 minute incubation period. The 
results are shown in. figure 76 and table 80 and it can be seen that under 
these conditions fibrinogen produces a marked increase in the percentage 
platelet adhesiveness of the samples. The average percentage adhesiveness 
01 the seven control samples was 61.7 - 11 .0 and of the seven fibrinogen 
treated samples 78.6 - 9.0 (t = 5.166, p < 0 .005).
Erom the observations of the effects of products ’a* and fb' on 
platelet clumping it would appear that both these proteins may possess a
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coagulant action since they can both cause enhancement of platelet 
aggregation. In order to determine whether this coagulant activity was 
also demonstrable in the conversion of fibrinogen to fibrin, the effects of 
products ’a' and 1 b* in a thrombin clotting time system were investigated. 
Thrombin clotting time. The effects of products 'a* and ‘b* were studied 
over the range of concentration 100 jj.g per ml plasma to 2 mg per ml plasma in 
a thrombin clotting time system. The results are shown in table 25.
Over the range of concentrations studied, it would appear that both 
degradation products inhibit the conversion of fibrinogen to fibrin which 
suggests that the presence of these products in the system can result in 
defective fibrin polymerization.
Discussion.
From the results presented above, it would seem that the various 
degradation products formed by enzymatic digestion of fibrinogen can exert 
a number of apparently different influences on platelet aggregation.
Product 'a', formed by mild tryptic digestion of fibrinogen, exerts no 
significant effect on ADP induced platelet aggregation (figure 64, table 
66) or on platelet adhesion (figures 65, 66 and 67, tables 67, 68 and 69) 
but can enhance platelet aggregation in an artificial circulation system 
(table 23). Product ’b1, formed by moderate tryptic digestion of 
fibrinogen, can enhance ADP induced platelet aggregation (figure 68, table 
70), aggregation in an artificial circulation system (table 24) and
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platelet adhesiveness (figure 71, table 73). Product 'c', formed by- 
prolonged tryptic digestion of fibrinogen, inhibits ADP induced platelet 
aggregation (figure 64, table 74). Finally, product *df, formed by 
moderate urokinase-activated plasminogen digestion of fibrinogen, enhances 
both ADP induced platelet aggregation (figure 72, table 75) and 
aggregation in an artificial circulations system (figure 73, table 76).
Conflicting reports have appeared in the literature concerning the
a
effect of fibrinogen degradation products on platelet aggregation. Some 
of the confusion has been caused by the fact that, for the most part, the 
degradation products have not been characterized according to their 
physicochemical properties. In many instances degradation products were 
not isolated from the fibrinogen incubation mixture so that the effect of 
a mixture of degradation products on platelet aggregation has been studied 
rather than an individual protein moiety. Degradation products prepared 
by digestion of fibrinogen with streptokinase-activated plasminogen have 
been shown to inhibit both ADP induced aggregation (Jerushalmy and 
Zucker, 1966; Kowalski et al., 1963) and fibrinogen induced aggregation 
(Kopec et al., 1966) in vitro. In addition, they have been shown to prolong 
the bleeding time in the presence of a normal platelet count following 
injection into dogs (Kowalski et al., 1964). However, degradation products 
prepared by plasmin digestion of fibrinogen have also been shown to exert
no influence on ADP induced platelet aggregation (Hirsh, et al., 1965) and 
to exert no influence on ADP induced aggregation except when ADP is added 
in trace amounts when they inhibit platelet aggregation (Larrieu et al,,, 
1966). Larrieu et al», (1966) have also demonstrated that degradation 
products, prepared by plasmin digestion of fibrinogen, inhibit the spreading 
of platelets on glass, inhibit spontaneous platelet aggregation and delay 
platelet aggregation after the addition of calcium chloride to plasma.
The degradation products investigated by Hirsh et al., (1965) had sedimen­
tation coefficients of 5.27 z 10 ^  sec and 3«0G z 10 ^  sec and molecular 
weights of 88,000 and 30,000 respectively (Fletcher et al., 1966). Two 
of the products studied by Larrieu et al., (1966} had very similar
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properties; the sedimentation coefficients were 5»2 x 10 sec and 3»0 x 
-1310 sec. These values are sufficiently different from the coefficients, 
(Chapter 9), of the products 'a1 and 'b* to conclude that the protein 
moieties examined by these workers were quite different from those examined 
in the present study. Further, the observation of the apparent variety 
of influences which the series of degradation products, prepared by tryptic 
digestion of fibrinogen appear to exert on platelet aggregation may account 
for the apparent divergence in the observations of earlier workers.
Recently, there has been published a report of the discovery of a fibrinogen 
degradation product which possesses the ability to decrease the number of 
circulating platelets after infusion into dogs and which can not only
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induce platelet aggregation in vitro but can also enhance ADP induced 
aggregation in vitro (Barnhart et al., 1966).
In the present study it has been demonstrated that fibrinogen can 
enhance ADP induced aggregation in platelet rich plasma (figure 74, table 
77) and that it can also, under certain conditions, increase the percentage 
platelet adhesiveness in citrated whole blood (figure 76, table 80).
This is in agreement with observations previously reported for the effect 
of the protein on ADP induced aggregation in platelet rich plasma (Kopec et 
al., 1966; McLean et al., 1964) and in suspensions of washed platelets 
(Gross, 1964; Solum and Stormorken, 1965).. Fibrinogen, which had been 
further purified by passage through a DMAci cellulose column, did not appear 
to be quite as effective as the initial fibrinogen sample in the enhancement 
of platelet aggregation although it still tended to enhance ADP induced 
aggregation (figure 74, table 78). Figure 45 shows the fibrinogen was 
eluted from the DMAh cellulose column as one major peak and two smaller peaks. 
The heterogeneity of the initial fibrinogen solution is also confirmed from the 
pattern obtained following sedimentation in a sucrose density gradient system 
(figure 55). On the other hand the purified fibrinogen solution was 
sedimentated in the gradient system as a single peak suggesting that it 
was a homogeneous protein (figure 56). Thus it is possible that some other 
protein or proteins, closely associated with fibrinogen, are able to 
influence platelet aggregation. If this were the case, it would explain the
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apparent quantitative difference between the actions of fibrinogen on 
platelet aggregation before and after it has been subjected to column 
chromatography.
Kopet et al., (1966) have shorn that fibrinogen degradation products can 
be adsorbed onto the surface of washed platelets more firmly and in greater 
amounts than fibrinogen. It may be that products ’b1 and ’d1, which have 
been shown to enhance platelet aggregation, have similar spatial arrangements 
of charged groups in their molecular structure as has the complex fibrinogen 
molecule and this might enable them to behave like fibrinogen on the surface 
of the platelet. It has also been shown that those degradation products 
which inhibit platelet aggregation also inhibit the release of adenine 
nucleotides from platelets in the presence of agents which can stimulate 
platelet aggregation (kopec et al., 1966). If, however, products *b' and ’d* 
can substitute for fibrinogen on the platelet surface they may not possess 
the required configuration or electrophoretic properties to produce this 
inhibition.
The ability of fibrinogen degradation products to inhibit the thrombin- 
fibrinogen reaction has been extensively reported in the literature 
(Alkjaersig et al., 1962; Bang et al., 1962; Beck and Jackson, 1966;
Fletcher et al., 1962; Godal and Helle, 1963; Hirsh et al,, 1965;
Jerushalmy and Zucker, 1966; Kowalski et al., 1964; Larrieu et al., 1966; 
Latallo et al,, 1964; Lewis and Wilson, 1964). As shown in table 25,
products 'a* and ‘b* also exhibit 1antithrombin like’ activity since they 
prolong the time taken for thrombin to convert fibrinogen to fibrin. This 
observation would seem to suggest that the ability of product ’b1 to enhance 
platelet aggregation depends on its effect on the platelets themselves 
since it produces inhibition of the later stages of coagulation and thrombus 
formation.
Platelet aggregation has been shown to play a critical role in the 
initial stages of haemostasis ( Grette, 1962; Hellem and Owren, 1964;
Hjort and Hasselback, 1961; Kaser-Glanzmann and Euscher, 1962; Marr et al., 
1965; Poole and French, 1961; Russel, 1961.). The attractive theoretical 
concept of a haemostatic balance mechanism suggests that fibrinolysis and 
coagulation may be continuously operating in parallel throughout the 
vascular bed (hstrup, 1958; Hiierry et al., 1959) and if such is the case, 
products of fibrinogen proteolysis may have an important homeostatic role 
in displacing the equilibrium of the system towards coagulation.
The possibility of a physiological role for a fibrinogen degradation 
product which can enhance platelet aggregation is strengthened by the 
circumstance that it can be produced not only with trypsin but with the 
intravascular fibrinolytic enzyme plasmin, produced by activation of human 
plasminogen by human urokinase, and that its activity is not confined to 
platelet rich plasma but can also be demonstrated in citrated whole blood.
Conclusions.
Three degradation products have been prepared by tryptic digestion of 
fibrinogen and one by plasmin digestion. The product prepared with plasmin 
has been 3hown to enhance ADP induced platelet aggregation and to acceleration 
aggregation in an artificial circulation system. In addition to these 
actions, one of the products prepared with trypsin can enhance platelet 
adhesion in whole blood. The tryptic degradation product exhibits coagulant 
action on the early stage of the haemostatic process while possessing an 
antithrombic activity on the late stage of the reaction sequence.
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CHAPTER 11
mcnssxQi^
The recognition of the key role of the platelet in normal and defective 
haemostasis has stimulated much research into platelet function. In view 
of the current concept that in vivo fibrinolysis and coagulation are in 
a state of dynamic equilibrium, the present studies were carried out to 
investigate the possible effect of fibrinolytic agents on one of the 
earliest steps in the haemostatic process, that is, platelet- aggregation.
(l) The functions of the platelet.
The platelet contribution to the haemostatic mechanism includes a 
phospholipid, platelet factor 3, which participates in the formation of blood 
thromboplastin; serotonin which can induce vasoconstriction and thrombosthenin, 
a contractile protein which, in conjunction with the large store of ATP 
contained within the platelet membrane, facilitates clot retraction.
Apparently the most complex and perhaps least understood aspect of platelet 
function is that of its role in the formation of haemostatic plugs and in 
thrombus formation. The first formed element demonstrate at a point of 
injury in the vascular lining is the platelet. The current concept of thrombus 
formation suggests that a clump of platelets gradually builds up round the 
platelets already adhering to damaged endothelium, so forming a plug which 
causes the slowing of the blood flow round the point of injury; fibrin
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formation then occurs round the platelet mass. The plug becomes impermeable 
to blood flow and forms an effect seal over the damaged area. When this 
reaction sequence occurs to arrest bleeding from a vessel in vivo it is 
beneficial but when it occurs within a vessel and results in the occlusion of 
that vessel it is a great potential hazard.
(2) Mechanism of platelet aggregation.
It is at present considered that, both in vivo and in vitro. ADP 
plays a key role in the formation of platelet aggregates. The nature of the 
reaction involved in the process of platelet to platelet interaction has not as 
yet been fully elucidated but it is thought to be dependent on either the 
presence of ADP or on the dephosphorylation of ADP to supply energy for the 
reaction between platelets or between platelets and a foreign surface.
Calcium ions and a plasma factor are also considered to be essential for the 
formation of bridges between platelets to hold them together, although 
neither the precise nature of such a binding reaction nor of the plasma 
factor involved is fully understood.
(3) Platelets and fibrinolysis.
Astrup (195S) was one of the first authors to suggest that, under 
physiological circumstances, a dynamic equilibrium may exist between the 
coagulation and fibrinolytic enzyme systems, the former leading to the de­
position of fibrin to seal any defect in endothelium tissue and the latter 
to remove such fibrin deposits after they have served their useful function
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and the integrity of the endothelium has been restored. However, the first 
stage in the repair of damaged endothelium is the adhesion of platelets to 
the site and it may be that a dynamic balance between the haemostatic and 
fibrinolytic mechanisms may also exist at an earlier stage in the reaction 
sequence than fibrin deposition, i.e. at the level of platelet aggregation and 
adhesion (Luscher, 1967).
The studies for this thesis included an in vitro assessment of the possible 
existence for such a mechanism by the investigation of the effect of fibrinoly­
tic agents on platelet aggregation and adhesion.
(4) Haemostasis and fibrinogenolvsis.
I Effect of btreutokinase.
(a) Streptokinase and platelet aggregation and adhesion.
The incubation of either citrated whole blood or platelet rich 
plasma with streptokina.se can lead to the enhancement of platelet adhesion 
and platelet aggregation of the samples (figures 40, 5 and 18). Streptokinase 
exerts its fibrinolytic activity by participating in the conversion of 
plasminogen to the active proteolytic enzyme plasmin (Sherry et al., 1959’).
The action of streptokinase on platelet function in vitro also appears to be 
mediated through this reaction. ADP induced aggregation can only be 
enhanced by streptokinase after the antiplasmin in the plasma had been 
destroyed (figure 18) and acceleration of the rate of formation of platelet 
aggregates in an artificial circulation system is accompanied by marked 
fibrinogenolysis (table 1) which is possibly the result of plasmin activity
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since streptokinase alone does not exhibit proteolytic activity (Sherry and 
Alkjaersig, 1957).
(b) Streptokinase and washed platelets.
Streptokinase causes only slight enhancement of ADP induced aggrega­
tion of washed platelets resuspended in buffer (figure J« The specificity 
of streptokinase towards plasminogen may account for this observation.
Adelson et al., (1961) have postulated that virtually all the plasma proteins 
can be concentrated by the platelet to form a ’plasmatic atmosphere* round the 
s u r f a . c e  o f  the cell. Since the washing procedure might be expected to remove 
most, if not all, the proteins from the system, the substrate for the 
enzyme, streptokinase, might no longer be present in the medium. The complete 
protein complement does not appear to be removed by the washing procedure, 
however, since a fibrin clot forms on the addition of thrombin to the 
platelet suspension (chapter 5). Wherever fibrinogen is present it is 
likely that some plasminogen may also be present. Thus the apparent slight 
enhancing effect of streptokinase on platelet aggregation of washed platelets 
may be due to the formation of plasmin.
(c) Platelet aggregation and fibrinogenolysis.
Uninhibited proteolytic activity appears to be a prerequisite 
for the enhancement of platelet aggregation in platelet rich plasma since 
the acceleration of the rate of formation of platelet aggregates in the 
Chandler tube (figure 5) is accompanied by a decrease in the amount of fibrin
incorporated into the Chandler thrombus (table 1) whereas if there is no 
enhancement of ADP induced aggregation (figure 17) neither is there a 
significant decrease in clottable protein (table 7). In vitro, it would 
seem, that at least one product formed by the proteolytic activity of plasmin 
on fibrinogen can cause enhancement of platelet aggregation (chapter 10).
(d) Streptokinase and coagulation.
Clot formation in recalcified plasma is delayed in the presence of 
streptokinase (table 3 ) ,  probably as a result of fibrinogen digestion by 
plasmin formed in the plasma. In vitro the conversion of prothrombin to 
thrombin also appears to be inhibited by the presence of streptokinase 
(table 2) although the results may be explained 011 the basis of digestion of 
thrombin by plasmin or by the fact that fibrinogen, which acted as a 
substrate for formed thrombin in the assay system, may have been digested by 
plasmin before thrombin could exert its activity.
II Effect of trypsin.
(a) Trypsin and platelet aggregation and adhesion.
As with streptokinase, the incubation of platelet rich plasma or 
citrated whole blood with trypsin can produce enhancement of platelet 
aggregation and platelet adhesion of the treated samples (figures 6, 20,
42 and 43)o
(*) Trypsin and washed platelets.
The ability of trypsin to cause enhancement of platelet aggregation 
does not appear to be due to its direct action on the platelet despite the
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observations that the presence of platelets during the incubation of trypsin 
and plasma seems to contribute to its activity towards platelet clumping 
(figures 8, 9, 25 and 26). The platelet contribution to this phenomenon 
is most probably due to the presence of the plasma proteins in the 'plasmatic 
atmosphere1 of the platelet since trypsin appears to abolish the ability 
of washed platelets to aggregate under the influence of ADP (figures 27 and 
28). Although fibrinogen is still present in the washed platelet system 
as evidence by the formation of a fibrin clot as a result of addition of 
thrombin, (chapter 5) the fibrinogen of the system may be present as an 
integral part of the platelet structure and consequently its digestion by 
trypsin would probably lead to the loss of cellular integrity of the 
platelet with consequent inability to aggregate. It has previously been 
reported that trypsinized platelets fail to aggregate in the presence of 
thrombin when the clot table protein has been fully digested (Morse et al., 
1965; bchmid et al., 1962).
(c) Platelet aggregation and fibrinogenolysis.
Prom the data at present available, it would appear that, as with 
plasmin, some degree of fibrinogenolysis is a prerequisite for the enhancement 
of platelet aggregation by trypsin; the acceleration in the rate of 
formation of platelet aggregates in the presence of trypsin in the Chandler 
tube (figure 7) is accompanied by a decrease in the amount of fibrin
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incorporated, into the ensuing thrombus, whereas when there is no significant 
enhancement of aggregation (figures 17 and 32) neither is there a significant 
decrease in the amount of clot table protein in the system (table 7)* Further 
evidence to suggest that fibrinogenolysis may be of importance in the 
enhancement of platelet aggregation and adhesion was obtained from the 
observations that a product formed by tryptic digestion of fibrinogen can 
produce enhancement of platelet aggregation in vitro (chapter 10).
(d) Trypsin and coagulation.
In addition to its proteolytic activity towards fibrinogen and fibrin 
in vitro (iiatnoff and Colopy, 1955), trypsin can activate plasminogen, although 
relatively slowly compared to the specific inhibitors streptokinase and 
urokinase (bherry et al., 1959)» Since this enzyme is also able to contribute 
to coagulation by its apparent ability to act as a cofactor for the conversion 
of prothrombin to thrombin (Ferguson and Ennis, 1963; Ferguson et al.,
1960; Stormorken 1956) it might be supposed that this could account for its 
ability to enhance platelet aggregation. However, in the present study its 
apparent ability to induce changes in plasma proteins which enhance platelet 
aggregation cannot be accounted for solely on the basis of thrombin generation. 
Under in vitro conditions, fibrinogen appears to be the preferred substrate for 
the proteolytic activity of trypsin when present in relatively high 
concentrations; the conversion of prothrombin to thrombin is apparently
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impaired by trypsin either because thrombin itself is destroyed by the 
enzyme or more probably because trypsin digests the substrate for the 
action of thrombin, namely fibrinogen (table 2); the acceleration of the 
rate of formation of platelet aggregates by trypsin in an artificial 
circulation system is accompanied by significant fibrinogenolysis (table 
1)o Further evidence which suggests that the effect of trypsin on platelet 
aggregation is not related to its coagulant activity was obtained from the 
observations that concentrations of trypsin which enhance clot formation in 
recalcified plasma (table 3) can inhibit platelet aggregation (figure 20) 
while concentrations of trypsin which inhibit clot formation (table 5) can 
enhance platelet aggregation (figure 20)»
III Other proteolytic enzymes and platelet aggregation.
(a) Urokinase.
If the hypothesis is valid that the action of streptokinase on 
platelet aggregation and fibrinogenolysis is mediated through plasminogen 
activation, on theoretical grounds and it would seem probable that urokinase 
would behave similarly since this enzyme is the naturally occurring in vivo 
activator of plasminogen. Although urokinase did not appear to enhance 
ADP induced platelet aggregation in the platelet rich plasma system 
examined (figure 33), antiplasmin was not removed or destroyed in the
I
specimens examined. This may have masked any possible activity of the 
urokinase towards platelet function since plasma antiplasmin had to be 
destroyed before the ability of streptokinase to enhance ADP induced
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platelet aggregation was observed (figure 18). Further, a fibrinogen 
degradation product formed under the action of urokinase-activated plasminogen 
on fibrinogen, in an antiplasmin free system, promotes platelet aggregation,
(b) Ficin and Chymotrypsin.
On the basis of the series of experiments performed with ficin
and chymotrypsin it is not possible to state categorically whether they
could enhance platelet aggregation or not, since they were not examined over 
a sufficiently wide range of concentrations. These enzymes have a similar 
action as trypsin on synthetic substrates but the results presented in table 
2 seem to indicate that neither enzyme is capable of contributing to the 
activation of prothrombin to thrombin.
IV Relationship between -platelet aggregation and fibrinogenolysis.
The observations presented above tend to support the concept of a
relationship between platelet aggregation and fibrinogenolysis; 
fibrinogenolytic agents seem to be able to simultaneously support platelet 
aggregation and adhesion and fibrinogenolysis in vitro. The concept 
for the existence of such a mechanism in vivo is largely conjectural.
Although it is now well recognised that platelets play an important part 
in haemostasis it is as yet not fully understood how accurately the 
ability of platelets to function in haemostasis is reflected by the in vitro 
tests currently available to assess platelet aggregation and adhesion.
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The lack of knowledge in this area of haemostasis leads to difficulties 
when an attempt is made to collate in vitro and in vivo observations.
The evidence available from in vivo studies suggests that streptokinase 
and urokinase are dominantly fibrinolytic and * antihaemostatic* .
Furthermore enzymatic agents such as trypsin are not found under normal 
circumstances free in the circulating blood. In vivo plasmin normally 
has fibrin as a substrate and it is only under conditions of enhanced 
fibrinolysis in which plasmin is produced faster than it can be neutralized 
by antiplasmin, that fibrinogen may equally readily be digested (Sherry 
et al., 1959)o However, it is possible that just as certain degradation 
products of fibrinogen exist which can enhance platelet aggregation, so 
there may be one or more products of fibrin degradation which possess 
the same potential activity. The existence of such activity might in fact 
contribute towards one of the potential hazards of fibrinolytic therapy, 
namely the formation of platelet emboli which are resistant to further 
fibrinolytic activity (iicHicol et al., 1965). It would appear unlikely 
that the concentration of degradation products of either fibrinogen or 
fibrin, would be present in sufficiently high concentrations to enhance 
or promote platelet aggregation except in areas of localized fibrinolytic 
activity.
The in vivo observations do not exclude the possibility that a 
dynamic balance exists in vivo, at a subclinical level, between
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haemostasis and fibrinolysis,, Such, a relationship could be reflected 
in vitro by the observations of enhanced platelet aggregation and adhesion 
in the presence of fibrinolytic agents and products of f ibrinogenolysis«,
(5) Mechanism of platelet aggregation and adhesion„
(a) Comparison of methods„
The results of the comparison of three methods of assessment of 
the ability of platelets to form aggregates show that there are no significant 
mathematical correlations between the observations made with each technique 
(table 19). However, as discussed in Chapter 7, the difference in the 
results obtained with each assay method, namely the Chandler tube, 
turbidimetric and glass bead column methods appears to be quantitative rather 
than qualitative. The effect of streptokinase and trypsin on platelet 
aggregation appears to differ according to the method of assay used* Once 
again however, the difference appears to be quantitative rather than 
qualitative since enhancement of platelet aggregation and adhesion can be 
produced in each system by the enzymes although the concentration of the 
enzymes required to produce this effect may vary0
(b) Hole of AhP.
The formation of platelet aggregates in each system depends on the 
availability of the nucleotide, ADP; in the turbidimetric system ADP 
added to platelet rich plasma is the stimulus for aggregation, in the glass 
bead column method AbP is supplied to the platelets from the red cells
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(chapter 6; Hellem, 1960) and as the formation of platelet aggregates 
in the Chandler tube can be enhanced by ADP and inhibited by adenosine 
(chapter 4) it may be concluded that ADP is involved in the reaction 
sequence. These observations are in agreement with the hypothesis of 
Haslam (1964-) that ADP is involved in the aggregation of platelets irrespective 
of the stimulus to aggregation. The influence of ADP and adenosine on the 
action of trypsin on platelet aggregation also seem to support the concept 
that ADP is involved at some stage in the reaction sequence. The ability 
of trypsin to enhance platelet aggregation in platelet rich plasma to which 
no exogenous ADP has been added can be suppressed by adenosine, the specific 
inhibitor of ADP (figure 21). In the Chandler tube the influence of trypsin 
can be enhanced by ADP and inhibited by adenosine (figures 13 and 15).
It has not bean possible to demonstrate any significant alteration in ADP 
and AMP concentrations in either citrated whole blood or platelet rich 
plasma samples following the incubation of the samples with trypsin prior 
to the investigation of platelet adhesiveness or subsequent to the passage 
through the column of glass beads even though platelet adhesion was 
increased by trypsin treatment of the samples (chapter 6). Possible 
explanations include: (i) insensitivity of the method for the assay of 
ADP and AMP to minor changes which may occur in the system; (ii) the 
concentration of ADP necessary to trigger the mechanism of platelet 
adhesion and to keep it operating may be infinitessimal; (iii) ATP,
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ADP and their derivatives are in a continual state of metabolic turnover
and consequently the relative concentrations of each nucleotide may act
as a more accurate guide of increased adhesiveness than absolute values.
(c) Effect of trypsin.
As discussed in Chapter 7, the various techniques used in this 
thesis to measure platelet aggregation and adhesion may possibly measure 
different stages in the reaction sequence leading from the presence of 
platelets as single cells in blood to their development into a solid mass, 
impermeable to blood flow, under conditions of trauma. This circumstance 
may, at least in part, account for the apparent differences in the action 
of an agent, such as trypsin, in the various in vitro systems. In the
turbidimetric system it would appear that trypsin at concentrations which do
not enhance platelet aggregation does not hinder platelet disaggregation 
when compared to that which occurs in the control samples (figures 17, 20,
23 and 24). As the concentration of trypsin is increased platelet 
aggregation is enhanced and platelet disaggregation impeded (figures 20 and 
21). There is some confusion in the literature as to the extent of 
destruction caused by the incubation of platelets with trypsin. Grette 
(1962) has shown that trypsin, like thrombin, can cause the release of 
serotonin and ADP from the cells and this has been confirmed by Morse et al., 
(1965) who have also demonstrated that trypsin removes the clot table 
protein from the platelet. Schmid et al., (1962) found, however, that' 
trypsinized human platelets remain morphologically intact. The extent of
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digestion of platelet proteins by trypsin probably depends on the conditions 
under which the incubation occurs„ ’./hen trypsin and washed platelets,
resuspended in buffer, are incubated together it irould seem that some degree 
of digestion of platelet proteins or proteins closely associated with the 
platelet occurs since the platelets apparently lose their ability to aggregate 
under the influence of ADP (figure 23 ) „ When the incubation is carried out 
in platelet rich plasma, plasma proteins may be the preferred substrate for 
the proteolytic activity of trypsin since, although platelet aggregation is 
enhanced, the platelet aggregates which are formed under the influence 
of trypsin are less readily disaggregated than those formed in the absence 
of trypsin (figures 21 and 25)» This phenomenon is unlikely to be caused 
by the direct action of trypsin in the platelet since the same phenomenon is 
observed when fibrinogen or fibrinogen degradation products cause enhancement 
of aggregation (figures 68, 72 and 74-) « It may be that the presence of 
trypsin in platelet rich plasma not only enhances the extent to which 
aggregation occurs after the addition of ADP to the system but can promote 
the sequence of changes involved in the platelet contribution to thrombus 
formation to a stage beyond that of initial ADP reactivity i.e., to a stage 
in the sequence in which the platelet clumping is irreversible „ It is this 
stage in the reaction sequence that is possibly being measured in the 
Chandler tube system and this may account for the apparent greater sensitivity 
of this technique to the action of trypsin and the other agents which can
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promote platelet aggregation,
(d) Platelet to -platelet interaction.
As outlined in chapter 2, it has been demonstrated that platelet 
aggregation requires a plasma factor which has characteristics in common 
with both fibrinogen and the protein, deficient in the plasma of patients 
suffering from Von ¥illebrand's disease (Born and Cross, 1964; McLean et - 
al,, 1964; Skalhegg et al,, 1964). If such a factor is vital to the 
initial stages of aggregation it must be closely associated with the platelet 
and not readily removed or destroyed since washed platelets resuspended in 
buffer appear to be able to aggregate effectively in vitro on the addition of 
ADP (figures 28, 29 and 30), It has been suggested that the protein factor 
involved in platelet aggregation may participate in the formation of ’bridges’ 
between platelets which would favour platelet aggregation (Born, 1965;
Clayton et al,, 1963; Caaraer and Laland, 1964; Salzman et al,, 1966; 
Skalhegg et al,, 1964; Spaet and Lejnicks, 1966), The suggested ability 
of fibrinogen to participate in the same 'binding1 reaction as the plasma 
factor may explain the enhanced platelet aggregation found in the presence 
of fibrinogen; further, the failure of disaggregation may be due to the 
irreversible nature of the ’bridges' formed in the presence of added 
fibrinogen (figure 74), As certain fibrinogen degradation products can 
also enhance aggregation and impair disaggregation (figures 68 and 72), some 
indications as to possible characteristics of agents which may participate 
in the binding reactions may be inferred. The size of the protein involved
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in the reaction would not appear to he significant since the degradation 
product 'b' which can enhance platelet aggregation or adhesion in vitro 
in each method studied has a molecular weight of approximately one tenth 
of that of fibrinogen (chapter 9)0 The availability of suitable groups 
on the surface of the protein e0g0 negatively charged groups, may be of more 
importance in the 'binding1 reactions than the size and shape of the 
molecule. Such a concept might possibly explain the apparent ability 
of agents, such as heparin, which would not normally be associated with 
any 'coagulant' action, to enhance platelet aggregation under certain 
conditions in vitro (figures 36 and 37).
201 .
CHAPTER 12 
SUMMARY AMD CONCLUSIONS.
The recognition of the importance of the physiological and pathological 
roles of the platelet has stimulated intensive study of the platelet and 
its mode of action within the haemostatic mechanism* This thesis gives 
an account of the investigation of the effect of the enzymes streptokinase 
and trypsin on the ability of platelets to adhere to a foreign surface and 
to form aggregates in vitro,
(1) Introduction
Described in chapter 2 are some of the functions currently ascribed 
to platelets in haemostasis and an outline of the mechanism thought to 
enable platelets to perform one such function, namely platelet aggregation.
An account is also given of the relationship between platelets and 
fibrinolysis,
(2) Materials and methods
Chapter 3 contains a description of the materials and standard 
coagulation and biochemical methods used in the work for this thesis. The 
methods outlined in this chapter include the assay systems used to study the 
effect of substances on platelet aggregation and adhesion, the Chandler 
tube method, the turbidimetric method of Born and the Hellem glass bead column 
method. These three methods have been adapted to meet the special 
requirements for this thesis and the modifications are outlined in
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chapters 4, 5 and 6 respectively. Also described in chapter 3 is a 
sensitivity test which gives an indication of the minimum concentration 
of the fibrinolytic enzymes streptokinase and urokinase which must be 
added to plasma in order that the inhibitors present in plasma may be 
overcome. A number of coagulation tests have been used to investigate 
particular aspects of the work and these include a thrombin clotting time 
assay described in chapter 3» a one-stage prothrombin time assay, plasma 
recalcification time and fibrinogen clotting time assays described in 
chapter 4. Chapter 3 also contains a description of a method of estimating 
the total protein content of a sample and of the methods used to estimate the 
concentration of two plasma, namely plasminogen and fibrinogen. The 
methods used to prepare and purify the proteins obtained by proteolytic 
digestion of fibrinogen are outlined in chapter 3 and described in detail 
in chapter 8. The methods used to characterize these proteins are detailed 
in chapter 3 and include methods of estimating molecular weight, 
electrophoretic charge and the degree of digestion involved in the formation 
of the fibrinogen degradation products. A further biochemical technique 
described in chapter 3 is the method of estimation of ADP and AMP 
concentrations in blood samples. The method of collection of blood for 
assay and for the preparation of plasma are presented in chapter 3 while 
the methods used to obtain suspensions of washed platelets are described 
in chapter 5«
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(3) Haemostasis and fibrinogenolvsis
An account of the effect on platelet aggregation and adhesion 
of the 'fibrinolytic’ agents streptokinase and trypsin is presented and. 
discussed in chapters 4, 5 and 6. The products of the fibrinogenolytic 
activity of trypsin and urokinase have been purified (chapter 8), their 
physico-chemical parameters studied (chapter 9) and their effect on 
platelet aggregation and adhesion examined (chapter 10).
(a) Enhancement of platelet aggregation and adhesion by streptokinase 
and trypsin
Addition of streptokinase or trypsin to citrated whole blood or 
platelet rich plasma can result in enhancement of platelet aggregation and 
adhesion in the samples. This effect of the two enzymes can be detected 
with each of the three in vitro methods used 'to investigate platelet function 
although the concentration of the enzymes required and the conditions under 
which enhancement is observed may vary for each method. The rate of 
formation of platelet aggregates in the artificial circulation of the 
Chandler tube is accelerated by streptokinase, at a concentration which 
produces maximum lytic activity, and by trypsin (10yug/ml plasma). The 
ability of platelets to respond to the challenge of ADP is enhanced by 
streptokinase, only after plasma antiplasmin has been destroyed, and by 
trypsin (100 ug/ml plasma). Platelet adhesion to glass beads is
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increased after citrated whole blood is thoroughly mixed with either 
streptokinase, at a concentration which produces maximum lytic activity or 
with trypsin (lO^ug/ml blood).
(b) Action of streptokinase and trypsin on washed platelets
Streptokinase causes slight enhancement of ADP induced aggregation 
of washed platelets resuspended in buffer. Although the presence of 
platelets during the incubation of trypsin and plasma appears to contribute 
to its enhancement of platelet clumping in platelet rich plasma, trypsin 
causes almost complete inhibition of ADP induced aggregation of washed 
platelets resuspended in buffer.
(c) Platelet aggregation and fibrinogenolysis
The acceleration of the rate of formation of platelet aggregates 
in the Chandler tube by streptokinase and trypsin is accompanied by marked 
fibrinogenolysis. In plasma samples in which streptokinase and trypsin 
fail to cause enhancement of the reactivity of platelets towards ADP no 
significant fibrinogenolysis was detected.
(d) Other proteolytic enzymes and platelet aggregation
Urokinase, at a concentration which produced maximum lytic 
activity, was not found to cause any enhancement of ADP induced platelet 
aggregation in platelet rich plasma. At the concentrations studied neither 
ficin nor chymotrypsin were observed to exert any influence on the ADP 
reactivity of platelets in platelet rich plasma.
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(d) Heparin and platelet aggregation
At the relatively low concentrations of 0.05 units and 10 units 
per ml plasma, heparin appears to enhance ADP induced platelet aggregation 
in platelet rich plasma. ADP reactivity of platelets was inhibited by 
heparin when present at a concentration of 500 units per ml plasma.
(e) Preparation of fibrinogen degradation products
Fibrinogen degradation products formed by the proteolytic activity 
of trypsin and urokinase-activated plasminogen on fibrinogen were 
prepared by incubating the enzyme preparations with fibrinogen. The 
proteolysis products were separated from the incubation mixture by 
chromatography on a DEAE cellulose column.
(«) Characterization of fibrinogen degradation products
(i) Molecular weight
The sedimentation patterns obtained for the various fibrinogen 
degradation products were examined in a sucrose density gradient system and 
compared to the patterns obtained for both the initial fibrinogen solution 
and fibrinogen which had been eluted from a DEAE cellulose column. From 
the results obtained it appeared that the degradation products were all 
smaller molecules than the parent fibrinogen but the technique did not 
reveal any significant difference between the various degradation products. 
When two of the degradation products were examined in the Spinco, Model E,
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ultracentrifuge it was confirmed that the degradation products had much 
lower molecular weights and dissimilar sedimentation and diffusion coefficients 
than fibrinogen. The two degradation products were also found to be 
dissimilar to each other.
(ii) Electrophoresis
The degradation products were examined by paper electrophoresis. 
Fibrinogen and fibrinogen eluted from a DEAE cellulose column were also 
examined for comparative purposes. The electrophoretic patterns obtained 
with both fibrinogen preparations were identical and showed that the 
fibrinogen molecules migrate towards the anode. The degradation products 
appeared as diffuse bands round the origin and the patterns could not be 
improved by current reversal at the end of electrophoresis.
(iii) Reaction kinetics
The number of peptide bonds broken during the formation of two 
of the degradation products formed by tryptic digestion of fibrinogen was 
examined in a pH stat.
(g) Fibrinogen degradation products and platelet aggregation
The effect of the three degradation products prepared by tryptic 
digestion of fibrinogen on platelet aggregation was examined. The 
product prepared under mild conditions of proteolysis exerted no action 
on the reactivity of platelets towards ADP or on the ability of platelets 
to adhere to glass beads. The degradation product prepared under the 
influence of a higher concentration of trypsin was found to accelerate
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the rate of formation of platelet aggregates in the Chandler tube, to 
enhance the ability of platelets to react to the challenge of ADP and to 
result in an increase in platelet adhesiveness to glass beads. The 
degradation product prepared by prolonged tryptic digestion of fibrinogen 
inhibited ADP induced platelet aggregation. The degradation product 
prepared by the action of urokinase-activated plasminogen on fibrinogen 
was found to accelerate the rate of formation of platelet aggregates in 
the Chandler tube and to enhance ADP induced platelet aggregation in platelet 
rich plasma. All the degradation products prepared were found to exhibit 
marked 'antithrombin1 activity.
(4) Comparison of methods of assessing platelet aggregation
The three in vitro methods used in the assessment of the ability 
of platelets to form aggregates were compared. There were no significant 
mathematical correlations found between the observations made with the 
Chandler tube, turbidimetric and glass bead column methods.
Conclusion.
The important role at present ascribed to the platelet in haemostasis 
has stimulated much interest in the platelet, its mode of action within the 
haemostatic mechanism and factors which can influence the platelets either 
to form aggregates or to remain as discrete cells.
The work for this thesis included the investigation of the action on 
platelet aggregation and adhesion of 'fibrinolytic' agents, particularly 
streptokinase and trypsin. In vitro these enzymes appear to be able to
208.
enhance platelet aggregation and adhesion and it would seem that they may 
do so by virtue of their fibrinolytic and fibrinogenolytic activity.
Products of the fibrinogenolytic action of plasmin (produced by streptokinase) 
and trypsin can cause marked enhancement of platelet aggregation and platelet 
adhesion while exhibiting pronounced 1 antitlirombin' activity. The 
results presented in this thesis seem to indicate that in vitro there is a 
relationship between platelet aggregation and fibrinogenolysis.
A comparative study of the in vitro techniques used to investigate 
platelet aggregation and adhesion is also presented. Ho apparent 
correlation was found for the assessment of platelet function with each test 
but from the evidence obtained with the effect of the fibrinolytic agents 
in each system it may be concluded that apparent lack of correlation 
may be due to quantitative rather than qualitative differences.
Much work remains to be done before the in vivo significance of the 
actions of the fibrinolytic agents and their fibrinogenolytic products on the 
initial stages of haemostasis can be fully assessed. Clearly the factors 
involved in platelet aggregation are complex and elucidation of the 
mechanisms of aggregation and disaggregation still present many challenging 
problems.
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This thesis gives an account of the investigation of the effect of a 
variety of proteolytic enzymes on platelet aggregation. The discovery of 
platelets in blood and the recognition of their importance in haemostasis 
and thrombus formation is described in an historical introduction, which is ^ 
followed by an account of materials and methods used, including three 
in vitro tests designed to estimate the ability of platelets to aggregate. 
Techniques for the preparation, purification and cnaracterization of 
degradation products formed by proteolytic digestion of fibrinogen are also 
described.
The experimental section of the thesis begins with an account of the 
assessment in vitro of the effect of fibrinogenolytic agents, particularly 
streptokinase and trypsin, and of products of fibrinogenolytic activity on 
platelet aggregation and adhesion. Platelet aggregation was assessed in 
two ways; by an artificial circulation system - the Chandler tube system, 
which measures the rate of formation of platelet aggregates in flowing 
recalcified citrated plasma, and by a turbidimetric method which measures 
the ability of platelets in response to adenosine-di-phosphate (ADP). As 
a measure of platelet adhesion, the diminution in platelet count as a result 
of passage of citrated whole blood or platelet-rich plasma through a column 
of glass beads was used (modified Hellem technique).
Platelet clumping, as estimated by all methods, was enhanced by both 
streptokinase and trypsin although the concentrations of each enzyme
required to produce this effect varied in the different assay systems. 
Streptokinase, at a concentration producing maximum lytic activity, 
accelerated the rate of formation of platelet aggregates in the Chandler 
tube and produced a marked increase in platelet adhesiveness in the Hellem- 
type technique. An increase in platelet ADP reactivity was only detected in 
the turbidimetric system after the plasma antiplasmin had been destroyed. 
Trypsin, at a concentration of 10 ug/ml sample produced a significant 
increase in the rate of formation of platelet aggregates in the Chandler 
tube system and an increase in platelet adhesiveness in the Hellem-type 
technique, but the concentration of enzyme had to be increased to 100 ug/ml 
sample before an increase in platelet ADP reactivity was detected.
Neither streptokinase nor trypsin influence platelet aggregation by a 
direct action on the platelet; streptokinase produces no significant 
enhancement and trypsin produces almost total inhibition of aggregation of 
washed platelets resuspended in buffer.
The effect on platelet aggregation of other proteolytic enzymes - 
urokinase, ficin, and chymotrypsin was also investigated, but none of these 
produced any enhancement of platelet reactivity to ADP in the turbidimetric 
system. These enzymes were however examined in less detail than 
streptokinase and trypsin.
Heparin was also studied and at the concentrations of 0.05 units and 10 
units per ml plasma was found to cause significant enhancement of ADP induced!
ji
aggregation in the turbidimetric system, but when present at a concentration | 
of 500 units per ml plasma caused significant inhibition of ADP reactivity. |
%The enhancement of platelet aggregation by streptokinase and trypsin was 
associated with marked fibrinogenolysis; several fibrinogen degradation 
products were prepared and their effect on platelet aggregation and adhesion 
examined. The degradation products were prepared by incubation of fibrinogen 
with either trypsin or urokinase-activated plasminogen followed by 
fractionation of the protein components of the incubation mixture on a DEAE 
cellulose column. The ultracentrifugal and electrophoretic properties of 
the breakdown products were determined and the number of peptide bonds broken 
during formation of two of the products determined.
The effect on platelet aggregation and adhesion was examined of three 
products of tryptic digestion of fibrinogen; the product of least digestion 
(molecular weight apprximately 83,000) produced no significant effect on 
platelet ADP reactivity or platelet adhesiveness, the product of prolonged 
digestion (molecular weight less than 13,000) inhibited ADP induced platelet 
aggregation while the product of intermediate digestion (molecular weight 
25,000) enhanced the rate of formation of platelet aggregates, ADP reactivity 
and platelet adhesiveness. A product prepared by digestion with urokinase- 
activated plasminogen enhanced both the rate of formation of platelet aggre­
gates in the Chandler tube and ADP induced platelet aggregation. The two ! 
larger fragments produced by trypsin both exhibited a marked 1 antithrombin1 
effect.
The three in vitro methods used to study platelet aggregation and adhesion] 
were compared. No mathematical correlations were found between the results 
obtained with the different methods; however the effect of trypsin and
streptokinase could be detected with each method and the observations made 
with each method could to some extent be influenced by the concentration of 
ADP in the system*
The experimental data presented demonstrate that under certain 
circumstances the enzymes streptokinase and trypsin can produce enhancement 
of platelet aggregation* The evidence suggests that they may do so by 
digestion of fibrinogen; in purified form, one of the products of fibrinogen 
digestion would appear to augment platelet aggregation* However, other 
fibrinogen degradation products appear to impair aggregation* These 
products of proteolytic activity may be important in maintaining a 
haemostatic balance in vivo*
The thesis concludes with a summary of the work*
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Tables 1 - 25•
Table 1 Incorporation of fibrinogen into the Chandler 
thrombus
Percentage radioactivity in thrombus
Subject Ho* Control Test
1 68*5 12,5
2 74.1 39»9
3 65 o3 7o7
4 50,0 10,1
Table 1 shows the percentage of radioactive fibrinogen 
incorporated into Chandler thrombi formed from saline 
treated platelet rich plasma and from trypsin■'"(l mg/ml) 
treated platelet rich plasma,.
Table 2 Effect of proteolytic enzymes on thrombin
generation
Reagent Clotting time (seconds)
Control 5.8; 5.2
Trypsin 10 ug/ml 
11 10Owug/ml 
" 1 m g / m l
5.5; 
162.0; 
180+ ;
5.2
180.0
180+
Chymo trypsin 100 yug/ml 29.0; 28.5
Ficin 10 yog/ml 6.9; 6.9
100 yug/ml 
1 1 'mg/ml
5.2;
*5.0;
5.0
7.5
Table 2 shows the effect of 0,2 ml of a series of incubation 
mixtures on the clotting time of 0.2 ml, fibrinogen. The 
incubation mixtures consisted of 0.3 ml of partially purified 
human prothrombin and 0.3 ml of the enzyme preparation which 
were maintained at 37 0 for 10 minutes before a sample was 
added to partially purified human fibrinogen.
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Table 4 Effect of adenosine on one stage prothrombin time
assay
System Clotting time (seconds)
Control
Adenosine 100 ug/ml 
200 Vug/ml 
500nag/ml 
1 mg/ml
27 «0;
25-5
27.0
25.0
tt 25-5 25.8
« 26.8 27-0
u 27-0 27.0
Table 4 shows the effect of adenosine, at various concentrations, 
on the one stage prothrombin time assay. 0.1 ml of a preparation 
of human brain, 0.1 ml plasma and 0.1 ml adenosine were incubated 
at 37°C for 10 minutes before the addition of 0.1 ml, M/40 CaCl^ 
to the system.
Effect of adenosine on the thrombin clotting time assay
System Clotting time (seconds)
Control
Adenosine
it
ti
i
100 ug/ml 
200vug/ml 
500vug/ml 
1 mg/ml
9-0; 9.0
9.0; 9-0 
9-0; 9-2 
8,8; 9-0 
9-0; 8,8
Table 5 shows the effect of adenosine, at various concentrations, 
,on the thrombin clotting time assay, 0,1 ml plasma, 0,3 ml 
’thrombin time mixture1 and 0,1 ml adenosine were incubated at 
37 C for 10 minutes before the addition of 0,1 ml thrombin 
(6 units /ml).
Table 6 Effect of ADP on fibrin formation
Rate of fibrin formation (seconds)
Subject Hb. Control Test
1 41 50
2 52 61
3 50 23
4 22 35
5 56 70
6 53 50
7 67 120
Mean 
-  SD
+ 46 
- 16
+ 58 
- 31
Table 6 shows the effect of AD? (0.5 Mg/ml plasma) on the rate of 
formation of fibrin following platelet aggregation in the Chandler 
tube. There is no significant difference between the results of the 
control and ADP treated samples; t = 1.704, 0.10 < p <0.20.
Table 7 Percentage clottable protein present after aggregation
Percentage clottable protein
System Subject No. Control Streptokinase Trypsin
ADP induced 1 74o2 14.1 61.4
platelet 2 78.3 57.7 89.3
aggregation in 3 76.7 61.5 81.7
diluted plasma 4 69 »4 68.8 68.6
5 88.2 33.3 85.9
Nor-adrenaline 6 64o4 84.0 62.1
induced 7 77.2 - 81.2
aggregation 8 74.1 38.9 68.3
9 62.7 53.6 64.1
10 54.4 41.7 87.7
Table 7 shows the effect of incubation of platelet rich plasma with 
saline, streptokinase (100 N.I.H. units/ml) and trypsin U0yug/ml) 
on the percentage clottable protein remaining in the samples after 
platelet aggregation.
Table 8 Effect of heparin on in vitro clot formation
Concentration of heparin 
units /ml plasma
Clotting time (minutes)
8 38
10 65
20 90
50 90
Shown is the effect of heparin on clot formation in vitro. 
The system consisted of 0.5 ml plasma, 0.05 ml heparin and 
0.05 ml H/4 CaCl2. ^
'Table 9 Effect of trypsin on platelet aggregation of washed
platelets suspended in a fibrinogen enriched solution
Time after addition 
of ADP (min)
Outical
Control
Density Readings 
Test
1 0 .568 0 .582
2 0 .562 0.580
3 0 .560 0.579
4 0 .560 0.579
5 0.552 0.578
6 0.550 0.577
7 0.548 0.572
8 0.545 0.572
9 0.545 0.570
10 0.545 0.570
Shown are the optical density readings, obtained after the addition 
of ADP (0.5 ug/ml suspension), of a control sample of washed platelets 
incubated ax 37 0 for 10 minutes with trypsin (100 u g / m l  suspension) 
and a test sample of washed platelets incubated wixh trypsin (lOOyug/ml 
suspension) and fibrinogen (4OO mg/ml suspension). The washed 
platelets were suspended in a buffer medium (Haslam, 1964).
Table 10 The effect of trypsin on platelet aggregation of washed
platelets
Time after addition 
of ADP (min)
Optical Density Readings
Control Test
1 0.548 0.562
2 0.540 0.560
3 0.535 0.555
4 0.535 0.548
cJ 0.540 0.542
6 0.539 0.542
7 0.542 0.541
8 0.535 0.540
9 0.538 0.540
10 0.538 0.540
Shown is the effect of addition of fibrinogen to a suspension of 
washed platelets on the action of trypsin on ADP induced aggregation. 
The optical density readings, obtained after the addition of ADP 
(0.5 ug/ml suspension), to a control sample of washed platelets in- 
cubaxed with trypsin (l mg/ml suspension) at y j ° Q  for 10 minutes and 
a test sample of washed platelets incubated with trypsin (l mg/ml 
suspension) and fibrinogen (400 mg/ml suspension), are presented.
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Table 12 ATP concentrations in citrated whole blood
pmoles per ml ATP
Subject Control Test
a b a b
1 0*068 0.082 0.225 0.068
2 0.116 0.191 0.136 0.150
3 0.184 0.130 0.041 0.048
4 0.041 0.136 0.239 0.259
5 0.130 0.136 0.150 0.109
6 0.130 0.116 0.041 0.136
7 0.177 0.123 0.136 0.136
8 0.252 0.136 0.136 0.205
Mean 
£ S.D.
0.121 0.131 . 0.138 . 0.139
£ 0.083 £ 0.030 £ 0.023 £ 0.022
Shown are the A.T.P. concentrations of citrated whole blood 
samples before (a) and after (b) passage through a column of 
glass beads. The control samples were treated with saline 
and the test samples with trypsin (lOpg/ml blood)* There is 
no significant difference between the results of either the 
control and trypsin treated samples before and after passage; 
t * 0*243, 0*80<p<0*90 and t - 0.033, 0.995<p<0.999 respectively.
Table 13. AMP concentrations in citrated whole blood
u moles per ml AMP
Subject Control Test
a b a b
1 0.24-9 0.249 0.263 0.297
2 0.273 0.232 0.310 0.324
3 0.222 0.191 0.218 0.252
4 0.263 0.280 0.273 0.276
3 0.201 0.171 0.218 0.218
6 0.273 0.222 0.225 0.211
7 0.239 0.211 0.208 0.211
8 0.143 O.198 0.252 0.273
Mean 0.233 0.222 0.246 0.258
- S.D. -  0.044 ± O.O36 - 0.035 i 0.042
Shown are the AMP concentrations of citrated whole blood samples 
treated with 0.9% sodium chloride and trypsin (10 pg/ml blood) 
before (a) and after (b) passage through a glass bead column.
The differences in concentration before and after passage are 
not significant in either the control or tyypsin treated samples; 
t = 0.929, 0.30 < p < 0.40 and t = I.98O, 0.03 < p < 0.10 
respectively.
Table 14 ADB concentrations in platelet rich plasma
(lx moles per ml ADP
Subject Control Test
a b a b
1 0.14-3 0.123 0.068 0.068
2 0.082 0.027 0.068 0.123
3 0.123 0.170 0.123 0.126
4 0.061 0.055 0.027 0.034
5 O.136 0.123 O.095 0.034
6 0.170 0.068 0.123 0.068
7 0.123 0.157 0.126 0.123
Mean 0.120 0.103 0.090 0.082
± S.D. • 0.037 ± 0.054 i 0.037 - 0.041
Shown are the ADP concentrations of platelet rich plasma 
samples treated with 0*9# sodium chloride or trypsin 
(10 |jg/ml plasma) before (a) and after (b) passage through 
a glass bead column. The differences between the results 
before and after passage are not significant in either the 
control or trypsin treated samples; t = 0.854, 0.30 < p < 0.4-0 
and t s 0.515, 0.60 < p < 0.70 respectively.
Table 15 AMP concentrations in platelet rich plasma
ji moles per ml AMP
Subject Control Test
a b a b
1 0.133 0.246 0.126 0.116
2 0.075 0.102 O.O89 0.068
3 0.061 0.068 0.058 O.O58
4 0.041 0.068 0.061 0.061
5 0.061 0.044 0.072 0.072
6 0.068 0.068 0.041 0.075
7 0.143 0.126 0.123 0.068
Mean O.O83 0.103 0.081 0.074
± S.D. -0.039 ±0.069 ±0.033 ±0.019
Shown are the AMP concentrations of platelet rich plasma 
samples treated with 0.9# sodium chloride or trypsin 
(10 fjg/ml plasma) before (a) and after (b) passage through 
a column of glass beads. The differences between the results 
before and after passage are not significant in either the 
control or trypsin treated samples; t = 1.184, 0.10 < p < 0.20 
and t a 0.728, 0.40 < p < 0.50 respectively.
Table 16 Percentage platelet adhesiveness and 
ADP concentrations in citrated whole 
blood and platelet rich plasma.
% Platelet Initial ADP Change in ADP
System adhesiveness concentration concentration
(jl moles/ml ji moles/ml
1 93.1 0.068 +0.014
2 67.6 0.116 +O.O75
Citrated
whole
blood
3
4
89.3
37.3
0.184
0.041
-0.054
+O.O95
3 3.6 0.130 +0.006
6 13.2 0.130 -0.014
7 24.6 0.177 -0.054
8 33.6 0.252 -0.116
1 13.2 0.143 -0.020
2 29.8 0.082 -0.055
Platelet 34
23.9
0
0.123
0.061
+0.047
-0.006rich
plasma 56
0
0
O.136
0.170
-0.013
-0.102
7 3.^ 0.123 +0.034
Table 17 Percentage platelet adhesiveness and ADP 
concentrations in citrated whole blood 
and platelet rich plasma treated with trypsin
% Platelet Initial ADP Change in ADP
System adhesiveness c one entration concentration
p. moles/ml moles/ml
Citrated
whole
blood
1 76.8 0.225 -0.157
2 90.7 0.136 +0.014
3 78.6 0.041 +0.007
4 62.1 0.239 +0.020
5 73.8 0.150 -0.041
6 39.7 0.041 +O.O95
7 61.6 0.136 0
8 41.8 0.136 +0.069
1 98.6 0.048 0
2 89.5 0.068 +0.055
3 25.9 0.123 +0.003
4 3.2 0.027 +0.007
3 18.2 O.O95 -0.061
6 45.6 0.123 -0.055
7 26.7 0.126 -0.003
Platelet
rich
plasma
Table 18 Packed cell volume and platelet adhesiveness
$ packed cell $ platelet f o  platelet
volume adhesiveness
(uncorrected)
adhesiveness
(corrected)
Mean . 40.3 49.8 , 50.4
S.D. ± 5.0 - 18.3 -  14.6
Shown are the mean and standard deviations of the packed 
cell volume and platelet adhesiveness estimated on a 
series of twenty-five subjects. The percentage platelet 
adhesiveness was corrected, for each sample, from the 
calibration curve shown in figure 44 to allow for the 
individual variations of packed cell volume from the 
mean value of 40$.
Table 19 Comparison of results of various methods of
measuring platelet aggregation
Methods Correlation
coefficient
Significance
Chandler and 
B o m  (1 minute reading) + 0.15 p < 0.1
Chandler and 
Born (4 minute reading) - 0.13 p <0.1
Chandler and
Eellem (no correction) + 0.19
p<0.1
Bora (l minute reading) 
Hellem (no correction) - 0.18 p< 0.1
Born (4 minute reading) 
Hellem (no correction) - 0.21
p<0.1
Chandler and 
Hellem (corrected) + 0.25 p<0.1
Born (l minute reading) 
Hellem ( corrected) - 0.39 0.1 < P<0.5
B o m  (4 minute reading) 
Hellem (corrected) - 0.46 0.5 < p<0.01
Shown are the mathematical correlations determined from the results 
of observations of platelet function estimated on a series of twenty- 
five subjects with each of three methods. In no instance is there 
significant correlation between the results obtained with the 
Chandler tube, turbidimetric (Born) or glass bead column (Hellem) 
methods.
Table 20 Comparison of platelet aggregation and platelet count
Mo. of
Method observations
Correlation
coefficient
Significance
Chandler 40 -  0.04 p< 0 .1
Born
(2 minute reading) 53 -  C.09 p< 0 .1
Hellem
(uncorrected) 25 -  0.23 p< 0 .1
Hellem
(corrected) 25 -  0.11 p < 0.1
Shown are the mathematical correlations determined from the 
results of observations on platelet aggregation and from platelet 
counts. The readings obtained with the three methods have been 
compared to their respective platelet counts. In no case is there 
significant correlation between the platelet count of a sample and 
the extent to which platelet aggregation occurs within the sample.
Table 21 Plasma protein concentrations
Method No* of 
observations
Plasminogen 
casein units per ml
Fibrinogen 
mgm per 100 ml
Chandler 40 2.7 -  0.7 300 -  120
System
Turbidimetric 53
K"\0
+ 
1 • 345 -  122
system
Shown are the means and standard deviations of the plasminogen and 
fibrinogen concentrations of the platelet rich plasma samples 
investigated in the Chandler tube series of experiments (Chapter 
4 ) and in the turbidimetric system (Chapter 5).
Table 22 The ■ultracentrifugation data for fibrinogen and the
fibrinogen degradation products faf and *b*
Frotein
Sedimentation 
coefficient 
x ICT^seCo
Diffusion
coefficient
x 10 cm per sec.
Molecular
Weight
Fibrinogen 7.6 1.97 341,000
Product 'a' 6.72 6.62 82,427
Product 'b‘ 4.37 14.40 24,642
Shorn are the values for the sedimentation coefficients, diffusion 
coefficients and molecular weights of fibrinogen, product *a‘ and 
product ‘V o  The values quoted for fibrinogen are from the data of 
Caspary and Kekwick (1954) as quoted by Seheraga and Laskowski (1957)»
Table 23 Effect of product 'a' on platelet aggregation
in the Chandler tube
Time of platelet aggregation (seconds)
Subject Nbo Control Test
1 522 464
2 447 392
3 420 386
Shown is the effect of product 'a* (20C n g  per ml plasma) on the 
rate of fomation of platelet aggregates in the Chandler tube. 
The product and plasma were incubated at 37 0 for 10 minutes 
before the system was recalcified.
Table 24 Effect of product fb' on platelet aggregation in
the Chandler tube
Time of platelet aggregation (seconds)
Subject No. Control Test
1 522 438
2 447 362
3 420 361
Shown is the effect of product 'b1 (200/ug/ml plasma) on 
pl atelet aggregation in platelet rich plasma in the Chandler 
tube. The product and plasma were incubated together at 37 C 
for 10 minutes before the system was recalcified.
Table 25 Effect of products 'a' and 'b' on thrombin
clotting time
Sample Thrombin clotting times (seconds,
Saline control 16.5; 16.0
Product 'a' 2 mg/ml 
1 mg/ml 
500 yug/ml 
200yug/ml 
1 CO yog/ml
30.2
25.2
25.5 
25.0
25.5
3 0 .0
25.4
25.5
25.5 
25.2
Product *b‘ 2 mg/ml 
1 mg/ml 
500 Aug/ml 
20(7 yug/ml 
100^ug/ml
28.5 
26.2
24.5 
23.2 
23.4
28.8
26.2
25.0
23.8
23.8
Shown are the effects of products 'a1, and ’b1 in a thrombin 
clotting time system. To 0.05 ml, plasma was added to 0.05 
ml, product and 0.3 nil, 'thrombin time mixture1. The 
sample was clotted with 0.1 ml thrombin (10 units per ml).
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Figaro 1 shows the function of the platelet in haemostasis.
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Figure 2 illustrates schematically the sequence of 
reactions leading to thrombus formation as postulated 
by Hellem and Ouren (1964)*
Figure 3 shows an artificial thrombus made in a Chandler's 
tube by rotation of 15 ml whole blood for 1 hour. The
white head and the fibrin tail can be seen.
Figure 4 shows a longitudinal section through a 
Chandler thrombus. The contrast between the 
platelet head and the fibrin tail can be seen. 
Original magnification x 500. Stain ~ Piero 
Mallory. (Photomicrograph prepared by Dr. F. 
Walker) •
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Figure 5 illustrates the influence of streptokinase, at 
a concentration which can produce maximum lytic activity, 
on the rate of formation of platelet aggregates in the 
Chandler tube. The speed of platelet aggregation is 
accelerated in each of the eleven plasma samples 
investigated following incubation of plasma with 
streptokinase at 37 C for 10 minutes. The mean time 
for platelet aggregation to occur in the control loops 
is 5S2 -110 seconds and in the test loops 276 - 81 
seconds, t = 6.602, p < 0.001. The figure is constructed 
from data in table 26.
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Figure 6 illustrates the effect of trypsin (10 yug/ml plasma) 
on the rate of formation of platelet aggregates in the 
Chandler tube. The speed of aggregation is accelerated in 
each of the seven plasma samples investigated as a result 
of incubating plasma with trypsin at 57°C for 10 minutes.
The mean time for platelet aggregation to occur in the 
control loops is 457 - 115 seconds and in the test loops 
151 - 41 seconds; t = 7.764, p <0.001. The figure is 
compiled from data presented in table 27.
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Figure 7 shows the effect of trypsin (l mg/ml plasma) on the 
rate of formation of platelet aggregates in the Chandler tube. 
The speed of platelet aggregation is accelerated in each of 
the seven plasma samples to which trypsin was added. The 
mean+time of platelet aggregation in the control loopj-s is 
666 - 64 seconds and in the trypsin treated loops 49 - 20 
seconds; t = 26.491, p <  0.001. The figure is prepared 
from table 23«
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i?igt:.re 8 illustrates the effect of incubating platelet poor 
plasma with trypsin (10 yug/ml plasma) at 37^0 for 10 minutes, 
before the addition of platelet rich plasma, on the rate of 
formation of platelet abrogates in the Chandler tube. The 
mean time of platelet aggregation in the test loops is 307 ~ 
124 seconds uhicli is significantly less than the mean time of 
the control loops 504 - 236 seconds; t = 2.970, 0.020 p< 
0.025. The data from which this figure was compiled is 
shovm in table 29•
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Figure 9 shows the effect, on the rate of formation of platelet 
aggregates in the Chandler tube, of incubating platelet rich 
plasma with trypsin (10jag/ml plasma) at 37°C for 10 minutes. 
The speed of aggregation is accelerated in each of the seven 
plasm simples investigated. The mean time of platelet 
aggregation in the control loojes is 462 - 114 seconds and in 
the trypsin treated loops 208 - 122 seconu.s. The difference 
between the two results is significant; t = 4.500, 0*001<
p <0.005. The figure is prepared from table 50o
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Figure 10 illustrates the effect of ADF (C.5 yug/ml plasma) 
on the rate of formation of platelet aggregates in the Chandle 
tube. Platelet aggregation is accelerated in each of the 
ten plasma samples investigated. The mean tzjmie of platelet 
aggregation of the 1-DP treated plasma is 583 -117 seconds 
which is significantly less than the mean time of the 
control samples 655 - 152 seconds; t = 4o324» p<0.001.
The figure is constructed from data in table 31 °
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Figure 11 illustrates the effect of ADP (0„5 Aig/ml plasma) 
on the rate of formation of platelet aggregates in recalcified 
and non-recalcified plasma in the Chandler tube. Over the 
series of seven plasma samples investigated there is no 
significant difference between the effect of ADP in the 
two systems. The mean time of platelet aggregation in 
the recalcified loops is 85 - 66 seconds and in the non­
recalcified loops 59 - 20 seconds; t = 0.958, 0.5KXp<
0.40. The figure is constructed from the data in table 52.
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Figure 12 shows the effect of adenosine (100yu&/ml plasma) on 
the rate of formation of platelet aggregates in the Chandler 
tube. The speed of platelet aggregation is retarded in each 
of the seven plasma samples treated with adenosine. The 
mean time of platelet aggregation in the control loops is 
377 - 62 seconds and in the adenosine treated loops 460 - 
65 seconds; t = 6.606, p< 0.001. The figure is compiled 
from table 55•
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figure 13 illustrates the combined effect of trypsin (iCyhg/ml 
plasma) and O F  (O.fyuj/inl plasma) on the rate of formation of 
platelet aggregates in the Chandler tube compared to the rate 
in plasma treated with 0.9:1 sodium chloride and the rate in 
plasma treated only -with O P  (O.g yuo/ml plasma). In each 
of the seven plasma samples investigated the speed of 
platelet aggregation is most rapid in the sample treated with 
trypsin end .IDF. The mean time of platelet aggregation in 
the control loops is 599 - 194 seconds, in the O P  treated 
loops 349 - 67 seconds end in the O P  plus trypsin treated 
loons 197 - 70 seconds. The differences between the means 
of the control and O P  treated loops and of the O P  and O P  
plus trypsin treated loops are significant; t = 2.970,
0.020<p < 0.C25 and t - 3.194, p< 0.001 respectively. The 
fimure is constructed from the data of table p4o
TRYPSIN TREATED TRYPSIN +ADENOSINE (100ugm/ml)
SAMPLE TREATED SAMPLE
350
300*
(/>u0)
&  250-
zo
§ 200-
LU
IT
OO<  150
I- MEAN
LU—I
LU
—I
100' MEAN
o.
50-
Figure 14 shows the effect of adenosine (100/ug/mi plasma) on 
the rate of formation of platelet aggregates in plasma treated 
with trypsin (10yug/nl plasma). Over the series of ten plasma 
samples investigated the speed of platelet aggregation is 
significantly retarded in the adenosine treated samples*
The mean time <j>f platelet aggregation in the trypsin treated 
samples is 96 - 28 seconds Lind in the trypsin mid adenosine 
treatel samples 139-71 seconds; t = 2.284, 0*Q25< P < 0.050. 
The data of table 33 was used to compile this figure.
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figure 15 illustrates the effect of adenosine (200 ug/ml plasma) 
on the rate of formation of platelet aggregates in plasma treated 
with trypsin (10 yug/ml plasma). The speed of platelet aggregation 
is retarded in each of the seven plasma samples treated with 
adenosine • The mean time of platelet aggregation in the control
locus i; 96 - 55 seconds and in the adenosine treated loops 135 +
42 seconds; t = 4.289, 0.005< p < 0.010. The figure is
constructed from the data, of table jS •
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Figure 16 shov;s the effect of streptokinase or --'DP induced platelet 
aggregation. The concentration of streptokinase was the 
concentration vhich produced maximum lytic activity as determine- f' 
plasma sample • Over the series of !••«:.. plasm samples investigated 
streptokinase causes significant inhibition of platelet aggregation 
4p minutes after the addition of Alip (0.5 yug/ml plasma), the mean 
optical density reading of the control samples is 0.366 - 0.208 
and of the streptokinase treated samples 0.499 - 0.129; t =
2.413» 0.025< p ^ 0 .050. fine values of the individual samples
at this time interval are presented in table 37»
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Figure 17 illustrates she effect of streptokinase (l00 N.I.H. unite/ 
ml sample j and trypsin (1C ug/ml sample) on 43? induced platelet 
aggregation in platelet rich plasma diluted 1: 2.5 with 0.9/- sodium 
chloride. Neither streptokinase nor trypsin treatment of diluted 
plasma results in a significant change in the extent of platelet 
aggregation. 3 minutes after the addition of ID? ( 1.Cyug/ml sample) 
the mean optical density readings of the control samples is 0.266 - 
0.119 and of the streptokinase treated samples 0.298 - 0.077; t = 
1.122, 0.3G<p< 0.40. 4 minutes after the addition of A3P, £he
mean optical density reading of the control samples is 0.254 - 
0,113 and of the trypsin treated samples 0.273 - 0.110; t = 0.965, 
0.30<^p<0.40. The individual readings, for each of the seven 
plasma samples investigated, at these time intervals, are tabulated 
ir_ tables 58 and 45.
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Figure 18 shows the effect of streptokinase (2,000 n.I.H. units/ml 
plasma) on the ADP induced aggregation of platelets suspended in 
plasma pre-treated with acid and alkali to destroy antiplasniin.
10 minutes after the addition of --DP (0.5 ng/ml plasma),+the mean 
optical density reading of the control samples .^s 0,499 - 0,066 
and of tin streptokinase treated samples 0,430 - 129. dhe 
difference between these results is significant; t = 2.574>
0,20< p< 0.025. Hie optical density readings at this time interval 
of each of 'the plasma sanroles investigated are presented in table 
39.
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Figure 19 illustrates the effect of streptokinase on nor-adrenaline 
induced platelet aggregation. fhere is no significant difference 
between the ertent of aggregation which occurs in tiie control 
samples treated with C.9,k sodium chloride and the test samples 
treated with streptokinase (100 IT.I,II. units/ml plasma). 10
»
24
minutes after the addition of nor-adrenaline (1.0 ng/ml plasma) 
the mean optical density of the control samples is 0.571 - 0.2  
and of the streptokinase treated samples 0.551 - 0.219; t = 0.625, 
0.50< p< 0.60. The optical density readings of the individual 
plasma samples, at this time interval, ore shown in table 4-0.
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Figure 20 r.Ciou.-. the of feet of trypsin, at concentrations of 10 ng/ml 
plasma and 100 plasm, on H P  induced platelet agyr e vation•
Trypsin at a concentration of 10 jag/uL plasma appears to produce 
no significant change in the extent of aggregation from that of 
the saline treated control samples; 1 minute after the addition 
of huP (0 01 u j/ul pi a ana.), the mean optical density reading of the 
control samples is C.51y — 0,061 and of the tost samples 0,544 ~
0*055; t = 2.11f, 0.C5 <p< 0.10. Platelet aggregation is significant! 
enhanced by trypsin at a concentration of 100 ng/ml plasma; 1-y 
ninutos after fie audition of H P  (0.5 Aj/nl plasma), the mean optical 
density reading of the control samples is 0.529 -* 0.041 and of the 
trypsin treated samples 0.501 t 0.041; t = 5.925, 0.001< p < 0.005.
The optical density readings of the individual plasma samples,
at fnese time inbervals, are presented in tables 41 and 42.
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Figure 21 illusi'',-tss the ability of trypsin (l mg/ml plasma) to 
promote platelet ay rogation in the absence of ADF and the 
ability of u/lenosine ^0.3 /ug/ml plasms.) to partially block this 
action. 2 minutes nit or the addition of 0.9 - sodium chloride 
to the control samples and trypsin to the test sample, the mean 
^pbical density reading of the trypsin treated sample is 0.26b 
- 0.204 which is sigiiificsuitly less than the control value of 
0.540 - 0.041 ; t = 1.030, 0.020<p< 0.025. The mean optical 
density reading of the trypsin treated samples i|> 0.177 - 0.182 
;md of the trypsin plus adenosine samples 0.30y - 0.036, 4 
minutes after the additions were made to these samples. The 
difference between the results is not significant; t = 1.318, 
0.1 Q< p <. 0.20. The optical density readings of the seven 
plasma samples, at these time intervals, are shorn in tables 
4b and 52.
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Figure 22 shows the effect of trypsin 0 ny/nl plasma) on ADP 
induced aggregation in plasma pre incubated ith streptokinase 
(1,000 h.I.H. LLj-iis../ml plasma) at 57°C for 10 minutes. Platelet 
ag rotation va.s enhanced in each of the seven plasma samples 
iuvestigrted. 30 seconds after the addition of 0.9;-' sodium 
chloride to the control samples raid of trypsin to the test 
samples, the mean optical density reading of the control samples 
is 0.325 - 0.009 mid of the tost samples 0.545 - 0.060; t = 
6.485, p <0.001. 1'he optical density readings of each of the 
seven plasma samples, at this time interval, are shown in 
table 44.
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figure 23 illustrates the effect of trypsin (10 /ue/ml plasma) on 
ADP induced platelet aggregation in platelet rich plasma to which 
calcium chloride (C.25 mmole/ml plasma) had been added. Trypsin 
has no significant effect on platelet aggregation in this system. 
1 minute after the addition of ADP (0.5yug/nl plasma), the mean 
optical density reading of the control samples is C .372 - 0.115  
and of the trypsin treated samples 0.331 — 0.113; t = 1.363 > 
C.20< pCO.dC. The optical density readings of the seven 
plasma, samples, at this time interval, are shown in table 46.
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Figure 24 slious the effect cf tripsin (lC» yug/ml plasma) on ADP 
induced platelet nyereyation i:i platelet rich plasma to uhich 
calcium clilcride eC nmolc/ml plasma) had been added. Trypsin 
has no significant effect on platelet ay /rogation in this system. 
9 minutes after the addition of ADP (0,9yup/ml plasma), the mean 
optical density reading of the control samples is 0,571 ~ 0,196 
and of the trypsin treated samples 0,446 - 0.143; t = 1.690, 
0.10<p <0.20. ihe optical density readings of the seven plasma 
samples, at this time interval, are presented, in table 47.
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Figure 25 illustrates the effect of incubation of trypsin (100jug/ 
ml plasma) ndth platelet poor plasiaa, before the addition of 
platelet rich plasma, on ADP induced platelet aggregation. There 
is no significant difference betireen the platelet aggregation of 
the control ■ nd trypsin treated samples; 10 minutes after the 
addition of /OP (0„5 ju^ /rnl plasm^.), the mean optical density reading 
of the control samples is 0.480 - 0*133 and of the trypsin 
treated samples C,453 ~ 0.121, t = 1.170, 0.20<p<0.30. The 
optical density readings of each of the seven plasma samples, at 
this time interval, are shown in table 42.
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Figure 26 shows the effect of incubation of trypsin (100 ng/ml 
plasma) with platelet rich plasma, before the addition ox platelet 
poor plasma, on ADI-' induced platelet aggregation. Trypsin treatment 
of the plasm.. samples results in significant enhancement of platelet 
approbation; 10 minutes after the addition of ADP (0,5 Mg/ml plasma), 
the metn optimal density reading of the control samples is 0,484 - 
0,104 and of the test samples 0,448 - 0.083, t = 2.765, 0.025<p < 
0,05o. '.fk; optic-il density readings, at this time interval, of the
seven plasma samples investigated are presented in table 49o
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l?igure 27 illustrates the effect of trypsin (10 yug/r.il suspension) 
and heparin (10 units /nil suspension) on ID? induced platelet 
aggregation of unshed platelets suspended in 0.1 K tris buffer, pH 
7.5* -hither trypsin nor heparin has a significant effect on 
platelet aggregation in this system; 10 minutes after the addition 
of -ID? (0.5 >ug/ml suspension)^ the mean optical density readings of 
the control samples is 0.505 - 0.058, of the trypsin treated samples 
0.516 - 0.025 and of the heparin treated samples 0.512 - 0.053, It = 
0.291, 0.70 <p <  0.30 said t = 0.756, 0.40<p<0.50 respectively).
The optical density readings, at this time interval, of the seven 
plasma samples investigated are shorn in tables 50 .and 60.
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ADP (0-5/igm /m l)
0-60
TRYPSIN
(10/jgm/ml)
0-55
TRYPSIN 
(1 mgm/ml)
0-50
0-45
0-40
0-35
0-30
8 1064
TIME (mins)
fipuro 25 si.ous the effect of trypsin, at concentrations of 15 
suspension u:f 1 u^/rl suspension, on iDP induced platelet 
: p. reps !;ion of s saddle of unshod pLotelcts suspended in a buf 
medium (idislau, 1£6'i )»
ADP (0-5 jugm/ml)
0-60
0-50
H 0-40
cn
CONTROL
^.SAMPLE
z
LU
Q 0-30
—i
<
O
H
Q.
o
0-20
010
FIBRINOGEN
1084 62
TIME (min)
Figure 29 illustrates the effect of fibrinogen (lOCyug/nl suspension) 
on ./DP induced platelet aggregation of a sample of hashed platelets 
suspended in a buffer medium (llaslam, 1 964-) *
0-60
0-55
>
H 0-50
(/)
z
LU
□
0-45_i
<
U
I—
Q_o
CONTROL 
V  SAMPLE
0-40
STREPTOKINASEV 
TREATED SAMPLE0-35
0-30
108642
TIME (mins)
Figure 3$ shows the effect of streptokinase (2,000 I\T0I.H. units/ml 
suspension) on ADP induced platelet aggregation of a sample of washed
0-58-
0-56-
TRYPSIN(100yL£gm/ml) 
+  ADENOSINEdOO/igm/ml) 
TREATED SAMPLE0-54-
>  0-52* 
</)
5  0-50' 
G
<  0-48’ 
H
O 0-46*
0-44-
0-42-
TRYPSIN  (100^ gm/mi) 
TREATED SAMPLE0-40-
T IM E (M in )
Fiyuro 31 illustrates the effect of adenosine (100 ny/ml plasma) 
on ADP induced platelet aggregation of platelet rich plasma treated
1 minute afterwith trypsin (100 up/ml plasma),
ADP (0.3 up/ml plasma), the mean c^ ptical density readings of th 
trypsin treated samples is 0,491 - 0,054 which is significantly 
than tljie mean value of the samples trc
0.567 - 0.059; t = 2.724, 0.025< p < 0.050. The optical density 
reedings, at this time interval, of the seven plasma samples 
investigated are shorn in table 51 •
addition of 
e
-mien mxioaubx less 
ted uith trypsin and adenosine
NOR-ADRENALINE l^gm/ml
0-60
0-55-
>-
H
CO
2
0-50
LUQ
0-45_i
<U
\ —
Q_
O
TRYPSIN (10/ag m/m I) 
TREATED SAMPLE
0-40
• • •
CONTROL SAMPLE0-35
6 82 4 100
TIME (Min)
Figure J>2 shows the effect of trypsin (1 C^ug/nl plasma) on nor­
adrenaline induced platelet aggregation. Over tho series of 
10 plasma samples investigated, trypsin lias no significant effect 
on platelet aggregation; 2 minutes after the addition of nor­
adrenaline (l .0yug/ml plasma), the mean optical density reading's 
of the control samples, is 0,440 - 0,141 and of the trypsin trashed 
samples O.395 t 0.20?,' (t = 1.691, 0.10 < p <  0.20). The optical 
density readings, at this time interval, of the ten plasma samples 
investigated are presented in table 53*
0-60*
UROKINASE 
TREATED SAMPLE0-55-
LU
CONTROL SAMPLE0-45-
0 2 4 6 8 10
TIME (Min)
Figure 35 illustrates the effect of urokinase, at a concentration 
which produces manimum lytic activity, on iDP induced platelet 
aggregation. Urokinase produces significant inhibition of platelet 
aggregation; 3 minutes after the addition of kUP (0.5 Ug/nl plasma), 
the mean optical density reading of the control samples is 0.400 - 
0.264 and of the trypsin treated samples 0.499 - 0.123, (t = 3.134, 
0.01 < p < 0.C2). the optical density readings, at this time interval, 
of the ten plasma samples investigated are shown in table 54.
ADP 0-5 /igm/bil
H 0-50
Or 0-40
CH YMOTRYPSIN (100 /xgm/ml) 
TREATED 
SAMPLES
CONTROL 
SAMPLES
4 6
TIME (MIN)
Figure 34 shows the effect of chymotiypsin (100 yug/ml plasma) on 
ADP induced platelet agprepation. There is no significant difference
between the platelet aggregation which occurs in the control and 
chymotrypsin treated samples; the mean optical density reading of the 
control samples, 5+minntes after the addition of -TOP (0.5 yng/ml 
plasma^, is 0.3 64 - 0.156 and of the chymo trypsin treated samples 
6.577 - 0.144, (t = 0.412, 0.60<p< 0.70). The optical density 
readings, at this time interval, of the seven plasma samples 
investigated are presented in table 55.
0 60
0-55-
I-  0-50-
UJ
0-45-
CONTROL
SAMPLES
FICIN
(10 mgm/ml) 
TREATED SAMPLES
a. 0-40-
0-35-
0-30-
2 64 8 10
TIME (M IN )
-'injure 55 illustrates tho effect of ficin (100/iig/nl plasma) on ADP 
induced platelet aggregation. there is no significant difference 
"between the platelet aggregation vdiich occurs in the control and ficin 
treated samples; 5 ;■ hnutes after the audition of ADP (0.5/Ug/ml plasma),
the mean optical density reading of the control samples is 0.560 - 
0.160 and of the ficin treated sarrolos 0.555 - 0.165, (t = 0.955, 0.50< p 
<e.4c). t’he optical density readings, at this time interval, of the 
twelve plasma sauplos investigated are shown in table 56.
CONTROL SAMPLE0-30'
0-20-
0-10-
HEPARIN flOunits/ ml) 
TREATED SAMPLE
0 42 6 108
TIME (Min)
injure %  sho:rs the effect of heparin (10 units/ml plasma) on if? 
induced platelet aggregation. Platelet aggregation is significantly 
enhanced in the samples treated uith heparin; 4 minutes after the 
addition of _1XP (0„5 Aij/ml plpsna). the mean optical density reading of 
the control samples Is 0.196 - 0.146 and of the heparin treated samples 
O.096 I O.091, (t = 2.594, 0.025<p< 0.020). The optical density 
readings, at this time interval, of the eight plasma samples investigated 
are presented in table 57«
ADP O S^gm/ml
0-60
0-55
0-50
CONTROL SAMPLEZO-45
HEPARIN (0 05units/ml) 
TREATED SAMPLE0-35
0-30
TIME (Min)
figure 37 illustrates the effect of heparin (O.Op units/ml plasma) on 
-DP induced platelet aggregation. The presence of heparin at this 
concentration recults in significant enhancement of platelet aggregation; 
10 minute::, after the addition of D P  (0„5yug/ml plasma), the mean optical 
density reading of the control sainples is 0.436 - 0,139 and of the 
heparin treats d samples 0.376 - 0.167, (t = 3.297, 0.005<p< 0.010). 
fhe optical density readings, at this time interval, of the fourteen 
plasma samples investigated are shown in table 58.
0-55
HEPARIN (500 units/ml) 
TREATED SAMPLE
P  0-50'
0-45-
CONTROL SAMPLE& 0-40
0-35
0 2 4 6 8 10
TIME (Min)
figure 3b shoera the effect of heparin (500 units/ml plasma) on ADP 
induced platelet aggregation* Platelet aggregation is significantly 
inhibited by the presence of heparin, at this concentration; 1C 
minutes after the addition of U P  (0*5 ytig/nl plasma), the mean 
optical density reading of the control samples is 0,422 - 0*184 and of 
the heparin treated samples 0,508 ~ 0,140, It = 2.563* 0.025< p< O.G3G) * 
The optical density readings, at this time interval, of the eight 
plasm-... samples investigated are shown in table 59.
CONTROL
SAMPLES
if)
if)
LLI
>
if)
LU
X
Q
<
LU
—I
CL
100
80
60
40
20
0
I TESTSAMPLES♦
mean
mean
figure 39 shows the effect of streptokinase, at the concentration 
which produces na-Uir lytic activity, on platelet adhesiveness of 
nitrated whole blood. flic presence of streptokinase, at this 
concentration, produces a significant decrease in the number of platelets 
lost during the passage of blood through the glass bead column. The 
mean percentage platale^ /->+* +U
47. /
2.402, 0.C23< p <0.Oto) 
of table 61«
t adhesiveness or the control samples is 
ana of the streptokinase treated samples 21 *3 - 17*4* (t =^ptom
The firure m constructed from the data
if)
if)
LU
2
LU
>
U )
LU
I
Q
<
I-
<
Q_
100
80
60
40
20
CONTROL
SAMPLESI
mean
TEST
SAMPLESI
— mean
0
figure 4C illustrates the effect of streptokina.se, at the concentration 
which produces marinum lytic activity, on platelet adhesiveness of 
citrated whole blood after agitating the blood and streptokinase to­
gether at 57 C for 10 minutes. ihe number of platelets lost, during 
the passage of blood through the glass bead column, is significantly 
greater in the streptokinase treated samples than the control samples; 
the mgan percentage platelet adhesiveness of the control samples is 
52.0 - 1 g„5 ;-nid of the test samples 65*9 - 25*7> (t = 2.7SU, 0.020 < 
p<0.C2g). The figure is compiled from the data of table 62 „
CONTROL TEST
SAMPLES SAMPLES
100
c/) 
<I )
LU
z
LU
>
i n meanLU
I
Q
< mean
LU
_l
LU
<C
CL
figure 41 shows the effect of trypsin (10 ng/ml blood) on platelet 
adhesiveness of situated uiole blood. There is no significant 
difference betreen hie mean percentage platelet adhesiveness of the 
control samples, 43.4 - 50.1, and of the trypsin treated samples, 
61.5 - 13.6; t = 1.515, 0.10 <p< 0.20. The data presented in 
table 65 mis used to compile this figure.
CONTROL
SAMPLES
TEST
SAMPLES
100
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c/)
LU
z
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i’ijure 42 illustrates the effect of trypsin (10jag/wl blood) on 
platelet adhesiveness in citrated whole blood after the trypsin 
and blood had been agitated together at 37 C for 10 minutes. The 
mean j^ercentaye platelet adhesiveness of the control samples is 
5b*9 -11.7 which is significantly less than the mean value of the 
trypsin treated samples 69.7 ! 8.9: t = 3*011. 0e01 < p< 0.02. The
finure was constructed from the data of table 64.
CONTROL TEST
C/)
U )
UJ
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LU
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100 1
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figure 43 shone the effect of trypsin (10/ug/ml plasma) on 
platelet adhesiveness in platelet rich plasma. Trypsin results 
in a significant increase in the percentage platelet adhesivenes 
of the plasma; the mean value of the control samples is 10.6 - 
and of the ti ^
0.025<p <0.0^0) 
in tahle 6!5c
aypsin treated mples 44<,0 - 36«6, (t = 2.801, 
ae figure is compiled from data presented
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figure 4A cIiovjv-: the effect of the packed cell volume on 
plutelet Ike:ivenegs•
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Figure 61 shows the ultracentrifugation patterns obtained, with 
the Schliern optical system of a opinco, Model E, Ultracentrifuge 
during the determination of the sedimentation coefficient of the 
fibrinogen degradation product ,bt. The patterns read from left 
to right and top to bottom and represent the patterns at the 
time intervals zero, 8, 16, 24, 32 and 64 minutes from the start 
of the run*
JV
Figure 62 shows the ultracentrifugation patterns obtained with the 
Schliern optical system of a Spinco, Model 3, Ultracentrifuge during 
the determination of the diffusion coefficient of the fibrinogen 
degradation product *b’. The patterns read from left to right and 
from top to bottom and represent the patterns obtained at the time 
intervals 8, 16, 24, 32, 40 and 48 minutes from the start of the run.
Purified Fibrinogen
Product "a"
Product b
Product ”c
Figure 63 illustrates the electrophoretic patterns obtained with 
fibrinogen, before and after passage through a DEiE cellulose 
col wan, and the fibrinogen degradation products 'a1, 'b', fc* and 
*d1 as a result of horizontal paper electrophoresis in 0.1 K 
barbitone buffer, pH 8*6 for 17 hours at 200 volts. The 
electrophoretic strips were stained with Bromophenol blue.
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Figure 64 shouo the effect of the fibrinogen degradation products
1 4-^,1 ^4- piie concentration
i1 has no significani
a :’na
of both products ras 1 00 n~Jnil plasma# Produci
effect on platelet aggregation; the mean optical density readings of
the control and _J_ minute after the+addition of DDP
1 on AI)r induced platelet aggregation#4
t sample? ^
(0.5 jug/ml plasma), are 0.456 - 0#090 end 0.442 - C#10p (t = 1 #172, 
0#20x.p< C.po)o Product 1c* causes significant inhibition of 
platelet aggregation; the mean optical density- readings of the 
control and test samples, 2 minutes after the addition of /DP, are 
0.445 - 0.121 and 0.475 - 0.105 (t = 5.255, 0.01 Cp< u.02). The 
optical density readings, at these time intervals, of the seven 
samples investigated are presented in tables 66 and 74°
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Figure o'; illustrates the effect of product 'a1 (l00yug/ml blood) on platelet 
adhesiveness in citrated whole blood„ There is no significant 
difference between the results of the control samples and the 
samples treated with product 'a1* The mean percentage platelet 
adhesiveness of the control samples is 41»9 - 17o4 and of the 
test samples - 16„7 (t = 2.149, C.05< p< 0.1C). The figure
is compiled from the data of table 67.
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Figure 66 shows the effect of product ’a1 (20C /j.g/ml blood) on platelet 
adhesiveness in citrated whole blood„ Produce ’a' has no significant 
effect on platelet adhesiveness; the mean percentage platelet 
adhesiveness <j)f the control samples is 43 <>4- - 17*8 and the test 
samples 40.6 - 17»4 (t = 0.626, 0.40<p < O.dO). The data of table 
68 was used to coiiroile this figure.
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figure 67 illustrates the effect of product !a' (lOOug/ml blood) on 
platelet adhesiveness in citrated "hole blood after uhe blood and 
product had been agitated together at 37 C for 10 minutes. There 
is no significant difference between the results of the control 
samples and the samples treated with product ’a’; the mean 
percentage platelet adhesiveness of the control samples is 72.3 - 
12o3 and of the test samples 70«4 - 15«o (t = 10CS4, 0 o3 0 <p < 0 o4 0)„ 
The figure was constructed from the data of table 69 o
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Figure 68 shows the effect of product ’b 1 (lOC ug/ml plasma) on 
ADP induced platelet aggregation* Product ’b’ causes significant 
enhancement of platelet aggregation; the mean optical density 
reading, 1y minutes after the addition of ADP (0*5 Aig/ml plasma), 
of the control samples is 0„37S - 0.1 AC and of the test samples 
0*341 - 0.141 (t = 3o2f3, 0.01 < p <0*02)* She optical density 
readings, at this time interval, of the seven plasma samples 
investigated are presented in table 70„
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Figure 69 illustrates the effect of ;ro6ic' 'V (100 Aig/ml blood) 
on platelet adhesiveness in citrated vhole blood. Product 'b' lias 
no significant effect on platelet adhesivess; the ne^n percentage 
platelet adhesiveness of the control samples is 41.9 - 17*4 and of the
test samples 99»6 - 17o6 (t = 0„594, 0.50 <p < 0.60) 
compiled from the data of table 71»
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Figure J O  shoves the effect of product *b* (200 yug/ml blood) on platelet 
adhesiveness in citrated whole blood* There is no significant alteration 
in the platelet adhesiveness of samples treated with product 'b1; the 
mean percentage platelet adhesiveness of |he control samples is 
43<>4 - 17o8 and of the test samples 38*5 - 15»7 (t = 1 <,251 > 0o20 
< p < 0 o30)o The results of table 72 were used to construct this 
figure*
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Figure 71 illustrates the effect of product 'b* (100 n g /ml blood) 011 
platelet adhesiveness in citrated whole blood after The blood and 
product had been agitated together at 57 0 for 10 minutes. Product 
’b1 causes a significant increase in platelet adhesiveness; the 
mean percentage platelet adhesiveness of £he control samples is 
72„5 - 12o3 and of the test samples 77.6 - 11.7 (t = 3.456, 0.01 
< P < 0 o02)o The figure is constructed from the data of table 73-
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Figure 72 shows the effect of product ’d1 (l00 ng/ml plasma) on 
ADP induced platelet aggregation of platelet rich plasma. Product
1d1 causes a significant enhancement of platelet aggregation; 1-y
minutes after the addition of ADr (0.5 plasma), :he mean
optical density reading of the control'samples is 0.505 - 0.159 and 
of the test samples 0.216 - 0.112 (t = 2.415, 0.025< p< 0.050). The 
optical density readings, at this time interval, of the ten plasma 
samples investigated are presented in table 75*
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Figure 73 illustrates the effect of product 'd' (ISO ng/ml plasma) 
on the rate of formation of platelet aggregates in the Chandler 
tube,, The speed of platelet aggregation is accelerated in each 
of the seven plasma samples investigated^ The mean time of platelet 
aggregation in the control loops is 4-77 - 168 seconds and of the test 
loops 294 - 45 seconds (t = 3.374, O.OOp< p < 0 .0 1 0 )„ The figure
is compiled from the data of table 7o.
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Figure 74 chons the effect of fibrinogen (l GO gig/ml plasma) and 
'purified* fibrinogen (10G ngy ml plasma) on hDF induced platelet 
aggregation of platelet rich plasma. Fibrinogen causes significant 
enhancement of aggregation but 'purified* fibrinogen has no effect 
on aggregation. 14- minutes after the addition of H P  (0.5 Mg/nil plasma) 
the mean optical density reading of the ^ ontrol samples is 0.406 - 0.135»
of the fibrinogen treated samples 0.270 - 0.193 and of the 'purified*
fibrinogen treated samples 0.;>12 - 0.1 23 t^ - p. 125, 0.020< p <0.025 
and t = 2„g61 , 0.05<p <0.10 respectively). 'The optical density 
readings, at this time interval, of the seven plasma samples
investigated are shomi in tables 77 and 73•
CONTROL
SAMPLES
TEST
SAMPLES
60 1
50 ■
c/)
co
LU
“  40-
>
if)
LU
g  30- 
<
20 «
z
LU mean
figure 75 illustrates the effect of fibrinogen (101 ng/ml blood) on 
platelet adhesiveness in citrated whole blood* There is no significant 
difference between the results of the control and fibrinogen treated 
samples; the mean percentage adhesiveness pf the control samples 
is 57.0 - 9„9 and of the tost samples 38.5 - o.8 (t = Q.35S> 0.70*
< T> <0.G0). The figure v<as constructed from the results of table 
79*.
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Figure 76 shorn the effect of fibrinogen (100 yug/ml blood) on platelet 
adhesiveness in citrated whole blood after the blood and fibrinogen 
had been agitated together at 57 C for 10 minutes. Fibrinogen 
produces a significant increase in platelet adhesiveness; the 
mean percentage platelet adhesiveness of the control samples is 
61„7 - 11.0 and of the test samples 73.6 - 9.0 (t - 5.166, 0.001 
< p< 0.005). 'i’he figure is compiled froi.i the data of table 80.
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Table 26 The effect of streptokinase on platelet aggregation
Time of platelet aggregation (seconds)
Subject No* Control Test
1 475 362
2 391 235
3 526 369
4 370 279
5 546 445
6 268 229
7 328 234
8 252 170
9 322 242
10 476 268
11 246 217
Mean . 382 . 276
S.D. - 110 - 81
Table 26 shows the effect of streptokinase on the rate of formation 
of platelet aggregates in the Chandler tube. The concentration of 
streptokinase used was the concentration which produced maximum lytic 
activity as estimated for each plasma sample* The difference between 
the results of the control and test loops is statistically significant; 
t = 6.602, p <  0.001. The data is presented in figure 5»
Table 27 Effect of trypsin (10 ng/ml) on platelet aggregation
Time of platelet aggregation (seconds)
Subject No* Control Test
1 306 164
2 390 113
3 471 149
4 537 227
5 508 151
6 351 100
7 636 152
Mean
S.D.
, 457 
- 115
, 151 
- 41
Table 27 shows the effect of trypsin (lOvug/ml plasma) on platelet 
aggregation in the Chandler tube* The differences between the 
results in the control and test loops are statistically significant; 
t = 7-764, p < 0*001. These results have been used to compile 
figure 6*
Table 28 Effect of trypsin (l mg/ml) on platelet aggregation
Time of platelet aggregation (seconds)
Subject Ho. Control Test
1 704 86
2 652 40
3 765 32
4 655 52
5 688 44
6 661 61
7 556 28
Mean • 666 x 49
S.D. i 64 - 20
Table 28 shows the effect of trypsin (l mg/ml plasma) on platelet 
aggregation in the Chandler tube. The differences between the results 
in the speed of formation of platelet aggregates in the untreated and 
trypsin treated plasma samples are statistically significant; t = 
26.491, p <0.001. Figure 7 is compiled from these results.
Table 29 The effect of trypsin on platelet poor plasma
Time of platelet aggregation (seconds)
Subject Ho. Control Test
1 328 169
2 347 379
3 348 349
4 395 184
5 980 507
6 630 351
7 503 213
Mean . 504 4. 307
3.1). - 236 - 124
Table 29 shows the effect of incubating trypsin (10 n g /ml plasma) with 
platelet poor plasma, before the addition of platelet rich plasma, on the 
rate of formation of platelet aggregates in the Chandler tube. The 
differences between the control and trypsin treated samples are 
statistically significant; t = 2.970, 0.020 < p < 0.025. The 
data is illustrated in figure 8.
Table 30 Effect of trypsin on platelet rich plasma
Time of platelet aggregation (seconds)
Subject ho. Control Test
1 550 135
2 546 434
5 573 117
4 395 140
5 322 99
6 553 250
7 315 283
Mean , 462 208
SJD. - 114 - 122
Table 30 shows the effect of incubating trypsin (l0/ug/ml plasma) with 
platelet rich plasma, before the addition of platelet poor plasma, on 
platelet aggregation in the Chandler tube. The differences between
the rate of formation of platelet aggregates in the control and trypsin 
treated plasma samples are statistically significant; t = 4.500, 0.001 < 
p <0.005. The results are also presented in figure 9.
Table 51 Effect of adenosine diphosphate (ADp) on platelet
aggregation
Time of platelet aggregation (seconds)
Subject No. Control Test
1 576 567
2 776 690
3 508 476
4 697 584
5 629 507
6 998 844
7 657 586
8 499 459
9 692 632
10 517 489
Mean a. 655 + 583
S.D. ± 152 - 117
Table 31 shows the effect of ADP (0.5 f i g / m l  plasma) on the rate of 
formation of platelet aggregates in tne Chandler tube. The difference 
between the results of the control and test loops is statistically 
significant; t = 4.824, p <0.001. The data is also presented in 
figure 10.
Table 32 Effect of ADP on platelet aggregation on recalcified and
non recalcified plasma
Time of platelet aggregation (seconds)
Subject No. Control Test
1 48 90
2 97 82
3 70 44
4 229 50
5 36 49
6 65 36
7 51 65
Mean
S oD o + 85 -  66 + 59 -  20
Table 32 shows the effect of ADP (0.5 yug/ml plasma) on platelet 
aggregation in plasma recalcified with one-tenth plasma volume 
M/4 CaCl^ and in plasma to which an equivalent volume of 0*9 per 
cent sodium chloride had been added. There is no significant 
difference between the speed of formation of platelet aggregates in 
the control and test loops; t = 0.938, 0.30<p<0.40. This data 
was used to compile figure 11.
Table 35 Effect of adenosine on platelet aggregation
• Time of platelet aggregation (seconds)
Subject No. Control Test
1 303 409
2 421 490
3 360 450
4 406 459
5 366 509
6 • 475 549
7 306 353
Mean . 377 460
S.D. ± 62 - 65
Table 33 shows the effect of adenosine (lOO ng per ml plasma) on platelet 
aggregation in the Chandler tube. The rate of formation of platelet 
aggregates is delayed in every plasma sample treated with adenosine.
The mean time for platelet aggregation to occur in the control loop is 
significantly less than that for the adenosine treated loop ; t =
6.606, p< 0.001. The results are presented in figure 12.
Table 54 Effect of combined action of trypsin and ADP
on platelet aggregation
Time of platelet aggregation (seconds)
Subject Ho. Control ADP ADP plus trypsin
1 576 300 53
2 454 415 252
3 636 227 143
4 508 336 82
5 537 407 204
6 421 386 109
7 998 375 117
Mean , 590 349 .137
S.D„ - 194 -67 - 70
Table 34 shows the effect of ADP (0.5 /ug per ml plasma) and the com­
bined action of ADP, at the same concentration, and trypsin (lOyug per 
ml plasma) on platelet aggregation in the Chandler tube. ADP alone 
produces significant acceleration of the rate of formation of platelet 
aggregates over that of the control loops; t = 2.970, 0.020<p< 0.025* 
The combined action of ADP and trypsin causes a significant increase 
in the rate of formation of platelet aggregation over the rate of the 
ADP treated plasma samples; t = 8.194, p <0.001. These results have 
been used to compile figure 13«
Table 55 Effect of adenosine (l 00 ng per ml) on trypsin
treated plasma
Subject Ko.
Time of platelet aggregation (seconds)
Control Test
1 46 169
2 106 333
3 93 79
4 86 136
5 55 92
6 117 98
7 96 227
8 88 53
9 122 115
10 127 138
11 131 124
12 119 166
13 125 107
14 98 101
15 59 70
16 66 213
Mean
S.D. + 96- 23
4. ^ 9
- 71
Table 35 shows the effect of incubating adenosine (l 00 ug/ml plasma) 
with plasma treated with trypsin (10 u g / m l  plasma) on platelet aggregation 
in the Chandler tube. The rate of formation of platelet aggregation 
is retarded in ten of the plasma samples investigated and the 
differences between the results of the control and test loops are 
statistically significant; t = 2,284, 0.025<p<£0.050. Figure 14 is 
compiled from these results.
Table 36 Effect of adenosine (200 ng per ml) on trypsin 
treated plasma
Time of platelet aggregation (seconds)
Subject No, Control Test
1 59 96
2 75 143
3 120 123
4 93 115
5 85 110
6 75 135
7 162 223
Mean
S.D. + 96 - 35 + 135 * 42
Table 36 shows the effect of incubation of adenosine (200 /ug per ml) 
with plasma treated with trypsin (10 ug per ml plasma) on platelet 
aggregation in the Chandler tube* The differences between the speed 
of aggregation in the control and test loops are significant; t = 
4.289, 0o005<p<0*0l0. The results are illustrated in figure 15.
Table 57 Effect of streptokinase on ADP induced platelet
aggregation
Subject I'To.
Optical Density Readings
Control Test
1 0.216 0.310
2 0.230 0.515
5 0.078 0.550
4 0.132 0 .520
5 0.545 0.560
6 0.580 0.575
7 0.590 0.590
8 0.215 0.218
9 0.521 0.590
10 0.555 0.585
Mean
3.D.
, 0.366 
i 0.208 +
0.499
0.129
Table 37 shows the effect of streptokinase on ADP induced platelet 
aggregation. The concentration of streptokinase was that concentration 
which produced maximum lytic activity as determined for each plasma 
sample. The optical density readings of the control and test 
samples, 4y minutes after the addition of ADP (0.5yug/ml plasma), are 
shown. The differences between the results of the two samples are 
statistically significant; t = 2.415> 0.025 p 0.050. The results 
are a detailed analysis of one of the points on the curves shown in 
figure 16.
Table 58 Effect of streptokinase on platelet aggregation in
diluted plasma
Optical Density Readings
Subject ho. Control Test
1 0.378 0.550
2 0.245 0.185
3 0.255 0.512
4 0.568 0.578
5 0.568 0.575
6 0.050 0.275
7 0.198 0.210
Mean 0.266 , 0.298
S.B. - 0.119 - 0.077
Table 58 shows the effect of streptokinase (l 00 U.I.H. units/ml 
plasma) on ADP induced platelet aggregation in plasma diluted with 
0,9 per cent sodium chloride in the ratio 1: 2.5 o The optical 
density readings of the control and test samples, 3  minutes after the 
addition of ADP (l .0 ng per ml plasma), are shown. There is no 
significant difference between the results of the control and streptokinase 
treated samples; t = 1.122, 0.50<p<0«40. These results were used 
to compile a section of figure 17»
Table 39 Effect of streptokinase on platelet aggregation in
acid - alkali treated plasma
Optical Density Readings
Subject No* Control Test
1 0.537 0.318
2 0*580 0.370
3 0*368 0.430
4 0*580 0.520
5 0.579 0*600
6 0.431 0.460
7 0.580 0*549
8 0.541 0.572
9 0.522 0.090
10 0.369 0.362
11 0.310 0.350
12 0*560 0.445
13 0*550 0*472
14 0.585 0.530
15 0.501 0.489
16 0.592 0*498
17 0.291 0.251
Mean , 0.499 . 0.430
S.D. I 0.066 -  0.129
Table 39 shows the effect of streptokinase (2,000 N.I.H. units/ml 
plasma) on ADP induced platelet aggregation in whibh the antiplasmin 
has been destroyed by acid - alkali treatment* The optical density 
readings of the control and test samples, 10 minutes after the 
addition of ADP (0.5 pg/ml plasma), are shown. The differences between 
the results of the control and streptokinase treated samples are 
significant; t = 2.574» 0*020<p *025« These results were used
to compile a section of figure 13*
Table 40 Effect of streptokinase on nor-adrenaline induced platelet
aggregation
Subject No.
Optical Density Readings
Control Test
1 0 0
2 0.457 0.492
3 0.251 0.240
4 0.515 0.520
5 0.600 0.600
6 0.459 0.500
7 0.558 0.248
8 0.560 0.520
9 0 0
10 0.314 0.385
Mean
S.D.
0.371 
- 0.224
, 0.351 
- 0.219
Table 40 shows the effect of streptokinase (lOO N.I.H. units/ml plasma) 
on nor-adrenaline induced platelet aggregation. The optical density 
readings of the control and test plasma samples, 10 minutes after the 
addition of nor-adrenaline (l .0 ug/ml plasma), are showne 
Streptokinase has no significant effect on platelet aggregation in this 
system; t = 0.623, 0.50 -<p <10.60. These results were used in the 
determination of the mean values of the control and test plasma 
samples shown in figure 19»
Table 41 Effect of trypsin (10/ug/ml) on platelet aggregation
Optical Density Readings
Subject Mo. Control Test
1 0.480 0.505
2 0.578 0.560
3 0.540 0.535
4 0.525 0.580
5 0.520 0.560
6 0.485 0.525
7 0.578 0.525
8 0.480 0.49C
9 0.578 0.590
10 0.565 0.570
Mean , 0.513 , 0.544
S.D. I 0.061 - 0.033
Table 41 shows the effect of incubating trypsin (lOyug/ml plasma) with 
platelet rich plasma on ADP induced platelet aggregation. The optical 
density readings of the control and test plasma samples, 1 minute 
after the addition of ADP (0*5 Mg/ml plasma), are shown. There is no 
significant difference between the results of the control and trypsin 
treated samples; t = 2.119, 0.05<p<0.10. These results were 
used to produce part of figure 20.
Table 42 Effect of trypsin (lOO ug/ml) on platelet aggregation
Subject Ho*
Optical Density Readings
Control Test
1 0,518 0.508
2 0.575 0.560
3 0.546 0,532
4 0.465 0.450
5 0.495 0.470
6 0.550 0.475
7 0,475 0.468
8 0.525 0.460
9 0,575 0.548
10 0.570 0.535
Mean
S.D.
0,529
-0.041
, 0.501 
- 0.041
Table 42 shows the effect of incubating platelet rich plasma with 
trypsin (lOOug/ml plasma) 011 ADP induced platelet aggregation. The 
optical density reading of the control and test samples, 1-g- minutes 
after the addition of ADP (0.5yog/ml plasma), are shown. The 
differences between the results of the control and trypsin treated 
samples are significant; t = 3.925» 0.001 < p< 0.005. A section of 
figure 20 is compiled from these results.
t
Table 45 Effect of trypsin (l mg/ml) on platelet
aggregation
Subject No*
Optical Density Readings
Control Test
1 0*478 0.480
2 0*578 0
3 0.580 0.088
4 0*538 0*490
3 0*560 0.C82
6 0*555 0.518
7 0.490 0*585
Mean 
c> »D *
, 0.540 
- 0*041
0.265 
1 0.204
Table 45 shows the effect of trypsin (l mg/ml plasma) on platelet 
aggregation* The optical density readings of the control and test 
samples, 2 minutes after the addition of 0*9/^  sodium chloride to the 
control samples and trypsin to the test samples, are shorn* The 
differences between the control and trypsin treated samples are 
significant; t = 5*080, 0«020<p<0*025* These results were used 
in the compilation of a section of figure 21 *
Table 44 Effect of trypsin on platelet aggregation in
fibrinogen depleted plasma
Optical Density Readings
Subject Ho. Control Test
1 0.522 0.322
2 0.515 0.412
3 0.518 0.260
4 0.530 0.390
5 0.521 0.280
6 0.540 0.350
7. 0.530 0.400
Mean . 0.525 , 0.345
S.D. - 0.009 - 0.060
Table 44 shows the effect of trypsin (l mg/ml plasma) on platelet 
aggregation in ulasma gretreated with streptokinase (1,000 H.I.H. 
units/ml plasma) at 37 C for 10 minutes. The optical density 
readings of the control and test plasma samples, 30 seconds after the 
addition of 0.9/° sodium chloride to the control samples and trypsin 
to the test samples, are shown. The differences between the results 
of the control and trypsin treated samples are significant; 
t = 6.485, p < 0.001. A portion of figure 22 is compiled from these 
results.
Table 45 Effect of trypsin on platelet aggregation in diluted plasma
Optical Density Readings
Subject Ho. Control Test
1 0.364 0.386
2 0.235 0.220
3 0.234 0.350
4 0.355 0.322
5 • 0.360 0.360
6 0.040 0.092
7 0.192 0.180
Mean 0.254 , 0.273
S.D. - 0.118 - 0.110
Table 45 shows the effect of trypsin (10 ng/ml plasma) on ADP induced 
platelet aggregation in plasma diluted with 0„9^ sodium chloride in 
the ration 1: 2.5. The optical density readings of the control and 
test samples, 4 minutes after the addition of ADP (l .0yog/ml plasma), 
are shown. The differences in the results of the control and trypsin 
treated samples are not significant; t = 0.965, 0.30<p<0.40„
This data was used to compile a section of figure 17.
Table 46 Effect of calcium chloride (0.25 m mole/ml) on the 
action of trypsin on platelet aggregation
Optical Density Readings
Subject ITo. Control Test
1 0.208 0.155
2 0.315 0.325
3 0.345 0.270
4 0.425 0.445
5 0.530 0.330
6 0.290 0.280
7 0.490 0.512
Mean . 0.372 0.331 
- 0.118S.D. - 0,115
Table 46 shows the effect of incubating trypsin (10 ug/ml plasma) 
with platelet rich plasma, to which calcium chloride (0.25 m mole/ml 
plasma) had been added, on ADP induced platelet aggregation. The 
optical density readings of the control and test plasma samples,
1 minute after the addition of ADP (0.5 ug/ml plasma), are shown.
The differences between the readings in the control and trypsin 
treated samples are not significant; t = 1 .363, 0.20<p<0„30.
These results were used to compile a section of figure 23.
Table 47 Effect of calcium chloride (l,0 m mole/ml) on the
action of trypsin on platelet aggregation
Subject No.
Optical Density Readings
Control Test
1 0.080 0.142
2 0.440 0.535
3 0.558 0.539
4 0.450 0.532
5 0.100 0.412
6 0.491 0.520
7 0.480 0.439
Mean
S.D.
, 0.371 
- 0.196
0.446 
- 0.143
Table 47 shows the effect of incubation of trypsin (lOng/ml plasma) 
with plasma, to which calcium chloride (l,0 m mole/ml plasma) had been 
added, on ADP induced aggregation,, The optical density readings 
of the control and test samples, 3 minutes after the addition of ADP 
(0.5yug/ml plasma), are shown. There is no significant difference 
between the results of the control and trypsin treated samples; t = 
1.690, 0.l0<p<0.20„ A portion of figure 24 was compiled from these 
results.
Table 48 Effect of trypsin on platelet poor plasma
Optical Density Readings
Subject Hio* Control Test
1 0.520 0.563
2 0.579 0.519
3 0.579 0.472
4 0.562 0.540
5 0.266 0.217
6 0.542 0.490
7 0.310 0.372
Mean 0.480 , 0.453
S.D. - 0.133 - 0.121
Table 48 shows the effect of incubating platelet poor plasma with 
trypsin (10G ug/ml plasma), before the addition of platelet rich 
plasma, on ADP induced platelet aggregation. The optical density 
readings of the control and test samples, 10 minutes after the 
addition of ADP (0.5 Mg/ml plasma), are shown. The differences 
between the results of the control and trypsin treated samples are 
not statistically significant; t = 1.170, 0.20<p<0.30„ These 
results were used to construct a section of figure 25.
Table 49 Effect of trypsin on platelet rich plasma
Subject Uo.
Optical Density Headings
Control Test
1 0.560 0.541
2 0.530 0.339
3 0.560 0.540
4 0.550 0.450
5 0.562 0.518
6 0.346 0.319
7 0.430 0.432
Mean
S.D.
'3-
o 
«
o 
o
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Table 49 shows the effect of incubating platelet rich plasma with 
trypsin (lOG ng/ml plasma), before the addition of platelet poor 
plasma, on ADP induced platelet aggregation. The optical density 
readings of the control and test samples, 10 minutes after the 
addition of ADP (0.5 ug/ml plasma), are shown. There is a significant 
difference between the results of the control and trypsin treated 
plasma samples; t = 2.768, 0.025< p <0.050. A part of figure 
26 is compiled from these results.
Table 50 Effect of trypsin on washed platelets
Subject No.
Optical Density Readings
Control Test
1 O.46O 0.480
2 0.540 0.515
5 0.590 0.522
4 0.522 0.490
5 0.555 0.540
6 0.520 0.519
7 0.556 0.548
Mean
S.D.
, O.5O5
- 0.058
0.516 
- 0.025
Table 50 shows the effect of trypsin (10 ug/ml suspension) on ADP 
induced platelet aggregation of washed platelets suspended in 0.1 M 
tris buffer, pH 7.5. The optical density readings of the control 
and test samples, 10 minutes after the addition of ADP (0.5 ug/ml 
suspension), are shown. The differences between the resulxs of the 
control and trypsin treated samples are not significant; t =
0.291, 0.70< p < 0.80. A section of figure 27 was compiled from these 
results.
Table 51 Effect of adenosine on trypsin treated plasma
Subject No.
Optical Density Readings
Control Test
1 0.521 0.578
2 0.412 0.580
3 0.468 0.595
4 0.548 0.578
5 0.535 0.580
6 0.522 0.480
7 0.432 0.580
Mean 
o ,D.
, 0.491 
- 0.054
. 0.567 
- 0.039
Table 51 shows the effect of adenosine (1 CO ug/ml plasma) on ADP 
induced platelet aggregation of platelet rich plasma treated with 
trypsin 1100/ug/ml plasma). The optical density readings of the 
control and rest samples, one minute after the addition of ADP (0.5 
f a g / m l  plasma) are shown. The differences between the results of the 
control and adenosine treated samples are significant; t = 2.724, 
0.025< p< 0.050. These results were used to construct a portion of 
figure .
Table 52 Effect of adenosine (0.5 mg/ml) on trypsin
treated plasma
Optical Density Readings
Subject Ho. Control Test
1 0.435 0.405
2 0 0.270
3 0.010 0.550
4 0.290 0.280
5 ' 0 0.358
6 0.155 0.138
7 0.546 0.320
Mean
S.D.
, 0.177 
- 0,182
, O.3O3 
- 0.086
Table 52 shows the effect of adenosine (0.5 mg/ml plasma) on 
platelet aggregation in platelet rich plasma to which trypsin 
X  1 mg/ml plasma) had been added. Trypsin alone was added to the
control samples and trypsin and adenosine were added simultaneously 
to the test samples. The optical density readings, 4 minutes after 
the additions were made to each sample, are shown. There is no 
significant difference between the results of the control samples 
and the samples to which adenosine had been added; t = 1.818, 0.10 
<p<0„20. A section of figure 22 was compiled from these results.
Table 53 Effect of trypsin on nor-adrenaline induced platelet
aggregation
Subject No.
Optical Density Readings
Control Test
1 0.215 0
2 0.420 0.410
3 0.533 0.425
4 0.560 0.540
5 0.275 0.458
6 0.560 0.522
7 0.540 0.552
8 0.582 0.545
9 0.260 0.025
10 0.450 0.470
Mean
S.D.
0.440
-0.141
, 0.395 
- 0.207
Table 53 shows the effect of trypsin (10/ug/ml plasma) on nor­
adrenaline induced platelet aggregation. The optical density readings 
of the control and test samples, 2 minutes after the addition of nor­
adrenaline (l .0yug/ml plasma), are shown. The differences between 
the results of rhe control and trypsin treated samples are not 
significant; t = 1.691, 0.10 < p<0.20. These results were used 
to construct a portion of figure 32.
Table 54 Effect of urokinase on platelet aggregation
Optical Density Readings
Subject No. Control Test
1 0.225 0.355
2 0 0.570
3 0.174 0.370
4 0.560 0.560
5 0.570 0.558
6 0.580 0.595
7 0.235 0.240
8 0.560 0.600
9 0.550 0.565
10 0.548 0.580
Mean 0.400 0.499
S.D. - 0.264 - 0.128
Table 54 shows the effect of urokinase on ADP induced platelet 
aggregation. The concentration of urokinase was the concentration 
which produced maximum lytic activity as determined for each plasma 
sample. The optical density readings of the control and test 
samples, 3 minutes after the addition of ADP (0.5 yug/ml plasma), are 
shown. The differences between the results of the control and uro­
kinase treated samples are statistically significant; t = 3.134, 
0.01 <p <  0.02. These results were used to compile a section of 
figure 33•
Table 55 Effect of chymotrypsin on platelet aggregation
Subject No.
Optical Density Readings
Control Test
1 0.252 0.226
2 0.253 0.179
3 0.200 0.312
4 0.400 0.422
5 0.520 O .466
6 0.302 0.455
7 0.620 0.582
Mean O .364 0.377
S.D. - 0.156 - 0.144
Table 55 shows the effect of chymotrypsin (l00 n g /ml plasma) on ADP 
induced platelet aggregation. The optical density readings of the 
control and test samples, 5 minutes after the addition of ADP 
(0.5 jug/ml plasma), are shown. There is no significant difference 
between the results of the control and chymotrypsin treated samples; 
t = 0.412, 0.60 < p <  0.70. A section of figure 34 is compiled from 
these results.
Table 56 Effect of ficin on platelet aggregation
Subject No.
Optical Density Readings
Control Test
1 0.472 0.389
2 0.485 0.388
3 0.252 0.238
4 0.253 0.158
5 0.200 0.272
6 0.400 0.445
7 0.520 0.480
8 0.302 0.434
9 0.602 0.620
10 0.225 0.256
11 0.490 0.315
12 0.C-96 0.024
Mean O.36Q 0.335
S.D. - 0.160 - 0.165
Table 56 shows the effect of ficin (10/ug/ml plasma) on ADP 
induced platelet aggregation. The optical density readings of the 
control and test samples, 5 minutes after the addition of ADP 
(0.5/ug/ml plasma) are shown. The differences between the results 
of the control and ficin treated samples are not significant; 
t = 0.996 , 0.30-< p<0.40. The results were used to construct a 
section of figure 35.
Table 57 Efiect of heparin (10 units/ml) on platelet
aggregation
Optical Density Readings
Subject No. Control Test
1 0.196 0.122
2 0.410 0.132
3 0.160 0.110
4 0 0
5 0.310 0.284
6 0 0
7 0.182 0.060
8 0.311 0.062
Kean , 0.196 , 0.096
S.D. - 0.146 - 0.091
Table 57 shows the effect of heparin (10 -units/nil plasma) on 
ADP induced platelet aggregation,, The optical density readings 
of the control and test samples, 4 minutes after the addition of 
ADP (0.5 ;ug/ml plasma) are shown* The differences between the 
results Of the control and heparin treated samples are significant; 
t = 2.594, 0.025<p<0o020. A section of figure 56 was compiled from 
these results.
Table 58 Effect of heparin (0.05 units/ml) on platelet
aggregation
Optical Density Readings
Sub.iect No. Control Test
1 0.210 0.192
2 0.558 0.540
3 0.502 0.512
4 0.582 0.488
5 0.581 0.512
6 0.480 0.280
7 0.590 0.522
8 0.522 0.493
9 0.588 0.409
10 0.190 0.202
11 0.530 0.410 :
12 0.240 0.212
13 0.524 0.488
14 0 0.005
Mean 4. °-436 0.376
S.D. - 0.139 0.167
Table 58 shows the effect of heparin (0.05 units/ml plasma) on ADP 
induced platelet aggregation. The optical density readings of the 
control and test samples, 10 minutes after the addition of ADP 
(0.5 ug/ml plasma), are shown. The differences between the results 
of the control and heparin treated samples are significant; t = 
3.297, 0.005<p<0.010. A portion of figure 37 was compiled from 
these results.
Table 59 Effect of heparin (500 units/ml) on platelet 
aggregation
Optical Density Headings
Subject No. Control Test
1 0.581 0.640
2 0.480 0.592
3 0.590 0.600
4 0.188 0.490
5 0.522 0.538
6 0.588 0.618
7 0.190 0.290
8 0.240 0.298
Mean 0.422 0.508
S.D. -  0.184 - 0.140
Table 59 shows the effect of heparin (500 units/ml plasma) on ADP 
induced platelet'aggregation. The optical density readings of the 
control and test samples, 10 minutes after the addition of ADP 
(0.5 ug/ml plasma), are shown. The differences between the results 
of the control and heparin treated samples are significant; t = 
2.563, 0„025<p<0.050. These results were used to compile a part 
of figure 38«
Table 60 Effect of heparin on washed platelets
Optical Density Readings
Subject Ho* Control Test
1 0.460 0.516
2 0.540 0.540
3 0.590 0.410
4 0.522 0.500
5 0.555 0.500
6 0.520 0.540
7 0.556 0.57S
He an 0.505 0.512
S.D. - 0.058 - 0.055
Table 60 shows the effect of heparin (l0 units/ml suspension) on 
ADP induced aggregation of washed platelets suspended in 0.1 M 
tris buffer, pH 7.5. The optical density readings of the control 
anrl test samples, 10 minutes after the addition of ADP (0 .5  #g/ml 
suspension), are shown. There is no significant difference between 
the results of the control and heparin treated samples; t = 0.756, 
0.40<p <0.50. These results were used to compile a section of 
figure 27.
Table 61 Effect of streptokinase on platelet adhesiveness
Subject I'To.
Percentage platelet adhesiveness
Control Test
1 40.5 57.8
2 26.3 7.1
3 60.1 14.9
4 90.1 0
5 84.2 22.8
6 36.5 13.3
7 26.3 20.1
8 19.7 13.0
Mean
S.D.
, 47.9 
± 27.2
21.3 
- 17.4
Table 61 shows the effect of streptokinase on platelet adhesiveness 
in citrated whole blood. The concentration of streptokinase was 
the concentration which produced maximum lytic activity as estimated 
for each sample. The difference between the results of the control 
and streptokinase treated samples is significant; t = 2.402, 0.025< 
p <0.050. These results were used to compile figure 39.
Table 62 Effect of streptokinase on platelet adhesiveness
Subject No.
Percentage platelet adhesiveness
Control Test
1 53*1 48.9
2 37-2 37.2
3 65-8 84-9
4 80.1 89.7
5 46.9 85.3
6 78.0 78.9
7 48.9 60.0
8 20.0 35.5
9 31 -3 32.5
10 59-1 86.3
Mean
S.D.
, 52.0 
- 19-5
, 63.9 
- 23-7
Table 62 shows the effect of streptokinase on platelet adhesiveness 
of citrated whole blood after agitating the blood and streptokinase 
together at 37 C for 10 minutes. The concentration of streptokinase 
was the concentrations which produced maximum lytic activity as 
determined for each sample. The difference between the results of 
the control and test samples is significant; t = 2.780, 0.020 <p< 
0.025. Figure 40 is compiled from these results.
Table 63 Effect of trypsin on platelet adhesiveness
Percentage platelet adhesiveness
Subject No* Control Test
1 93.1 76.8
2 67.6 90.7
3 89-3 78.6
4 37.3 62.1
5 5.6 73.8
6 15.2 39.7
7 24.6 61.6
8 48.4 35.7
9 35.6 41.8
10 67.2 54.5
Mean
S.D.
, 48.4 
- 30.1
, 61.5 
- 18.6
Table 6 3  shows the effect of trypsin (10 W m l  blood) on platelet 
adhesiveness in citrated whole blood. There is no significant 
difference between the results of the control and trypsin treated 
samples; t = 1.513» 0.10<p <0.20. These results were used to 
construct figure 41.
Table 64 Effect of trypsin on platelet adhesiveness
Percentage platelet adhesiveness
Subject No. Control Test
1 70 .0 78.0
2 80.4 78.7
3 49.4 62.2
4 58.4 79-7
5 43-4 72.7
6 52.5 56.2
7 57-0 62.2
8 60.2 67.6
Mean
S.D.
, 58.9 
- 11.7
4. 69-7 
± 8 .9
Table 64 shows the effect of trypsin (lOyug/ml blood) on platelet 
adhesiveness in citrated whole blood after the blood and trypsin had 
been agitated together at 37 C for 10 minutes. The difference 
between the results of the control and trypsin treated samples is 
significant; t = 3-011, 0.01 < p <0.02. The results were used to 
compile figure 42*
Table 65 Effect of trypsin on platelet adhesiveness
Percentage platelet adhesiveness
Subject No. Control Test
1 13.2 98.6
2 29.8 89.5
3 25.9 25.9
4 0 3.2
5 0 18.2
6 0 45.6
7 5.4 26.7
Mean + 10-6 + 44.0
S.D. ±- 12.7 - 36.6
Table 65 shows the effect of trypsin (lOyug/ml plasma) on platelet 
adhesiveness in platelet rich plasma. The differences between the 
results of the control and trypsin treated samples are significant; 
t = 2.801, 0.025< p < 0.050. rjLnhe results are also presented in 
figure 43.
Table 66 Effect of product 'a1 on platelet aggregation
Optical Density Readings
Subject No. Control Test
1 0.480 0.480
2 0.310 0.272
3 0.535 0.532
4 0.380 0.405
5 0.470 0.460
6 0.576 0.576
7 0.442 0.370
Mean , 0.456 . 0.442
S.D. - 0.090 - 0.103
Shown is the effect of product ’a1 (100 yug/ml plasma) on ADP 
induced platelet aggregation in platelet rich plasma. The 
optical density readings of the control and test samples 1 minute 
after the addition of ADP (0.5 ng/ml plasma) are shown,, Product 
'a' has no significant effect on platelet aggregation (t = 1,172, 
0.20 <p<0.30). These results were used to construct a section 
of figure 64.
Table 67 Effect of product 'a' on platelet adhesiveness
Percentage platelet adhesiveness
Subject No. Control Test
1 40.5 36.5
2 58.1 33.7
3 46.4 49.0
4 68.8 59.1
5 43.9 21.2
6 22.3 10.3
7 40.3 42.1
8 15.0 16.3
Mean . 41.9 4. 33.5
S.D. 17.4 .16.7
Shown is the effect of product 'a1 (100yug/ml blood) on platelet 
adhesiveness in citrated whole blood. Product ‘a1 has no significant 
-effect on platelet adhesiveness (t = 2.149» 0.05< P < 0 .1 0 ) .  Figure 
65 is compiled from these results.
Table 68 Effect of product ’a1 (200 ng/ml) on platelet
adhesiveness
Subject No.
Percentage platelet adhesiveness
Control Test
1, 24.6 • 28.9
2 56.5 55.8
3 36.2 27.1
4 65.0 62.2
5 40.5 31.8
6 58.1 42.0
7 46.4 65.4
8 68.8 61.9
9 43.9 23.8
10 22.3 26.9
11 15.0 21.1
Mean
S.D.
. 43.4 
- 17.8
. 40 .6  
- 17.4
Shown is the effect of product 'a' (200 jug/ml blood) on platelet 
adhesiveness in citrated whole blood. There is no significant 
difference between the results of the control samples and the 
samples treated with product 'a1, (t = 0.826, 0.40<p <0.50). 
These results were used to compile figure 66.
Table 69 Effect of product 'a1 ("ICO ng/ml) on platelet adhesiveness
Percentage platelet adhesiveness
Subject No. Control Test
1 80.1 73.4
2 63 08 64.7
3 76.2 74.5
4 82.7 89.3
5 55.3 48 .6
6 61.3 54.3
7 87.9 87.9
Mean . 72.5 , 70.4
S.D. - 12.3 - 15.6
Shown is the effect of product ’a’ (lOO ug/ml blood) on platelet 
adhesiveness in citrated whole blood afrer blood and product ’a' 
had been agitated together at 37 0 for 10 minutes. The 
differences between the results of the control and product 'a' 
treated samples are not significant (t = 1.084 , 0.3 0< p < 0 .40). 
Figure 67 was compiled from these results.
Table 70 Effect of product 'bf on platelet aggregation
Optical Density Readings
Sub.iect No. Control Test
1 0.331 0.268
2 0.256 0.250
3 0.360 0 .300
4 0.590 0.582
5 0.430 0.415
6 0.500 0.420
7 0.182 0.155
Mean , 0.378 0.341
S.D. - 0.140 0.141
Shown is the effect of product ’b1 (iGO n g / m l  plasma) on ADP 
induced platelet aggregation of plateler rich plasma. The optical 
density readings of the control and test samples, \ \  minutes after 
the addition of ADP (0.5 /ug/ml plasma), are sham. Product fb! 
causes significant enhancement of platelet aggregation; t =
3.253, 0.01 < p <  0.02. These results were used to compile a 
section of figure 68.
Table 71 Effect of product ’b1 on platelet adhesiveness
Sub.iect No.
Percentage platelet adhesiveness
Control Test
1 40.5 35.1
2 58.1 51.2
3 46.4 66.0
4 68.8 54.5
5 43*9 32.3
6 22.3 30.9
7 40.3 37.7
8 15.0 8.8
Mean
S.D.
. 41.9 
- 17.4
, 39.6 
17.6
Shown is the effect of product ’b1 (lOO n g / m l  blood) on platelet 
adhesiveness in citrated whole blood. Product ’b1 has no 
significant effect on platelet adhesiveness (t = 0.594, 0 .5 0< p <  
0.60). Figure 69 is constructed from these results.
Table 72 Effect of product ,bl (200 /ug/ml) on platelet
adhesiveness
Subject No.
Percentage platelet adhesiveness
Control Test
1 24.6 56.1
2 56.5 29.2
3 36.2 36.7
4 65 o0 62.9
5 40.5 41.9
6 58.1 23.4
7 46.4 54.2
8 68.8 36.4
9 43.9 32.3
10 22.3 25.1
11 15.0 25.2
Mean
S.D.
43.4 
± 17.8
, 38.5 
- 13.7
Shown is the effect of product *b' (200 ng/ml blood) on platelet 
adhesiveness of citrated whole blood. Product 'b* has no 
significant effect on platelet adhesiveness (t = 1.251, 0.20 
<p<0.30). These results were used to construct figure 70.
Table 73 Effect of product 'b1 (lOOyUg/ml) on platelet adhesiveness
Percentage platelet adhesiveness
Sub.iect ho. Control Test
1 80.1 88.6
2 63.8 74.9
3 76.2 80.2
4 82.7 83.0
5 55.3 62.6
6 61.3 62.4
7 87.9 91.8
Mean
S.D.
, 72.5 
- 12.3
A 77.6
i 11.7
Shown is the effect of product *b' (100 ng/ml blood) on platelet 
adhesiveness-in citrated whole blood afxer the blood and product ’b’ 
had been agitated together at 37 C for 10 minutes. The 
differences between the results of the control and product 'b* 
treated samples are significant; t = 3*456, 0.01 < p <0.02. Figure 
71 is compiled from these results.
Table 74 Effect of product ' c* on platelet aggregation
Sub.iect ho.
Ontical Density Readings
Control Test
1 0.430 0.482
2 0.252 0.285
3 0.559 0.570
4 0.326 0.390
5 0.445 0.470
6 0.561 0.560
7 0.542 0.555
Mean , 0.445 , 0.473
S.D. - 0.121 i 0.105
Shown is the effect of product ' c* (100 ug/ml plasma) on ADP induced 
aggregation in platelet rich plasma. The optical density readings of 
the control and test samples, 2 minutes after the addition of ADP 
(0.5 /Jg/ml plasma), are shown. Product 'c' results in significant in­
hibition of platelet aggregation (t = 3.233> 0.01 < p  < 0.02). A 
section of figure 64 was constructed from these results.
Table 75 Effect of product ’d* on platelet aggregation
Optical Density Readings
Subject Ho. Control Test
1 0 .050 0
2 0.525 0
3 0.272 0
4 0.292 0 .272
5 0.290 0 .240
6 0.150 0.153
7 0.550 O.45O
8 0.480 0.463
9 0.452 0.425
10 0.228 0.200
Mean , O.5O5 0.216
S.D. - 0.159 - 0.112
Shown is the effect of product 'd' (lOOyug/ml plasma) on ADP induced 
platelet aggregation in platelet rich plasma. The optical density 
readings of the control and test samples, 1-g- minutes after the 
addition of ADP (0.5 wg/ml plasma), are shown. Platelet aggregation is 
enhanced in the presence of product fdf (t = 2.415, 0.025 < p< O.Q50).
A section of figure 72 was compiled from these results.
Table 76 Effect of product fd‘ on platelet aggregation in the
Chandler tube
Sub.iect Ho.
Time of nlatelet afirfireaation (seconds)
Control Test
1 533 303
2 418 286
3 270 242
4 556 289
5 255 237
6 678 356
7 629 342
Mean . 477 294
S.D. - 168 45
Shown is the effect of product 'd‘ (180 ng/ml plasma) on the rate of form­
ation of platelet aggregates in the Chandler tube. The speed of 
platelet aggregation is accelerated in the samples treated with product 
’d’ (t = 3.874, 0 *005<p <0.010). Figure 73 is compiled from these 
results.
lafefeJZ Effect of fibrinogen on platelet aggregation
Sub.iect ITo.
Ontical Densitv Readings
Control Test
1 0.520 0.480
2 0.482 0.302
5 0.427 0.405
4 0.272 0
5 0.180 0.105
6 0.408 0.130
7 0.550 0.500
Mean
S.D.
^ 0.406
-  0.135
, 0.275 
0.198
Shown is the effect of fibrinogen (100 ng/ml plasma) on ADP induced 
platelet aggregation in platelet rich plasma., The optical density 
readings of the control and test samples, 1-g- minutes after the 
addition of ADP (0.5/ug/ml plasma), are shorn. Pibrinogen produces 
significant enhancement of platelet aggregation (t = 3.126, 0.020<p< 
0.025). A section of figure 74 is compiled from these results.
Table 78 Effect of ’purified’ fibrinogen on platelet aggregation
Sub.iect No.
Optical Density Readings
Control Test
1 0.520 0.451
2 0.482 0.170
3 0.427 0.361
4 0.272 0.280
5 0.180 0.160
6 0.408 0.295
7 0.550 0.470
Mean
S.D.
0.406 
- 0.135
0.312 
- 0.123
Shown is the effect of 'purified* fibrinogen (100 ng/ml plasma) on ADP 
induced platelet aggregation in platelet rich plasma. The fibrinogen 
was ’purified1 by passage through a DEA3 cellulose column. The 
optical density readings of the control and test samples, 1-g- minutes 
after the addition of ADP (0.5 ug/ml plasma), are shown. The 
differences between the results of the control and test samples are not 
significant (t = 2.361, 0.05<p<0.10). These results were used to 
compile a section of figure 74.
Table 79 Effect of fibrinogen on platelet adhesiveness
Sub.iect Ho.
Percentage platelet adhesiveness
Control Test
1 44.4 49.5
2 38 .0 43.3
5 40.7 36 .6
4 45.9 28.1
5 43.8 40.3
6 22.9 35.0
7 23.2 36.4
Mean
S.D.
, 37.0 
- 9.9
. 38.5 
± 6 .8
Shown is the effect of fibrinogen (lOO mg/ml blood) on platelet 
adhesiveness in citrated whole blood. The difference between the 
control and the fibrinogen treated samples is not significant (t = O.359, 
0.70< p<0.80). Figure 75 was constructed from these results.
ITable 80 Effect of fibrinogen (100yug/ml) on platelet adhesiveness
/ 1
Percentage platelet adhesiveness ' / '
Subject Mo. Control Test
1 71.3 71.3
2 58.8 83.6
5 47.5 70.1
4 64.3 82.7
5 79.6 94.0
6 55.2 69.4
7 55.2 79.0
Mean , 61.7 , 78.6
S.D. - 11.0 -  9.0
Shown is the effect of fibrinogen (l00 ng/ml blood) on platelet 
adhesiveness in citrated whole blood alter the blood and fibrinogen 
had been agitated together at 37 C for 10 minutes. The difference 
between the results of the control and fibrinogen treated samples is 
significant (t = 5.166, 0,001 <p<0.005). Figure 76 is compiled from 
these results.
